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Management of Rheumatoid Arthritis
Treatment outcomes in rheumatoid arthritis (RA) have improved enormously in the 
last decades due to early initiation of therapy, a treat-to-target approach, and use 
of biological disease-modifying anti-rheumatic drugs (DMARDs).[1] A treat-to-target 
strategy, aiming at a pre-set outcome measure, is well-embedded in daily practice 
for management of RA. The ultimate aim of every treat-to-target strategy is reaching 
sustained remission, defined as the total absence of both articular and extra-articular 
manifestations of RA, with low disease activity as the best alternative. This is obtained 
with treatment intensifications until the target is reached. This treatment strategy has 
the highest chance of inducing remission and preventing joint damage.[2, 3] 
As a result, remission in RA occurs more often.[4] Approximately 75%-80% of patients 
are able to reach low disease activity or even sustained remission.[4] This has raised 
the question whether we need to continue, taper or discontinue treatment. Reasons 
for tapering are reduction in costs, since treatment with biologicals is very expensive, 
prevention of possible long term side effects, and patient preference. However, 
by tapering medication the risk of disease flares increases, which can have a great 
impact on patients lives, and on society due to productivity loss, i.e. sick leave or 
unemployment. Therefore, before tapering treatment is considered, it is important 
to evaluate both the clinical-, patient-, and societal viewpoint to make informed 
decisions. Moreover, the optimal tapering strategy leading to the least amount of 
disease flares has not been developed yet. 
Clinical perspective
Management of RA must be both effective and affordable, which can be accomplished 
by efficient use of DMARDs. Therefore, when RA patients have a well-controlled 
disease, and reach a symptom-free state, continuation of all DMARDs is no longer 
required. Especially since the benefits of treatment should always outweigh possible 
side-effects, which may not be the case when RA patients have a well-controlled 
disease. Long term use of biologicals, for example, is not without risks and includes 
adverse events related to the immunosuppressive mode of action, such as infections 
and malignancies.[5, 6]
Although rheumatologists carefully consider initiation of biologicals, uniform tapering 




patients with a well-controlled disease.[7] A possible reason behind this trend is the 
increased risk of disease flares during tapering. Previous studies, in which biologicals 
were most frequently discontinued instead of gradually tapered, have shown that it 
is possible to withdraw treatment, but this is accompanied with a higher chance at 
disease flares. Flare rates within these studies varied from 38-76.6%.[8-11] 
To optimize treatment for symptom-free patients, a more tailored treatment 
approach is needed. Building further on a treat-to-target strategy with disease activity 
as outcome parameter, tapering treatment should be performed as soon as patients 
reach well-controlled disease. Current EULAR treatment guidelines recommend 
that rheumatologists should consider tapering of biologicals when a RA patient is 
in sustained remission, especially when combined with a csDMARD. If a patient is in 
remission with only a csDMARD, the csDMARD may be tapered.[1] However, neither 
remission criteria are defined nor a time interval is given for the term sustained. 
Furthermore, the best method to taper treatment still needs to be unraveled. 
Patient perspective 
Tapering treatment implies less medication use, which is often preferred by patients. 
It also decreases the amount of burden due to subcutaneous or intravenous 
administration of biologicals. 
However, the main concern for patients is that tapering of treatment will lead to a 
disease flare, which could lead to more pain and disability.[8, 12-14] It has also been 
shown that only 41 – 67% of the patients that experience a flare will regain remission 
within 6 months after treatment intensification.[8, 15] Thus, for some patients 
tapering seems feasible, while for others it could lead to a flare followed by a reduced 
or no response to previous effective therapy.
Nowadays, a paradigm shift in the delivery of health care is emerging and is shifting 
towards patient centered health care. Patient centered healthcare focuses on the 
individual patient preferences and needs, which can be objectified with patient 
reported outcomes (PROs).[16, 17] In order to optimize the delivery of care during 
tapering we need to know the consequences of a flare, which could be measured 
with these PROs. A previous study already showed that discontinuation of treatment 
has a short significant impact on PROs.[18] However, data on the effect of a disease 




One of the main reasons for tapering treatment is saving costs, especially since 
health care costs are rising due to the use of biological treatment. Annually, more 
than 250 million euros are spent on the use of biological therapy for rheumatic 
diseases in the Netherlands.[19] To keep health care affordable, tapering treatment 
in RA patients with a well-controlled disease could lead to considerable cost-savings. 
However, the costs that are saved by tapering biologicals may be counterbalanced 
by increased costs due to productivity loss as a result of the higher flare rates during 
tapering of treatment. Currently, it is unclear whether health care costs outweigh 
the possible increase in societal costs, especially because recent cost-effectiveness 
analyses only take into account sick leave (absenteeism), while working while being 
sick (presenteeism), is neglected. 
Ultimate treatment outcome: DMARD-free remission?
If we are able to safely taper and discontinue medication in RA patients who have 
a well-controlled disease, patients will reach a state of DMARD-free remission (DFR; 
the absence of synovitis after cessation of DMARD therapy). The ability to achieve 
and sustain DFR is often considered unlikely.[20] Nonetheless, there is increasing 
interest in achieving DFR, because this is currently the best proxy of a cure for RA.[21] 
Previous research showed that 10-20% of RA patients are able to achieve sustained 
DFR.[21, 22] However, definitions for DFR are heterogeneous. Although, DFR has 
been mentioned as an outcome for early RA patients, there is no to little evidence 
that DFR is also achievable in an established RA population. 
TARA trial
The TApering strategies in Rheumatoid Arthritis (TARA) trial was set-up to investigate 
the best tapering order for RA patients with a well-controlled disease who were 
using both a TNF-inhibitor and a csDMARD. The TARA, a multicenter, single-blinded 
(research nurses), randomised trial was carried out in twelve rheumatology centers 
in the south-western part of the Netherlands. Inclusion started in September 2011 
and ended in July 2016. Adult RA patients with a well-controlled disease, defined as 
a disease activity score (DAS) ≤ 2.4 and a swollen joint count (SJC) ≤ 1 for more than 
three months, using a combination of a csDMARD and TNF-inhibitor, were included. 




followed by the TNF-inhibitor in the second year, or vice versa. csDMARD tapering 
was realized by cutting the dosage into half, a quarter and thereafter it was stopped. 
The TNF-inhibitor was tapered by doubling the dose interval, followed by cutting the 
dosage into half, and thereafter it was stopped. The total tapering schedule took six 
months, with dose adjustments every three months as long as there was still a well-
controlled disease. If a disease flare occurred, defined as DAS > 2.4 and/or SJC > 1, 
tapering was stopped and the last effective treatment was restarted and if necessary, 
medication was intensified further according to a treat-to-target approach, until low 
disease activity was reached again. After a flare, no further attempts were taken to 
taper medication during the remainder of the study. 
Patients were examined at baseline and every three months thereafter. At each time 
point, the DAS, medication usage, and self-reported questionnaires were collected, 
except for hand and foot radiographs, which were obtained at baseline and after 
one and two years of follow-up. Throughout the whole study follow-up adverse event 
were recorded.
Objectives and outline of this thesis
More and more RA patients will reach remission with current improved treatment 
strategies. As a result, tapering of treatment will become more common, but the 
optimal tapering strategy leading to the least amount of flares, has not been developed 
yet. Furthermore, the impact of tapering and flares on a patient and a societal level is 
currently not well known.
To objectify the possible impact of tapering in daily practice, we described current 
biological use in the Netherlands in chapter 2. For this we used a real-world 
observational cohort in which we investigated factors influencing biological survival, 
thereby taking into account various reasons for discontinuation.
In chapter 3 we present the first year results of the aforementioned TARA trial. We 
compared two gradual tapering strategies, namely tapering the TNF-inhibitor first 
followed by the csDMARD and vice versa. We assessed which therapy should be 
tapered first based on the tapering strategy leading to the least amount of flares. In 
chapter 4 additional information is given on the treatment strategies that patients 
were using before inclusion, which is also an indicator for the treatment strategies 
that are currently used in daily practice.
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When treatment is completely tapered and discontinued, a patient will reach the 
state of DMARD-free remission. In chapter 5 we present a systematic literature review 
investigating the feasibility of DMARD-free remission as a novel and sustainable 
outcome for RA. 
Following this, in chapter 6 we investigated whether DMARD-free remission is also 
an achievable treatment outcome in an established RA population. In chapter 7 we 
compared data from the TARA trial to real-world tapering data.
In chapter 8 we determined the impact of a disease flare on patient’s lives. We took 
into account patient reported outcomes (PROs) and investigated whether these PROs 
changed if a flare occurred, and if so, the duration of this effect was determined. 
An important reason for tapering treatment is to save costs. In chapter 9 we investigated 
the societal impact of tapering, in which we evaluated the cost-effectiveness of the 
two tapering strategies in the TARA trial. Health care costs as well as societal costs, 
i.e. costs due to loss of productivity, are taken into account to decide which tapering 
strategy is most cost-effective.
Last, in chapter 10 a general discussion is provided of the main findings of this thesis 
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FACTORS THAT INFLUENCE 
BIOLOGICAL SURVIVAL IN 
RHEUMATOID ARTHRITIS: RESULTS 
OF A REAL-WORLD COHORT FROM 
THE NETHERLANDS







Objectives We aim to explore real-world biological survival stratified for discontinuation 
reason and determine its influenceability in rheumatoid arthritis(RA) patients. 
Methods Data from the local pharmacy database and patient records of a university 
hospital in the Netherlands were used. RA patients who started a biological between 
2000-2020 were included. Data on age, anti-citrullinated protein antibody (ACPA) and 
rheumatoid factor (RF)-status, presence of erosions, gender, body mass index, time to 
first biological, biological survival time, use of csDMARDs and discontinuation reasons 
were collected. 
Results Of the included 318 patients, 12% started their first biological within 6 
months after diagnosis. Median time to first biological was 3.6 years (95%CI,1.0-
7.2). Median survival of the first- and second-line biological was respectively 1.7 
years (95%CI,1.3-2.2) and 0.8 years (95%CI, 0.5-1.0)(p=0.0001). Discontinuation 
reasons for the first-line biological were ineffectiveness(47%), adverse events(17%), 
remission(16%), pregnancy(30%), or patient preference(10%). Multivariable Cox 
regression analyses for discontinuation due to inefficacy or adverse events showed 
that concomitant use of csDMARDs (HR=1.32,p<0.001) positively, while RF-positivity 
negatively (HR=0.82,p=0.03) influenced biological survival. ACPA-positivity was 
associated with longer biological survival due to inability to discontinue due to 
remission (HR=1.43,p=0.023). Second-line TNF-inhibitor survival was similar between 
patients with a primary and secondary non-response on the first-line TNF-inhibitor 
(HR=1.28,p=0.34).
Conclusion Biological survival diminishes with the number of biologicals used. 
Biological survival is prolonged if patients use csDMARDs. RF and ACPA were negatively 
associated with respectively biological survival and discontinuation due to remission. 
Therefore, tailoring treatment based upon autoantibody status might be the first step 
towards personalized medicine in RA. 




Management of RA has improved in the last decades due to early diagnosis, a 
treat-to-target approach, and the introduction of biological disease modifying anti-
rheumatic drugs(bDMARDs).[1] Tumor necrosis factor inhibitors (TNF-inhibitors) 
were the first bDMARDs to be developed for rheumatic diseases and are currently 
most frequently prescribed after an inadequate response to conventional synthetic 
(cs)DMARDs. It has been suggested that prolonged biological survival is a surrogate 
for treatment effectiveness.[2] However, an increasing amount of patients reach 
remission nowadays, and will taper and discontinue treatment.[1] Therefore, solely 
taking into account overall biological survival will dilute outcomes, and to properly 
analyze biological survival, results should be stratified according to discontinuation 
reasons.
Previous studies, based on biological registries throughout Europe, have shown that 
50% of patients discontinue their TNF-inhibitor within 3-5 years.[3] Main reasons for 
discontinuation were inefficacy and adverse events.[3, 4] Within trials and biological 
registries longer survival times were seen for first-line biologicals and when bDMARDS 
were combined with csDMARDs.[5-7] However, factors influencing biological survival 
based on separate reasons for discontinuation have not been previously explored. 
Therefore, the aim of this Dutch real-world rheumatoid arthritis cohort is to explore 
first and second-line biological survival and to determine its influenceability when 
stratified for discontinuation reasons. 
PATIENTS AND METHODS
Study design
Data from the local pharmacy database and patient records of the Erasmus MC, an 
academic hospital in the Netherlands, were used. We included data from rheumatoid 
arthritis(RA) patients starting a biological between 2000-2020. We excluded patients 
for whom non-adherence was reported, and if start and stop dates for bDMARDs 
were not available. Standard treatment of RA in the Netherlands is based upon a 
treat-to-target approach aiming for low disease activity. If patients have an inadequate 
response to >1 csDMARD, a bDMARD can be prescribed. In case of an inadequate 
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response, rheumatologists can prescribe another TNF-inhibitor(cycling) or a bDMARD 
with another mode of action(switching).[8] 
Data collection
Biological survival was the main outcome and was defined as skipping ≥2 gifts and/or 
≥2 months without biological treatment. Reasons for discontinuations were evaluated 
and classified into: inefficacy;  adverse events (AEs), which we divided into primary (<6 
months) and secondary (≥6 months) non-response; remission; pregnancy; patient 
preference; and other reasons. 
Analyses
We compared first- and second-line biological survival with Kaplan-Meier curves and 
with Wilcoxon-Breslow-Gehan tests at 3 years. Thereafter, fi rst-line biological survival 
with and without concomitant use of csDMARD(s) was compared. Subsequently, we 
investigated whether primary and secondary inefficacy to a first-line TNF-inhibitor 
leads to differences in second-line TNF-inhibitor survival. Patients stopping their 
bDMARD due to remission or pregnancy were censored. 
Cox proportional hazard models were used to estimate hazard ratios (HRs) of 
candidate baseline predictors (age, gender, ACPA, RF, erosions, BMI, disease duration, 
or co-medication) for bDMARD survival stratified for reasons for discontinuation, 
namely (1) inefficacy or adverse events and (2) remission. First univariable Cox 
regression analyses were performed, and candidate predictors with a p<0.20 were 
entered into a multivariable model, after which backward selection was applied until 
significance was reached. To prevent overfitting, an entry model was created and 
backward selection was applied. Schoenfeld residuals were assessed to check the 
proportional hazard assumption. 
All data was analyzed using STATA15. P-values ≤0.05 were considered statistically 
significant.





Data were derived from 318 RA patients(table 1). Time until first bDMARD prescription 
remained constant between 2000 and 2020. In our cohort 50% of patients  started 
their first biological after 2013, thus in most recent years more bDMARDs were 
prescribed. A total of 39 (12%) patients started their first bDMARD within 6 months 
after diagnosis. 




   -  Age at diagnosis, mean (sd) 40.9 (16)
   -  Gender, female, n (%) 264 (83)
   -  BMI, mean (sd) 26.9 (6.3)
Disease characteristics
   -  ACPA positive, n (%) 224 (70)
   -  RF positive, n (%) 226 (71)
   -  Erosive disease, n (%) 141 (44)
Medication
   -  Time to first biological, years, median (IQR) 3.6 (1-7)
   -  First-line biologicals
• Etanercept, n (%) 142 (45)
• Adalimumab, n (%) 90 (28)
• Certolizumab Pegol, n (%) 59 (19)
• Infliximab, n (%) 15 (5)
• Golimumab, n (%) 5 (2)
• Anakinra, n (%) 3 (1)
   -  csDMARDs used with first-line biological
• MTX, n (%) 66 (21)
• MTX + SASP and/or HCQ , n (%) 147 (46)
• Other csDMARDs (SASP, HCQ, LEF), n (%) 53 (17)
• No combination therapy, n (%) 52 (16)
ACPA: anti-citrillunated protein antibody, BMI: body mass index, csDMARD: conventional 
synthetic disease modifying anti-rheumatic drug, HCQ: hydroxychloroquine, IQR: inter quartile 




First- and second-line biological survival
Median (95%CI) survival time of the first-line biological was 1.7 years (1.3-2.2), and for 
the second-line bDMARD 0.8 years (0.5-1). Most prescribed first-line bDMARDs were 
Etanercept (45%), Adalimumab (28%), and Certolizumab Pegol (19%)(table 1). Since 
only 9% of patients were using non-TNF-inhibitors as second-line bDMARD, a direct 
comparison between a cycling or switching strategy could not be performed. 
bDMARD survival was significantly longer for the first-line bDMARD compared to the 
second (p=0.0001)(figure 1A). Discontinuation reasons for the first-line bDMARD were 
inefficacy (47%), adverse events (17%), remission (16%), pregnancy (30%), or patient 
preference (10%). Discontinuation reasons for the second-line bDMARD were similar 
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Figure 1 Kaplan-Meier curves for biological survival. (A) Kaplan-Meier for first- versus second-line 
biological survival, (B) Kaplan-Meier curve of patients with or without combination therapy, (C) 
Kaplan-Meier curve of patients without combination therapy, and for patients with combination 
therapy stratified for methotrexate, methotrexate combined with one or more other csDMARDs 
(sulfasalazine, hydroxychloroquine, and/or leflunomide), or one or more other csDMARDs and 
(D) Kaplan-Meier of second-line TNF-inhibitor survival, stratified for primary and secondary 
inefficacy for the first-line TNF-inhibitor.
csDMARD: conventional synthetic disease modifying anti-rheumatic drugs, MTX: methotrexate.
Biological survival in a real-world cohort
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First-line biological survival with or without concomitant use 
of csDMARDs
A total of 48(25.3%) and 6(15.4%) patients respectively with and without concomitant 
use of csDMARD(s) were still using their first-line biological after 3 years of follow-
up. Median (95%CI) survival time of the first-line bDMARD with csDMARD(s) was 2.0 
(1.3-2.3) years, and without csDMARDs 1.0 (0.5-5.3) year (figure 1B,p=0.031). First-
line bDMARD survival was longest for treatment regimens with methotrexate (MTX) 
followed by other csDMARDs, and no csDMARD use (figure 1C). However, no significant 
differences were found between MTX and the other csDMARDs as concomitant 
therapy (p=0.14)(figure 1C).
Primary and secondary failure
Median (95%CI) survival time for the second-line TNF-inhibitor was 0.42(0.25-1.58) 
years for patients with a primary non-response for the first TNF-inhibitor and 
0.92(0.83-1.83) years for patients with a secondary non-response for the first TNF-
inhibitor. Although overall survival time on the second-line biological did not differ 
significantly between patients with a primary and secondary non-response (HR 
1.28,p=0.34), a trend could be observed (figure 1D).
Predictors for biological survival 
Univariate cox regression for discontinuation due to inefficacy and adverse events 
showed that RF (HR=0.80,p=0.014), and presence of erosions(HR=0.65,p<0.001) were 
negatively associated with first-line bDMARD survival. Concomitant use of csDMARD(s) 
(HR=1.35,p<0.001) on the other hand was positively associated with first-line bDMARD 
survival. Aforementioned factors as well as time to first-line bDMARD, age, gender and 
ACPA were included in our multivariable model with backward selection. In the final 
model only RF(HR=0.82,p=0.03), and concomitant use of csDMARDs(HR=1.32,p=0.001) 
were significantly associated with first-line bDMARD survival (table 2). When we used 
an entry model and applied backward selection, aforementioned predictors were 
again in the final model, but also the presence of erosions was included. 
The same procedure was followed for investigating which factors were associated 
with a higher chance of discontinuing bDMARDs due to remission. Only a positive 




Table 2 Predictors for biological survival 
Univariable Multivariable1
HR (95% CI) p HR (95% CI) p
Biological survival taking into account discontinuation due to inefficacy or AEs2
Age at diagnosis 1.00 (1.00-1.01) 0.514
Gender (female) 1.00 (0.82-1.23) 0.985
BMI  0.99 (0.98-1.01) 0.296
Rheumatoid factor 0.80 (0.67-0.96) 0.014 0.82 (0.69-0.98) 0.03
ACPA 0.90 (0.75-1.07) 0.223
Erosions 0.65 (0.55-0.76) <0.001
Time to first-line biological 0.98 (0.95-1.01) 0.163 
Combination therapy 1.35 (1.14-1.59) <0.001 1.32 (1.13-1.57) 0.001
Prolonged biological survival due to inability to taper3
Age at diagnosis 1.00 (0.99-1.01) 0.717
Gender (female) 1.08 (0.75-1.56) 0.676
BMI 0.98 (0.95-1.01) 0.175
Rheumatoid factor 1.26 (0.94-1.96) 0.121
ACPA 1.43 (1.05-1.93) 0.023 1.43 (1.05-1.93) 0.023
Erosions 0.70 (0.53-0.92) 0.481
Time to first-line biological 1.04 (0.99-1.09) 0.119
Combination therapy 0.93 (0.69-1.26) 0.643
1Backward selection, variables with p<0.20 in univariable analyses were entered. 2HR>1 indicates 
prolonged biological survival, HR<1 indicates reduced biological survival due to inefficacy or AEs. 
3HR>1 indicates prolonged biological survival due to inability to taper, HR<1 indicates reduced 
biological survival due to tapering of bDMARD due to remission.
ACPA: anti-citrullinated protein antibody, AE: adverse events, BMI: body mass index, CI: 
confidence interval, HR: hazard ratio.




Optimal management of RA is based on reaching the lowest possible disease activity 
with a treat-to-target approach.[1] Despite the improved management approach 
and increasing treatment options, only 60-70% of RA patients will reach a long-term 
clinical response.[4] Within our study we found a significant difference in survival time 
between the first- and second-line bDMARD, implicating the importance to prolong 
first-line bDMARD survival. Several factors can influence bDMARD survival of which 
some can be influenced.
Main reasons for discontinuation in our and in other studies were inefficacy and 
adverse events.[3] Primary inefficacy indicates no effect at all, and is thought to be due 
to a mismatch between the bDMARD and the specific RA-subtype, causing the biologic 
agent not to be effective.[9] Secondary inefficacy indicates that the clinical response is 
first obtained, but not maintained, and is thought to be caused by formation of auto-
antibodies against the biologic.[4] Although we did not find a significant difference in 
second-line TNF-inhibitor survival between RA patients with a primary or secondary 
non-response to the first TNF-inhibitor, a trend could be observed. This was probably 
due to a low number of patients in the group with a primary non-response for the 
first-line bDMARD (n=42). However, these data indicate that rheumatologists should 
consider to switch to another mode of action in case of primary inefficacy instead of 
cycling to another TNF-inhibitor, but validation is needed.[10, 11]
Compared to previous findings, bDMARD survival seems to be short. This can be 
explained by our real-life cohort in a tertiary care university hospital. We also noticed 
that in our cohort a high number of patients were using Certolizumab Pegol, and 
discontinued their bDMARD due to pregnancy. This is related to the fact that the 
ErasmusMC has an ongoing cohort for patients with a wish to conceive.[12] 
Outcomes of our study on the other hand are in accordance with previous findings. 
Benefits of combining a bDMARD with a csDMARD have been previously described.
[6, 13, 14] Reasons for this synergistic effect are not fully understood. One of the 
reasons could be that csDMARDs can prevent development of neutralizing anti-drug-
antibodies. It is also thought that csDMARDs affect clearance of the bDMARD by 
modulating either the expression of Fc receptors on monocytes or the interaction of 
the Fc receptor and the bDMARD.[4] 
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RF positivity was also found to be predictive for shorter bDMARD survival, which is 
again in accordance with previous literature.[15] Furthermore, ACPA positivity has 
shown to reduce the chance of discontinuing due to remission. This reconfirms that 
the presence of autoantibodies are a marker for more severe disease. 
In conclusion, bDMARD survival diminishes with the number of bDMARDs used. 
Combining a bDMARD with a csDMARD increases bDMARD survival, which supports 
current EULAR recommendations to combine a bDMARD with a csDMARD. RF 
and ACPA were negatively associated with respectively bDMARD survival and 
discontinuation due to remission. Therefore, the possible first step to personalized 
medicine in RA might be tailoring of treatment based upon autoantibody status. 
Table S1 Discontinuation reasons for first- and second-line biological




Total number of patients 
discontinuing biological
treatment
226 (71) 127 (66)
Ineffective 106 (47) 63 (51)
Adverse event 38 (17) 28 (23)
Remission 35 (16) 13 (10)
Pregnancy 30 (13) 15 (12)
Patient preference 10 (4) 4 (3)
Unknown 6 (3) 1 (2)
DAS28 at time of discontinuation, 
mean (sd)
3.19 (4.8) (n=107) 2.90 (1.4) (n=52)
All results are indicated as n (%), unless indicated otherwise. DAS: disease activity score, sd: 
standard deviation
Biological survival in a real-world cohort
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ABSTRACT
Objectives The aim of this study is to evaluate the effectiveness of two tapering 
strategies after achieving controlled disease in patients with rheumatoid arthritis (RA), 
during one year of follow-up.
Methods In this multicenter single-blinded (research nurses) randomised controlled 
trial RA patients were included who achieved controlled disease, defined as a DAS≤2.4 
and a SJC≤1, treated with both a conventional synthetic DMARD (csDMARD) and a 
TNF-inhibitor. Eligible patients were randomised into gradual tapering csDMARDs or 
TNF-inhibitors. Medication was tapered if the RA was still under control, by cutting 
the dosage into half, a quarter and thereafter it was stopped. Primary outcome 
was proportion of patients with a disease flare, defined as DAS>2.4 and/or SJC>1. 
Secondary outcomes were DAS, quality of life (EQ5D) and functional ability (HAQ-DI) 
after one year and over time. 
Results A total of 189 patients were randomly assigned to tapering csDMARDs (n=94) 
or tapering anti-TNF (n=95). The cumulative flare rates in the csDMARD and anti-TNF 
tapering group were respectively 33% (24-43%, 95% CI) and 43% (33-53%, 95% CI) 
(p=0.17). Mean DAS, HAQ-DI and EQ-5D did not differ between tapering groups after 
one year and over time.
Conclusion Up to 9 months, flare rates of tapering csDMARDs or TNF-inhibitors 
were similar. After one year, a non-significant difference was found of 10% favouring 
csDMARD tapering. Tapering TNF-inhibitors was therefore not superior to tapering 
csDMARDs. From a societal perspective it would be sensible to taper the TNF-inhibitor 
first, because of possible cost reductions and less long-term side effects.




Treatment outcomes of rheumatoid arthritis (RA) have improved enormously during 
the past decades due to earlier detection of the disease, a treat-to-target approach 
and intensified treatment, especially combination therapy with conventional synthetic 
disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs 
(bDMARDs). As a result, 50-60% of early RA patients are able to reach low disease 
activity or even sustained remission.[1-4] Because of these improved outcomes, it is 
nowadays more common to taper medication in RA patients, who are in sustained 
remission. This is in accordance with current treatment guidelines.[4] However, an 
optimal tapering approach, including in which order, still has to be unraveled.
The benefits of tapering treatment are (i) a decreased risk of long-term adverse events 
due to immunosuppression, i.e. increased infection risk and possibility of malignancy 
development, (ii) a reduction of health care costs, especially when biologicals are 
tapered, and (iii) a possibly improved compliance.[5, 6] On the other hand, tapering 
treatment may lead to more transient or persistent disease flares with potential 
harmful consequences.[1, 7, 8] 
Previous studies have shown that it is possible to taper DMARDs in various ways, 
which has been extensively reviewed by several research groups.[7, 9-15] bDMARDs 
are most frequently completely withdrawn. However, with this tapering strategy 
the risk of disease flares in the first year of follow-up is very high. Other bDMARD 
tapering studies used a dose-reduction approach, which resulted in less disease 
flares. However, to our knowledge no randomised trials have been performed that 
investigate which DMARD should be tapered first. 
Therefore, the aim of this study is to compare the effectiveness of two tapering 
strategies, namely gradually tapering csDMARDs or TNF-inhibitors, in RA patients with 
controlled disease under a combination of csDMARDs and a TNF-inhibitor.




Data were used from a clinical trial (NTR2754) – namely, TApering strategies in 
Rheumatoid Arthritis (TARA). TARA, a multicenter, single-blinded (research nurses) 
randomised trial, was carried out in twelve rheumatology centers in the south-
western part of the Netherlands. Inclusion started in September 2011 and ended 
July 2016. Medical ethics committees of each participating center approved 
the protocol and all patients gave written informed consent before inclusion. 
Patients
Adult RA patients with controlled disease, defined as a disease activity score (DAS) 
≤2.4 and a swollen joint count (SJC) ≤1 at two consecutive time points within a 
3-month interval, with a combination of a csDMARD and TNF-inhibitor, were included. 
Exclusion criteria were: (1) not being able to understand, speak and write in Dutch; 
(2) being diagnosed with a psychiatric or personality disorder; and (3) tapering or 
stopping therapy due to other reasons. 
Randomisation and blinding
Patients were randomised using minimization randomisation stratified for center. 
Trained research nurses, blinded to the allocated treatment arm throughout the 
study, examined patients and calculated the DAS.
Tapering schedule
Patients were randomised into gradual tapering their csDMARD or TNF-inhibitor. 
csDMARD tapering was realized by cutting the dosage into half, a quarter and 
thereafter it was stopped. The TNF-inhibitor was tapered by doubling the dose 
interval, followed by cutting the dosage into half, and thereafter it was stopped. The 
total tapering schedule took 6 months, with dose adjustments every 3 months as long 
as there was still a controlled disease. At the start of the study, patients were asked 
to refrain from glucocorticoids (GCs). There were no restrictions on the use of NSAIDs 
or intra-articular GC injections.
If a disease flare occurred, defined as DAS>2.4 and/or SJC>1, tapering was stopped 
and the last effective treatment, when RA was under control, was restarted. In case of 
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a flare, one intra-muscular GC injection was allowed as bridging therapy. After a flare, 
no further attempts were taken to taper medication during the remainder of the first 
year of follow-up. 
Outcomes
The primary outcome was the proportion of patients with a disease flare within one 
year. Secondary endpoints were disease activity, functional ability, quality of life, 
medication usage, and radiographic progression. 
Disease activity was measured with the DAS. Functional ability was measured with 
the health assessment questionnaire disability index (HAQ-DI).[16] Higher HAQ-DI 
scores indicate poorer function. Quality of life was measured with the European 
Quality of Life – 5 Dimensions (EQ-5D) and short form 36 (SF36).[17-19] A higher EQ-
5D index or SF36 score indicates a better quality of life. Radiographic progression was 
measured with the modified total Sharp score (mTSS).[20] Radiographs were scored 
chronologically by two out of three qualified assessors, who were blinded for study 
allocation and the identity of the patients.[21] Median mTSS are reported.[22] The 
weighted overall κ was 0.75 with >99% agreement. The percentage of patients with 
radiographic progression, defined as a change in mTSS>0.5 and >0.9 (the smallest 
detectable change), are given.[22]
Follow-up and assessments
Treatment strategies were tightly controlled, with patients being examined at baseline 
and every 3 months thereafter. At each time point the DAS, medication usage , 
development of complications and self-reported questionnaires were collected, 
except for hand and foot radiographs, which were obtained at baseline and after one 
year of follow-up. 
Safety monitoring
Safety monitoring took place according to Dutch guidelines, and included laboratory 
tests every 3 months.[23-25] The medication was stopped or the dosage was lowered 
in case of adverse events related to medication use. 
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Statistical analysis
The TARA study was a superiority trial, powered to detect a 20% difference in flare 
rates between both tapering strategies. Based on related prospective cohort studies 
from 2011 and before, following assumptions were made: (1) 40% of the patients 
tapering their TNF-inhibitors to half will have controlled disease after 6 months, and 
(2) 60% of the csDMARD-tapering group will have controlled disease after 6 months.
[26-28] Therefore, to detect this 20% difference using a significance level of α=0.05 
and a power of 80%, 107 patients were needed in each treatment arm, also taking a 
10% dropout ratio into account. 
Outcomes were calculated in an intention-to-treat analysis, using all available data. 
Differences in cumulative flare rates between groups were analysed with a logistic 
regression model. To account for stratified randomisation by center, intercepts 
for each center were included. Flare-free survival was visualized with Kaplan-Meier 
curves. Descriptive statistics were used to assess the proportion of patients with a 
controlled disease after 12 months of follow-up. A linear mixed model with maximum 
likelihood optimisation was used to compare DAS, HAQ-DI, and EQ-5D over time. 
Random intercepts were included for both hospital and individual patients. Residual 
correlation was modeled by inclusion of an autoregressive order correlation structure. 
In the final model the differences in evolution over time for the outcome DAS, HAQ-DI, 
and EQ-5D between the two groups were assessed. 
Statistical comparison of the baseline characteristics and outcomes were made by 
Student’s t test, χ2 test, or Wilcoxon rank-sum test, when appropriate. 
All data was analyzed using STATA15. A p-value ≤0.05 was considered statistically 
significant.





A total of 330 patients were assessed for eligibility and 189 of those were randomly 
assigned to tapering their csDMARD (n=94) or tapering their TNF-inhibitor (n=95). 
Most patients who were not eligible did not meet the inclusion criteria for remission or 
refused participation (figure 1). During the first year of follow-up 14 patients withdrew 
from the study, mainly because of refraining from further participation (figure 1). 
Table 1 shows the baseline characteristics for both tapering strategies. Patients had 
an average symptom duration of 6.8 years and were predominantly female (66.1%) 
with an average age of 56.6 years. Baseline mean (sd) HAQ-DI was 0.52 (0.47) and 
0.47 (0.53) and EQ-5D was 0.86 (0.12) and 0.87 (0.11) for respectively the csDMARD 
and TNF-inhibitor tapering group. 
At baseline, 81% of the csDMARD tapering group and 88% of the TNF-inhibitor 
tapering group was in remission (DAS<1.6) (table 1). The majority of patients in the 
csDMARD and TNF-inhibitor tapering group used MTX (respectively 97% and 86%) in 
combination with etanercept (respectively 54% and 55%) or adalimumab (respectively 
39% and 42%). Oral glucocorticoids were taken by 4 (4%) patients in the csDMARD 
tapering group and 2 (2%) patients in the TNF-inhibitor tapering group, while NSAIDs 
were taken by 14 (15%) and 20 (21%) patients (table 1).
At baseline respectively 39% and 27% of patients within the csDMARD or TNF-inhibitor 
group had erosive disease.
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Figure 1 Trial profile and patient participation. Results are shown as number of patients. 
csDMARDs: conventional synthetic disease modifying anti-rheumatic drugs
Assessed for eligibility (n=330)
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Age (years), mean (95% CI) 55.9 (53.0-58.8) 57.2 (55.0-59.4)
Gender, female, n (%) 67 (71) 58 (61)
Disease characteristics
Symptom duration (years), median (IQR) 6.0 (4.1-8.5) 6.4 (4.2-8.9)
RF positive, n (%) 50 (57) 59 (65)
ACPA positive, n (%) 62 (71) 67 (75)
Disease activity 
DAS44, mean (95% CI) 1.1 (0.9-1.2) 1.0 (0.9-1.1)
DAS clinical remission, DAS44<1.6, n (%) 76 (81) 87 (88)
TJC44, median (IQR) 0 (0-2) 0 (0-1)
SJC44, median (IQR) 0 (0-0) 0 (0-0)
VAS disease activity (0-100mm), median 
(IQR)
20 (4-32) 12 (4-23)
ESR in mm/h, median (IQR) 8 (3-14) 8 (2-15)
CRP in mg/L, median (IQR) 2.2 (1-5) 2 (1-6)
Use of csDMARDs* 
MTX, n (%) 90 (96) 84 (88)
SASP, n (%) 10 (11) 12 (13)
HCQ, n (%) 24 (26) 37 (39)
Leflunomide, n (%) 2 (2) 4 (4)
Use of TNF-inhibitor
Etanercept, n (%) 51 (54) 52 (55)
Adalimumab, n (%) 37 (39) 40 (42)
Others, n (%) ** 6 (6) 3 (3)
Radiographs (hand/foot)
mTSS (0-488), median (IQR) 2 (0-6.5) 1 (0-3.5)
Erosion score (0-280), median (IQR) 0 (0-2.5) 0 (0-2)
JSN score (0-168), median (IQR) 0.5 (0-2.5) 0 (0-2.5)
Erosive disease, n(%) *** 37 (39) 26 (27)
Patient-reported outcomes
HAQ-DI, mean (95% CI) 0.52 (0.42-0.62) 0.47 (0.35-0.58)
SF-36, median (IQR)
-   PCS 43 (29-48) 47 (39-51)
-   MCS 60 (56-63) 57 (51-62)
EQ5D index, mean (95% CI) 0.86 (0.83-0.88) 0.87 (0.85-0.89)
*some patients used a combination of csDMARDs, **certolizumab or golimumab, *** Erosive 
disease is characterized as having >1 erosion in three separate joints. ACPA: anti-citrullinated 
protein antibody; CI: confidence interval; CRP: C-reactive protein; csDMARD: conventional 
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synthetic disease modifying anti-rheumatic drug; DAS44: disease activity score measured in 44 
joints; ESR: erythrocyte sedimentation rate; EQ5D: European Quality of Life – 5 Dimensions; 
HAQ-DI: Health Assessment Questionnaire Disability Index; HCQ: hydroxychloroquine; IQR: 
interquartile range; JSN: joint space narrowing; MCS: mental component summary; mTSS: 
modified Sharp/Van der Heijde score; MTX: methotrexate; PCS: physical component summary; 
RF: rheumatoid factor; SASP: sulfasalazine; SF-36: short form 36; SJC: swollen joint count; TJC: 
tender joint count; VAS: visual analogue scale
Outcomes
After one year of follow-up, the cumulative flare rate was 33% (24-43%, 95% CI) in the 
csDMARD and 43% (33-53%, 95% CI) in the anti-TNF tapering group (figure 2). This 
means that 63/94 (67%) in the csDMARDs tapering group and 54/95 (57%) in the TNF-
inhibitor tapering group still had a well-controlled RA (p=0.17). Of the patients who 
flared and restarted the last effective treatment strategy, 46% regained a DAS<2.4 
within 3 months, which increased to 67% by 6 months. Two patients (1%) were unable 
to get back in remission within the first year. 
No significant differences were seen in DAS (p=0.72), HAQ-DI (p=0.63), and EQ-5D 
(p=0.58) after one year between both tapering strategies (table 2). Also over time, 
the DAS (p=0.49), and EQ-5D (p=0.35) were not significantly different between both 
tapering strategies (figure 3). Although the TNF-inhibitor tapering group seems to 
have lower HAQ-DI scores over time, this was not significantly different (p=0.15)(figure 
3). Over time, the patients with a disease flare increased and thus the proportion of 
patients with a DAS<2.4 decreased in both tapering strategies. A similar trend was 
seen for the HAQ-DI and EQ-5D over time (figure 3). 
Median mTSS scores were 2 (IQR 0-6.5) in the csDMARD and 1 (IQR 0-4) in the TNF-
inhibitor tapering group after one year of follow-up (table 2). Radiographic progression 
was seen in 5% of the csDMARD tapering group and 6% of the anti-TNF tapering 
group (p=0.82). Also, the cumulative probability plots were overlapping (figure 3B).
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Figure 2 Percentages flares and Kaplan-Meier curves for maintenance of controlled disease in 
the first 12 months. % with flare indicates the cumulative number of patients with flares. Error 
bars indicate 95% confidence intervals. Kaplan-Meier curves indicate loss of controlled disease 
(DAS44>2.4 and/or SJC>1) over time. Numbers below the Kaplan-Meier curve indicate the 
number of patients at risk per time point. csDMARD: conventional synthetic disease modifying 
anti-rheumatic drug.
Kaplan-Meier curve




































Number of patients at risk
Tapering csDMARD n=94 n=86 n=75 n=63 n=63
Tapering TNF-inhibitor n=95 n=86 n=76 n=66 n=54
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Tapering csDMARD Tapering TNF-inhibitor
Figure 3 Disease activity, cumulative probability plot for radiological progression, functional 
ability and quality of life over time per tapering arm. (A, C, D) Error bars indicate 95% confidence 
intervals. (B) Each point represents radiological progression (T12-T0) of an individual patient, 
measured with the modified Sharp/Van der Heijde (mTSS) score at 0 and 12 months. csDMARD: 
conventional synthetic disease modifying anti-rheumatic drug; DAS: disease activity score; EQ-
5D index: Dutch EuroQol index; HAQ: Health Assessment Questionnaire; mTSS: modified Sharp/
Van der Heijde score.
Table 2 Clinical response after 12 months for both tapering groups, according to 
intention-to-treat. 





DAS44, mean (95% CI) 1.31 (1.17-1.46) 1.35 (1.19-1.51)
TJC44, median (IQR) 0 (0-2) 0 (0-3)
SJC44, median (IQR) 0 (0-0) 0 (0-1)
VAS disease activity (0-100mm), median (IQR) 17 (5-36) 19 (6-42)
ESR in mm/h, median (IQR) 11 (5-21) 11 (4-19)
CRP in mg/L, median (IQR) 2.9 (1-6) 4 (1-9)
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DAS clinical remission, DAS44<1.6, n (%) 57 (69) 58 (66)
ΔDAS44 (T12-T0), mean (95% CI) 0.28 (0.16-0.40) 0.40 (0.22-0.57)
Radiographic progression (hand/foot)
mTSS (0-488), median (IQR) 2 (0-6.5) 1 (0-4)
Erosion score (0-280), median (IQR) 0.5 (0-2) 0 (0-2)
JSN score (0-168), median (IQR) 0.5 (0-2.5) 0 (0-2.5)
ΔmTSS (T12-T0), median (IQR) 0 (0-0) 0 (0-0)
Patients with progression >0.5, n (%) 4 (5) 5 (6)
Patients with progression >0.9, n (%) 4 (5) 5 (6)
Erosive disease, n(%)* 37 (44) 30 (34)
Patient-reported outcomes
HAQ-DI, mean (95% CI) 0.59 (0.46-0.73) 0.55 (0.43-0.66)
ΔHAQ-DI (T12-T0), mean (95% CI) 0.05 (-0.05-0.13) 0.07 (-0.01-0.16)
SF-36, median (IQR)
-   PCS 43 (32-50) 44 (35-50)
-   MCS 58 (53-62) 59 (51-62)
EQ5D index, mean (95% CI) 0.80 (0.76-0.84) 0.82 (0.79-0.85)
ΔEQ5D index (T12-T0), mean (95% CI) -0.06 (-0.09- -0.02) -0.05 (-0.08- -0.02)
*Erosive disease is characterized as having >1 erosion in three separate joints. CI: confidence 
interval; CRP: C-reactive protein; csDMARD: conventional synthetic disease modifying anti-
rheumatic drug; DAS44: disease activity score measured in 44 joints; ESR: erythrocyte 
sedimentation rate; EQ5D: European Quality of Life – 5 Dimensions; HAQ-DI: Health Assessment 
Questionnaire Disability Index; IQR: interquartile range; JSN; Joint space narrowing, MCS: mental 
component summary; mTSS: modified Sharp/Van der Heijde score; PCS: physical component 
summary; SJC: swollen joint count; TJC: tender joint count; VAS: visual analogue scale
Treatment
After 12 months, 58 patients in the csDMARD tapering group and 45 patients in the 
TNF-inhibitor tapering group completely tapered their medication (p=0.09). On the 
other hand, 8 and 16 patients were using the same dosage as at start of the trial. 
The remaining patients were able to taper their medication partially (figure 4C). The 
course of the tapering schedule is visualized in figure 4A and 4B. There was an overall 
significant difference in tapering status after 12 months of follow-up between the 
two tapering strategies (p=0.02). During the follow-up period we found no significant 
differences in glucocorticoid and NSAID usage between both tapering groups (figure 
4D). 
Table 2 (Continued)
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Figure 4 Status of tapering in the first year of follow-up. (A, B) Overview of tapering status per 
time point. Results are shown as percentages of patients. According to protocol, the doses were 
halved every 3 months, starting at T0, and after 6 months patients could stop their tapered 
medication when they were still in a controlled disease state. (C) Tapering status after 12 months. 
Columns indicate the percentage of patients that tapered medication until the indicated amount 
of the original dose. (D) Overview of glucocorticoids and NSAID use in the first year of follow-up. 
csDMARD: conventional synthetic disease modifying anti-rheumatic drug; NSAID: Non-Steroidal 
Anti-Inflammatory Drugs.
Adverse events
In the csDMARD tapering group 82 adverse events were self-reported versus 98 in 
the TNF-inhibitor tapering group (online supplemental table S1). Serious adverse 
events (SAEs) were seen in 10 (12%) patients tapering csDMARDs and 5 (6%) 
patients tapering TNF-inhibitor (p=0.3, online supplemental table S1). Reported SAEs 
were hospitalization, herpes zoster infection, basal cell carcinoma, large cell lung 
carcinoma, and a bruised rib. None of the SAEs were considered to be related to the 
trial treatment.




Tapering csDMARDs resulted in a 33% (24-43%, 95% CI) flare rate (DAS44>2.4 and/
or a SJC>1), while tapering TNF-inhibitors gave a 43% (33-53%, (95% CI) flare rate over 
a one-year period in the randomised controlled TARA trial. At 12 months, 103 (59%) 
patients were able to stop either their TNF-inhibitor or csDMARD, while 47 (37%) 
patients were using a lower dosage. Clinical and patient reported outcomes were 
comparable in both tapering groups over time and after one year of follow-up. Also, 
no significant differences in adverse events or radiological progression were seen 
between both tapering strategies.
Nowadays, more RA patients achieve a state of sustained remission, which makes them 
eligible for tapering treatment. This is reflected in current EULAR recommendations 
for the management for RA. The advice is to taper DMARD therapy in RA patients who 
are in sustained remission in the following ordering: glucocorticoids, bDMARDS, and 
csDMARDs.[4] Our results and the fact that TNF-blockers are more expensive than 
csDMARDs support aformentioned tapering order. 
The majority of previous tapering trials focused on the withdrawal of TNF-inhibitors 
alone. Flare rates for tapering TNF-inhibitors varied between 51% and 77%. The POET 
study, for example, reported a 51.2% flare rate (DAS28>3.2 or ΔDAS28>0.6) after 
stopping the TNF-inhibitor.[7] The STRASS showed a 76.6% flare rate (DAS28>2.6 or 
ΔDAS28>0.6) when extending the dosage interval of the TNF-inhibitor.[14] The DRESS 
study reported a 55% flare rate (ΔDAS28-CRP>0.6) after a dose-reduction of the 
TNF-inbitor.[13] Finally, the PRESERVE trial reported a 57.4% flare rate (DAS28>3.2) 
when the TNF-inhibitor was stopped, and a 20.9% flare rate (DAS28>3.2) when 
the TNF-inhibitor dose was cut into half.[15] Only few randomised controlled trials 
investigated tapering of csDMARDs, but the majority looked at the combined tapering 
of csDMARDs and biologicals. Flare rates within these studies varied between 35 – 
56%.[1, 6, 29-32] 
Although flare rates of aforementioned studies are similar to or higher than our 
findings, direct comparison is difficult, because of the differences in study design. The 
most important study design differences are: (1) no common definition for relapse 
or flare, (2) no comparison between tapering of csDMARDs and TNF-inhibitors, and 
(3) DMARD therapy could only be tapered or stopped once during follow-up. If we 
would use other criteria to define a flare in the TARA population, we would observe 
higher hypothetical flare rates. We would have encountered a 74.1% flare rate if using 
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DAS28>3.2 or ΔDAS28>0.6, an 80.5% flare rate if using DAS28>2.6 or ΔDAS28>0.6, a 
52.3% flare rate if we use ΔDAS28-CRP>0.6, and a 39.1% flare rate if using DAS28>3.2. 
Mostly, these flare rates are higher than our reported flare rates, but are similar to 
previous mentioned trials. This indicates that our criteria were more strict than other 
studies, but that flare rates are comparible between the tapering studies.
Also, the flare duration was longer in the TARA trial compared to other trials, which 
could be due to the measurement intervals of 3 months. If patients did not have a 
controlled disease 3 months after flare, we assumed that the duration of flare was 6 
months. That might be a reason that our results seem to have a long flare duration 
compared to the DOSERA or DRESS study, in which they knew the exact duration of 
flare in weeks.[12, 13] 
In this study there are several strengths and limitations. Strengths of the study are 
that we performed a randomised controlled trial to asess tapering in RA patients with 
a controlled disease. The TARA trial is one of the first trials which assess differences 
in tapering strategies, and elaborates on current viewpoints concerning tapering 
treatment, instead of only determining if tapering is feasible or not. 
Some limitations should be noted as well. First of all, inclusion was terminated earlier 
due to difficulties with recruiting. This was due to the initial inclusion criteria being too 
strict (DAS≤1.6), and the start of another trial (POET study) which used the same pool 
of eligible patients.[7] The study sample size was based on a 20% difference between 
both tapering strategies resulting in 96 patients per arm. We found, however, a 10% 
difference with 85 patients in the csDMARD and 89 patients in the TNF-inhibitor arm. 
This resulted in a power of 70% instead of 80%. For this reason, we performed a 
worst case scenario analysis to see if our results were valid. We used the following 
assumptions: (1) all extra included patients in the csDMARD tapering group had no 
flares and (2) all extra included patients in the TNF-inhibitor tapering group flared. This 
analysis showed an 18% difference in flares, which is still below the 20% difference on 
which our power calculation was based. Therefore, we think our current results and 
conclusions are valid. 
Second, rheumatologist could have only referred patients who achieved low disease 
activity quickly and had less severe disease and, therefore, creating selection bias. 
However, we think that our target population is the same as the one we would apply 
our results to, because those are the patients who are suitable for tapering and are 
willing to taper their medication. Second, only research nurses, who did the DAS 
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assessment, were blinded. Rheumatologists, therefore, knew the tapering strategy 
of their patients. This design was chosen to mimic daily practise as much as possible. 
However, it could be a possible source of bias, since rheumatologist might prefer one 
of the two tapering strategies and would possibly treat patients differently depending 
on the tapering strategy. 
Third, the time frame of follow-up was only one year. Although the differences in flare 
rates were not significantly different between both tapering strategies, the largest 
difference was seen at 12 months. Data of the second year are needed to investigate 
if this difference will increase. 
Last, we encountered 19% protocol violations , which could underestimate the effect 
of one of the two tapering strategies. We analyzed the type of violations and we 
can conclude that most protocol violations were randomly distributed over the two 
treatment arms and were made due to a treat-to-target approach. 
To ensure optimal rheumatic care in the future, efficient use of biological treatment is 
needed.[33] By tapering medication, costs can be reduced, especially when tapering 
bDMARDs. On the other hand, 38% of the patients in the TARA study flared within the 
first year, which may have a direct impact on patients’ lives (i.e. worker productivity 
and unemployment). Therefore, it is important to know which tapering strategy is 
most cost-effective, which will be addressed in a follow-up analysis.
In conclusion, the TARA study showed that up to 9 months, flare rates of tapering 
csDMARDs or TNF-inhibitors were similar. After one year, a non-significant difference 
in flare rates was found of 10% in favor of csDMARD tapering. Tapering TNF-inhibitors 
was therefore not superior to tapering csDMARDs. From a societal perspective it 
would be sensible to taper the TNF-inhibitor first, because of possible cost reductions 
and less long-term side effects.
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Serious Adverse events (SAEs) 10 (12) 5 (6)
Hospitalization 7 (8) 4 (4)
        -  Total hip or knee replacement surgery 3 (4) 1 (1)
        -  Pneumonia 1 (1) -
        -  Decompression shoulder 1 (1) -
        -  Pancreatitis 1 (1) -
        -  Angina pectoris 1 (1) -
        -  Peripheral vascular disease - 1 (1)
        -  Myocardial infarction - 1 (1)
Herpes zoster 1 (1) -
Basal cell carcinoma 1 (1) -
Large-cell lung carcinoma 1 (1) -
Bruised rib - 1 (1)
Observed AEs
Patients >1 AE 23 (27) 21 (24)
Gastrointestinal complaints 20 (24) 27 (31)
Fatigue 7 (8) 11 (13)
Off day 10 (12) 5 (6)
Hair loss 3 (4) 4 (5)
Acne 0 (0) 3 (3)
Mouth 1 (1) 5 (6)
Headache 2 (2) 0 (0)
Skin irritation 18 (21) 16 (18)
Pain of injection 16 (19) 12 (14)
Fear of injection 5 (6) 2 (2)
All results are shown as n(%).  AEs: adverse events. csDMARD: conventional synthetic disease 
modifying anti-rheumatic drug.
Supplemental table S2 Detailed overview of percentages of patients in the indicated 
tapering status per time point
T0 T3 T6 T9 T12
Tapering csDMARD
Full dose 0% 11% 7% 11% 10%
½ dose 100% 8% 7% 8% 15%
¼ dose 0% 77% 31% 10% 7%
Tapered 0% 4% 55% 71% 68%
Tapering TNF-inhibitor
Full dose 0% 4% 11% 15% 18%
½ dose 100% 18% 12% 10% 11%
¼ dose 0% 78% 66% 17% 20%
Tapered 0% 0% 11% 58% 51%
csDMARD: conventional synthetic disease modifying anti-rheumatic drug
Gradual tapering TNF inhibitors versus csDMARDs
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We are pleased about the interest in our article by Mishra et al. and we would like to 
respond to their questions so that there can be no ambiguity.[1, 2]
First of all, there is some clarification needed on the csDMARD that were used in 
combination with the TNF-inhibitors at baseline. In table 1 we elaborate on the different 
combination of csDMARDs that were used for each intervention arm separately. In 
the csDMARD tapering group the methotrexate (MTX) was tapered, except for the 
3 patients that did not use MTX. These patients gradually tapered leflunomide (n=1) 
and sulfasalazine (n=2).
Table 1 Use of csDMARDs at baseline in the TARA study specified for two groups: 
tapering csDMARDs and tapering TNF-inhibitors.




MTX monotherapy, n(%) 64 (69) 49 (52)
MTX + hydroxychloroquine, n(%) 17 (18) 27 (29)
MTX + sulfasalazine + hydroxychloroquine, n(%) 5 (5) 6 (6)
MTX + sulfasalazine, n(%) 3 (3) 2 (2)
MTX + leflunomide, n(%) 1 (1) 0 (0)
Sulfasalazine monotherapy, n(%) 0 (0) 3 (3)
Sulfasalazine + hydroxychloroquine, n(%) 2 (2) 0 (0)
Sulfasalazine + leflunomide, n(%) 0 (0) 1 (1)
Leflunomide monotherapy, n(%) 1 (1) 3 (3)
Leflunomide + hydroxychloroquine, n(%) 0 (0) 1 (1)
Hydroxychloroquine monotherapy, n(%) 0 (0) 3 (3)
csDMARD: conventional synthetic disease modifying anti-rheumatic drugs; MTX: methotrexate
Mishra et al. also had a question about our intention-to-treat (ITT) analysis. In an ITT 
analysis patients are analyzed in the groups to which they were randomised, regardless 
of whether they received or adhered to the allocated intervention. Therefore, in the 
clinical response table (table 2) of the original article we should have given the total 
numbers instead of the patients who were still participating in the TARA trial at 12 
months.[1] If we had given the total numbers the results would be similar. 
Third question was about explaining the difference between the number of patients 
who are in remission after 12 months of follow-up and the number of patients below 
the Kaplan Meier (KM)-curve at 12 months. In a KM-curve only the patients at risk 
are given. Patients are censored if they experience a flare or drop out, which results 
in a decreasing number of patients at risk over time. In table 2, on the other hand, 
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the number of patients in clinical remission (defined as a DAS<1.6) at 12 months of 
follow-up are given. Thus, the interpretation of the numbers given in the KM-curve 
and table 2 are different and, therefore, the numbers are non-identical. 
Finally, it would be interesting to know if the primary outcome would change if we 
use a modified per-protocol approach as brought up by Mishra et al. For this reason 
we excluded the patients that used oral glucocorticoids, n=4 and n=5 in respectively 
the csDMARD and TNF-inhibitor tapering group, or had more than one intramuscular 
injection, n=3 in each tapering group. With aforementioned approach a 30% (95% 
confidence interval (CI) 21%-41%) flare rate was seen in the csDMARD tapering group, 
and a 39% (95% CI, 31%-52%) flare rate in the TNF-inhibitor group (p=0.15). The 
difference in flare rates between both tapering arms is similar to the original article.[1]
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OBJECTIVES Although current treatment guidelines for rheumatoid arthritis (RA) 
suggest tapering DMARDs, it is unclear whether DMARD-free remission (DFR) is 
an achievable and sustainable outcome. Therefore we systematically reviewed the 
literature to determine prevalence and sustainability of DFR, and evaluated potential 
predictors for DFR. 
METHODS A systematic literature search was performed in March 2019 in multiple 
databases. All clinical trials and observational studies reporting on discontinuation of 
DMARDs in RA-patients in remission were included. Our quality assessment included 
a general assessment and assessment of the description of DFR. Prevalence of DFR 
and its sustainability, flares during tapering and after DMARD-stop were summarized. 
Also, potential predictors for achieving DFR were reviewed. 
RESULTS From 631 articles, 51 were included, comprising 14 clinical trials and 5 
observational studies. DFR-definition differed, especially for the duration of DMARD-
free state. Considering only high and moderate-quality studies, DFR was achieved in 
5.0%-24.3%, and sustained DFR (duration>12 months) in 11.6%-19.4% (both relative 
to number of patients eligible for tapering). Flares occurred frequently during DMARD-
tapering (41.8%-75.0%) and in the first year after achieving DFR (10.4%-11.8%), whilst 
late flares, >1 year after DMARD-stop, were infrequent (0.3%-3.5%). Many patient 
characteristics lacked association with DFR. Absence of auto-antibodies and shared 
epitope alleles increased the chance of achieving DFR.
CONCLUSIONS DFR is achievable in RA, and is sustainable in ~10%-20% of patients. 
DFR can become an important outcome measure for clinical trials, and requires 
consistency in the definition. Considering the high rate of flares in the first year 
after DMARD-stop, a DMARD-free follow-up of >12 months is advisable to evaluate 
sustainability.




In rheumatoid arthritis (RA) early treatment, with disease-modifying anti-rheumatic 
drugs (DMARDs), aiming at sustained remission, is nowadays the key element of each 
management approach.[1, 2] As a result, RA has become a controllable disease in 
which sustained clinical remission is achievable for an increasing number of patients, 
and tapering and discontinuation of DMARDs has become of emerging interest.[3] 
Current international guidelines recommend tapering of DMARDs in RA patients 
with sustained remission.[1, 2] Nevertheless, these guidelines are less clear whether 
DMARDs can be stopped and the systematic literature review supportive of the most 
recent EULAR guidelines was not focussed on DMARD-cessation.[4]
Despite the recommendations in the guidelines, tapering of DMARDs has not been 
adopted structurally in many clinical practices, presumably because the risk of a 
disease flare[5], and because the ability to achieve and sustain DMARD-free remission 
(DFR) is often considered unlikely.[6] On the other hand, there is increasing interest 
in achieving DFR, because this is currently the best proxy for cure.[7, 8] Clinical 
trials occasionally report on DFR, but usually not as primary outcome. Absence of 
knowledge of DFR prevalence, its sustainability and the characteristics of patients 
achieving DFR currently hampers the use of DFR as primary outcome.[9]
We aimed to expand the comprehension of the ability to achieve and sustain DFR in 
RA. Therefore, we conducted a systematic literature search. In addition to the DFR 
prevalence and sustainability, potential predictors for achieving DFR were explored. 
METHODS
Search strategy and selection criteria
This systematic literature review was conducted in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines and the 
Cochrane review handbook.[10, 11] The protocol was registered in the International 
Prospective Register of Systematic Reviews (CRD42019132558).[12] 
The search strategy was developed and performed in collaboration with an 
experienced librarian (JS). Key terms used for the search were ‘Rheumatoid arthritis’, 
‘Antirheumatic drugs’, ‘Discontinuation’ and ‘Remission’. These search items were 
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translated into multiple matching synonyms in order to broaden our results. All 
search elements were combined with the Boolean operators AND/OR. PubMed, 
Embase, Web of Science, COCHRANE Library, Emcare and Academic Search Premier 
were systematically searched (supplementary table S1). 
All observational cohorts and clinical trials reporting on discontinuation of DMARDs 
in RA-patients, in remission, were included. Study selection was independently 
carried out by two reviewers (MV and EvM). Cases of disagreement were discussed 
until consensus was reached. First, all obtained titles were screened, subsequently 
abstracts were reviewed after which full-text articles were screened for the predefined 
in- and exclusion criteria (supplementary table S2). If multiple articles were based on 
the same study, the article which described prevalence and sustainability of DFR most 
clearly was selected. Subsequently, the article describing the longest follow-up was 
used for data extraction. 
Data extraction 
A standardized data collection form was used to extract the following information: study 
design, patient characteristics, interventions, glucocorticoid (GCs) usage, organization 
of follow-up, outcome measures and loss to follow-up (LTFU) (supplementary table 
S3). Furthermore, data regarding eligibility criteria for tapering, tapering methods, 
numbers of patients tapering, description and timing of achieving DFR, sustainment 
of DFR over time and the occurrence of flares were extensively explored. Also 
information regarding predictors of DFR was collected. Data extraction was done 
independently by two reviewers (MV and EvM), disagreements were discussed until 
consensus was reached.
If the methods were incomplete or unclear, the methods of the original study could 
be used if a reference was available. Clinical trials and observational studies were 
handled separately, because of fundamental differences in the study design, which 
could influence achievement and sustainment of DFR; i.e. protocolized versus non-
protocolized tapering, frequency of monitoring and duration of follow-up.
Quality assessment
Our study-quality assessment consisted of 2 parts, namely a general assessment 
and an assessment of the description of DFR. For the general quality assessment 
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we used 13 predefined quality criteria, which were based on Cochrane guidelines 
(supplementary table S4).[11] The general study-quality was considered ‘good’ if >75% 
(≥10 items) of these criteria were scored positive. For the DFR quality assessment we 
used the following criteria: (1)‘DFR definition’, referring to whether a definition (e.g. 
remission criterion) of DFR was included, and (2)‘DFR-duration’, referring to whether 
information on the time between DMARD-stop and being appointed as DFR (i.e. the 
duration of DMARD-free status) was reported. Specific emphasis was put on duration 
of DMARD-free state since this attains insight in sustainability of DFR. When both DFR-
quality criteria were scored positive, DFR-quality was regarded as ‘good’. 
Studies were regarded as ‘high-quality’ if the general, as well as the DFR quality were 
good . When general study-quality was good but only one DFR-criterion was fulfilled, 
studies were regarded as ‘moderate-quality’. Studies lacking both DFR-criteria, or 
without a good general quality assessment were scored as ‘low-quality’. 
Data analysis
Extracted data was used to calculate DFR prevalence, defined as the proportion of 
patients achieving DFR, compared to those eligible for tapering medication. For each 
prevalence the confidence interval (CI) was calculated. Patients were considered 
eligible for tapering when they had achieved remission and subsequently were 
allowed to start tapering their medication. GCs were also considered as DMARDs. We 
specifically chose not to use the total study population as denominator, because in 
some studies specific groups of patients were not allowed to taper their medication 
due to study protocol. 
Sustained DFR (SDFR) was defined as the percentage of patients with a DFR-duration 
of >12 months since DMARD-stop, relative to the number of patients eligible for 
tapering. Reported flares were categorized and summarized according to the time-
period in which they occurred: (i) during tapering, (ii) in the first year after achieving 
DFR (‘early flares’) and (iii) after more than one year of DFR (‘late flares’). Results on 
DFR were summarized in a narrative overview, also in relation to study-quality. Due 
to expected heterogeneity in study design and study populations, pooled effect 
estimates were not calculated.
Additionally, the data was reviewed on potential predictors for achieving DFR. We 
used the same methods for data extraction and assessment as described for DFR-
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prevalence. Predictors of DFR were summarized. Results on variables evaluated in 
more than one high or moderate-quality article were graphically presented, based on 
statistical significance obtained with regression analysis. If univariate and multivariate 
analysis were both conducted, results of the multivariate analysis were used. For 
each predictor, the number of studies and the total number of patients within these 
studies were presented and the direction of the effect was indicated. 
RESULTS
Study selection 
Our search resulted in 631 articles, of which 51 articles were considered eligible for 
inclusion (figure 1). These 51 articles comprised data from 19 studies, 14 clinical trials 
and 5 observational cohorts. 
Quality assessment
Both the quality of the study in general and the description of DFR were evaluated, 
resulting in a final quality rating. Eleven out of 14 clinical trials and 2 out of 5 
observational cohorts showed a good general quality (table 1). Notably, the tapering 
methods were better described for clinical trials than for observational cohorts. Of 
the 13 studies with a good general quality, 7 fulfilled both quality criteria for DFR 
and were regarded as high-quality. These 7 high-quality studies comprised 5 clinical 
trials and 2 observational cohorts. Of the remaining 6 studies, two studies were of 
moderate quality since only one DFR criterion was fulfilled. The four other studies did 
not fulfil any DFR-quality criteria and were regarded low quality (table 1). 
Because of fundamental differences in study design, DFR-prevalence and flare rates 
from clinical trials and observational cohorts were presented separately. Also, only 
high or moderate-quality studies were presented in the result section. Nonetheless, 
all prevalence, including those of low-quality studies, can be found in table 2. 
DMARD-free remission as novel treatment target in rheumatoid arthritis 
5
65 
Figure 1 Flow diagram of study selection. 
DMARDs: disease-modifying antirheumatic drugs. 
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Table 1 Assessment of general study quality and DFR quality, resulting in final 
categorization as high, moderate or low-quality study.
Studies were assessed for quality of DMARD-free remission: whether definition (yes “+” or no 
“–“) and duration of drug-free state were reported (yes “+” or no “–“). DFR-quality was considered 
good (“ “) when both items were scored as ‘+’, and moderate (‘±’) when only 1 of 2 was scored 
as good. Subsequently, studies were assessed on general study-quality. Criteria for general 
study-quality could be scored: “+” indicating sufficient, “-“ indicating not sufficient, “±” indicating 
moderate, “?” indicating unclear reporting and quality could not be assessed. Study-quality was 
considered good (“ “) when minimally 75% (10 items) were scored as ‘+’. DFR: DMARD-free 
remission; DMARD: disease-modifying anti-rheumatic drug; LTFU: lost to follow-up; n.a.: not 
applicable; RA: rheumatoid arthritis. The combined study-quality was considered high (‘HQ’) 
when both DFR-quality, as study-quality was good. It was considered moderate (‘MQ’) when DFR-
quality was moderate, and study-quality was good. Low quality (‘LQ’) indicates studies with either 
insufficient DFR-quality and/or study-quality.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Study populations varied in RA classification (1987 versus 2010 criteria), disease stage/
duration (early versus established) and disease activity (supplementary table S5). 
Overall, trials were performed in two ‘settings’: early, DMARD-naïve RA and established 
RA. Studies including early RA had a treat-to-target approach and when remission was 
achieved, DMARDs were tapered. This was all conducted in a relative short period of 
time (n=7)[13-19]. The established RA studies (disease duration 3.1-11.3 years, n=6) 
either included patients with active disease who first changed DMARD-treatment and 
subsequently became eligible for tapering (n=2)[20, 21], or selected patients who 
were in longstanding remission and were directly considered eligible for tapering 
(n=4)[22-25]. All established RA studies were of low-quality, except 1 which was of 
moderate-quality.[20] One study, including patients in sustained remission, did not 
report disease duration.[26]
DMARD tapering 
Tapering of DMARDs was initiated when patients fulfilled the study-specific eligibility 
criteria for tapering, in which some were stricter than others (supplementary table 
S5). Methods of tapering varied from immediate DMARD-stop to one-by-one gradual 
tapering of DMARDs over the course of a year. In general, tapering of biologic 
DMARDs took place before tapering of conventional synthetic DMARDs. Flare rates 
during tapering ranged from 41.8%-75.0% (table 2, figure 2). 
Definitions of DMARD-free remission
Overall, the remission criterion used to define DFR was mainly DAS44 or DAS28 
remission. The DFR rates were either given as a point-prevalence, thus at the moment 
of DMARD-stop, or combined with a minimal DFR-period of several months (table 
2, figure 2). Nevertheless, most studies did not put much emphasize on a minimal 
duration of drug-free state as requirement to achieve DFR. Importantly, 3 studies that 
clearly defined DFR (2 high-quality, 1 moderate-quality) allowed i.a. or oral GCs during 
DFR, without reporting the actual use.[13, 17, 20]
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Figure 2 Summary of flare rate and DFR-prevalence, all as percentage of the number of patients 
that were eligible for DMARD-tapering, depicted on a timeline. DFR-prevalence was grouped by 
the duration of DFR.
Legend: Data is presented as DFR percentage (confidence interval). Data were based on high or 
moderate-quality studies. Prevalence and confidence intervals were calculated using number of 
DFR patients divided by the number of patients eligible for tapering. Results from observational 
studies are indicated in italic. 
*indicates that studies that allowed the use of i.a. or systemic corticosteroids in patients that 
were considered to be in DFR (absolute number of patients that used corticosteroids after 
DMARD-stop was not reported). X indicates moderate-quality studies.
DMARD: Disease-modifying antirheumatic drugs, DFR: DMARD-free remission, SDFR: sustained 
DMARD-free remission.
Prevalence of DMARD-free remission 
In the 5 high-quality clinical trials, the reported prevalence of DFR (DFR <12 months) 
ranged from 5.0% to 24.3% (relative to the number of patients eligible for tapering). 
The 2 moderate-quality studies reported a DFR-prevalence of 5.9% respectively 
21.9% (table 2, figure 2). When studies allowed GCs while being in DFR were excluded, 
DFR occurred in 5.0%-23.0%. SDFR (DFR >12 months) was only reported in 2 clinical 
trials, and showed a prevalence of 11.6% and 19.4% (relative to patients eligible for 
tapering). 
Evaluation of DFR-prevalence, in high and moderate-quality studies, in relation 
to the trial ‘settings’ was hampered by the fact that only 1 study was performed in 
established RA where DMARDs were tapered after prolonged remission[20], revealing 
a DFR-prevalence of 5.9% compared to the prevalence of 5.0%-24.3% in studies that 
tapered DMARDs in early RA.[13-17, 27]
DMARD treatment DMARD-free status Sustained DMARD-free remissionTapering
tREACH                   41.8% (34-50%)
ACT-RAY*                42.4% (38-47%)
El Miedany et al.   75.0% (58-87%)
BeSt*             10.4% (8-13%)
DREAM cohort*  11.8% (8-17%)
Leiden EAC   0.3% (0.1-1%)
IMPROVED  3.5% (2-6%)
Flares during tapering Early flares
(≤ 12m a�er achieving DMARD-free status)
Late flares 









ACT-RAY*   5.9% (4-8%) tREACH                 5.0% (2-10%)
AVERT            18.4% (14-24%)
BeSt*            22.6% (19-26%)
DREAM cohort*  23.6% (19-30%)
U-Act-Early*        24.3% (20-29%)
El Miedany et al.   21.9% (11-39%)
IMPROVED             23.0% (19-27%)
BeSt*            11.6% (9-15%)
DREAM cohort*  11.8% (8-17%)
Leiden EAC           17.8% (15-20%














Early flares (≤12 months after DMARD-stop) were reported in one high-quality study 
and occurred in 10.4% of patients eligible for tapering. Late flares (>12 months after 




Patients included in the observational cohorts were diagnosed between 1986-2011 
(n=5). Patients in the observational cohorts were, compared to clinical trials, included 
in an earlier time period, but had a longer follow-up. Diagnosis was based on the 
1987-criteria,[28-30] or expert opinion.[31, 32] Treatment was less protocolized 
compared to the clinical trials and a treat-to-target approach was only used in three 
studies,[28, 29, 31] of which two had a high quality (table 2). 
DMARD tapering 
Eligibility for tapering was only clearly reported in 1 study.[31]
Definitions of DMARD-free remission 
Remission within DFR was defined as the absence of clinical synovitis (table 2), except 
for 1 study that used a DAS28 cutoff (DAS28<2.6).[31] All 5 observational cohorts 
reported on SDFR (DFR>12 months), whereas 1 also reported on DFR after 6 months. 
In two studies, of which 1 high-quality study, i.a. and oral glucocorticoid were allowed 
while being in DFR; the actual use was not reported. 
Prevalence of DMARD-free remission 
DFR prevalence (<12 months) was 23.6% of patients eligible for tapering, and was 
reported in one high-quality study.[31] The prevalence of SDFR ranged from 11.8%-
17.8% (relative to patients eligible for tapering)(table 2, figure 2)[28, 31] If we exclude 
the studies that allowed GCs during DFR, one high-quality study remained with a 
SDFR-prevalence of 17.8%.[28] We did not compare DFR-prevalence between studies 
that did and did not apply a treat-to-target approach, because all studies without a 
treat-to-target approach were of low-quality. 
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Early flares (≤12 months after DMARD-stop) were reported in one high-quality study 
and occurred in 11.8% of patients eligible for tapering. Late flares were reported by 
the other high-quality study and were seen in 0.3% of patients eligible for tapering 
(table 2). 
Predictors of DFR
All factors that were analyzed for their potential association with achieving DFR 
were evaluated (supplementary table S6). Due to heterogeneity in evaluated effect 
estimates, effect sizes could not be compared and meta-analyses not performed. For 
predictors that were studied in more than one high or moderate-quality study the 
association with achieving DFR was summarized in figure 3 (see also supplementary 
table S7). The figure includes information on the number of studies with/without an 
association, the total number of patients in these studies, and the directionality of 
the effect (if present). The absence of autoantibodies and HLA shared epitope alleles 
were predictive for achieving DFR. Many patient characteristics (e.g. age, BMI, SJC, ESR, 
erosions at baseline) were not associated with the chance of achieving DFR. For some 
characteristics findings were inconsistent. Results on symptom duration, for example, 
showed ambiguous results (supplementary table S6/7). 
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Figure 3 Overview of studied predictors of achieving DMARD-free remission. Data are presented 
from variables that were reported in >1 study, based on statistical significance obtained in 
regression analysis. If both univariable and multivariable regression was applied, the result of 
the multivariable regression was used. Presented are the absence (left panel) and presence of 
an association with achieving DFR over time (right panel), the number of studies are indicated 
per predictor, the total number of patients in these studies is plotted on the x-axis. The 
directionality of the effect is indicated in colours, green indicates an increased risk of achieving 
DFR, red indicates a decreased risk of achieving DFR. For symptom duration no differentiation 
was made for analyses using this as continuous or categorical variable. BMI: Body Mass Index, 
DAS: Disease Activity Score, SJC: Swollen Joint Count, HAQ: Health Assessment Questionnaire, 
ESR: Estimated Sedimentation Rate, CRP: C-Reactive Protein, RF: Rheumatoid Factor




This systematic literature review was conducted in accordance with PRISMA guidelines 
and provides insight in the occurrence and sustainability of DFR in RA. The prevalence 
of DFR (DFR ≤12 months) was 5.0%-24.3%[14-17, 27], while SDFR (DFR >12 months) 
was achievable in 11.6%-19.4% of patients eligible for tapering. 
Remission criteria used to define DFR varied widely, and the temporal aspect 
(sustainability) varied as well or was not reported. Moreover, in some studies 
concomitant use of glucocorticoids was allowed while patients were in DFR. This 
might falsely inflate DFR-prevalence, but to what extend this occurred is unclear as 
actual use was not reported. Exclusion of aforementioned studies did not affect our 
results. To increase homogeneity, quality criteria were used, and final conclusions 
were only based on high and moderate-quality studies, which resulted in a narrative 
overview of DFR prevalence (figure 2).
We observed different DFR prevalence depending on the duration of the DFR period. 
To allow fair comparison of DFR-prevalence we categorized the duration of DFR in 
groups. SDFR was defined as a DMARD-free period >12 months. Higher prevalence 
were observed when DFR had a less stringent criterion for sustainability (figure 2). In 
line with this, flares occurred most often during tapering and in the first months after 
DMARD-stop. This time-effect underlines the relevance of defining sustainability of 
DFR in future studies. 
DFR and SDFR might be fundamentally different. Short-term DFR might indicate 
that disease activity was suppressed, but not necessarily resolved, and could revive 
after disappearance of suppressive treatment. Moreover, early flares (≤12 months 
after DFR) occur more often than late flares (>12 months after DFR), which might 
indicate that auto-immunity was not completely silenced. In our opinion, patients in 
SDFR (DFR >12 months) better resemblance silencing of autoimmunity and may have 
achieved a proxy for cure. Therefore, SDFR can become an important outcome for 
clinical trials. Because, late flares (often occurring years after DMARD-stop) might be 
pathophysiological different from early flares; it is an interesting subject for future 
studies to explore the triggers or pathophysiologic mechanisms involved in late 
reactivation of the auto-immune process. 
Notably, despite differences in study design, the DFR-prevalence observed in 
observational cohorts and clinical trials were comparable. This supports the 
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robustness of the observed frequencies. We were unable to investigate how long 
remission should be sustained before tapering can be initiated, because too few 
high-quality studies were performed in patients with established RA and longstanding 
remission. Additionally, due to an insufficient amount of studies, nothing can be said 
about the change of achieving DFR after treatment with certain conventional or 
biologic DMARDs. 
We could not evaluate whether the method of tapering influenced the frequency of 
SDFR. It has been suggested that gradual tapering results in less flares compared 
to abrupt cessation.[2] Also the stringency of the remission criterion for initiation of 
tapering might be of influence, whereby less stringent criteria might increase the risk 
of flares. Evaluation of the methods of DMARD-tapering was beyond the scope of 
this review, and a relevant subject for further studies as insight in the most effective 
tapering method may positively influence the chance to achieve SDFR. Another 
issue for further studies is the assessment of the likelihood to achieve remission for 
patients that flare after having been in DFR. From studies on patients that flared during 
tapering it is known that the majority of patients achieve remission by restarting the 
same DMARD.[33] Whether this is similar for patients that flare after DMARD-stop is 
not yet systematically studied.
Studying the prevalence of DFR and predictors for DFR does not answer the question 
whether the absence of clinical signs and symptoms without treatment exhibited the 
natural course of RA in these patients[34], or was induced by DMARD-treatment. This 
could not be answered within our SLR, nor could we compare studies for treatment 
intensity (e.g. reflected by treat-to-target) due to the lack of high-quality studies 
without a treat-to-target approach. One high-quality study compared a treat-to-target 
approach that aimed for a DAS<1.6 with an approach that aimed for a DAS<2.4, and 
reported that patients achieved DFR more often when aimed for a DAS<1.6 (18% 
versus 8%, respectively), suggesting that intensive treatment is helpful in inducing 
DFR.[35] However, the clinical trials rarely used DFR as a primary outcome and, 
therefore, the question to what extent the frequency of DFR can be achieved by 
treatment remains a subject for future studies. 
Although we tried to find predictors for DFR, it remains uncertain which patients 
are able to stop their DMARDs successfully. Meta-analyses could not be performed 
due to the heterogeneity of studies and effect estimates. Therefore, we summarized 
and graphically presented data on predictors using predefined criteria, but this 
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methodology is far less optimal than meta-analysis. Several patients characteristics 
(e.g. age, SJC, ESR and erosiveness) were not associated with a higher chance 
of achieving DFR. Results on symptom duration were conflicting, as the relation 
between DFR and symptom duration was non-significant, but showed a strong 
tendency towards significance in part of the studies. Furthermore it is known that 
the association with DFR is not linear but refined to a short period of time[32] (i.e. 
the window-of-opportunity) and associations may remain undetected if symptom 
duration is analyzed as a continuous variable. Absence of auto-antibodies was the 
best predictor for DFR. Although effect sizes were not involved in our analyses, 
absence of auto-antibodies alone is not sufficient to accurately guide taper-decisions 
in daily practice. Therefore, effective pursuit of SDFR in clinical practice requires more 
insight in subsets of patient that are likely to achieve SDFR.
Acknowledging the importance of the auto-antibody status as predictor, the SDFR 
prevalence will be different for auto-antibody positive and negative patients. We 
could not stratify the results on SDFR prevalence for autoantibody status as the 
prevalence reported in the included cohorts and trials was not always stratified for 
auto-antibodies. However, the studies that included information on autoantibody 
status in their patient characteristics reported that 52-100% of patients were auto-
antibody positive(supplementary table S5). 
Since conducting a thorough systematic literature review is time-demanding, a 
time-gap exist between the actual literature search (March 2019) and publication 
of the results. As a result, relevant articles in this time interval are not included. A 
non-systematic screen of articles published in this period revealed that the BioRRA-
study[36], published in December 2019. This study focusing on predictors of flare 
after DMARD-cessation and reported a 52% flare rate (DAS28-CRP≥2.4) after abrupt 
DMARD-cessation. Predictive of flares were amongst others absence of Boolean 
remission at baseline, RF-positivity and IL-27. Biomarkers predictive of DFR, as 
identified in other recent studies, were calprotectin levels and several serum protein 
levels among which SAA. [37, 38] Calprotectin and SAA are both acute phase reactants. 
However none of these markers were yet validated in independent studies. 
From patients’ perspective achieving SDFR is beneficial; it was recently reported to be 
associated with normalization of functional disability and resolution of symptoms, e.g. 
fatigue.[28] Unfortunately, clinical trials infrequently evaluated SDFR. If future trials 
would be designed with DFR/SDFR as primary outcome, consensus of the definition of 
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remission and the duration of DMARD-free state is required to promote comparability 
of findings between studies. This may require OMERACT initiatives. 
In conclusion, DFR is achievable in RA, and is sustainable in ~10%-20% of patients. 
DFR can become an important outcome measure for clinical trials, and requires 
consistency in the definition. Considering the relative short follow-up after DMARD-
stop in current clinical trials and the high rate of flares in the first year after DMARD-
stop, we propose to incorporate a DMARD-free follow-up of at least 1 year, to ensure 
that DFR is sustainable. 
Supplementary table S1 – Search strategy
((”disease modifying anti rheumatic”[tw] OR ”disease modifying anti rheumatoid”[tw] OR ”disease 
modifying antirheumatic”[tw] OR ”disease modifying antirheumatoid”[tw] OR ”DMARD”[tw] OR 
”DMARDs”[tw] OR ”bDMARD”[tw] OR ”bDMARDs”[tw] OR ”cDMARD”[tw] OR ”cDMARDs”[tw] OR 
”csDMARD”[tw] OR ”csDMARDs”[tw] OR ”Antirheumatic Agents”[Mesh:noexp] OR ”Antirheumatic 
Agents”[Pharmacological Action] OR ”1-((4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-
methylpiperazine”[tw] OR ”1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)
pyrazole”[tw] OR ”1-(4-chlorobenzoyl)-3-(2-(1H-imidazol-1-yl)-2-oxoethyl)-5-methoxy-2-methyl-1H-
indole”[tw] OR ”2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid”[tw] OR 
”2-(4-acetoxyphenyl)-2-chloro-N-methylethylamine”[tw] OR ”2-aminomethyl-4-t-butyl-6-iodophenol”[tw] 
OR ”2-diethylaminoethanol”[tw] OR ”3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid”[tw] OR ”4,5-Dihydro-
1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine”[tw] OR ”4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-
pyrazol-1-yl)benzenesulfonamide”[tw] OR ”4-(acetylamino)benzeneacetic acid”[tw] OR ”4-bromo-2,7-
dimethoxy-3H-phenothiazin-3-one”[tw] OR ”6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)
thiazole”[tw] OR ”6-acetylaminocaproic acid”[tw] OR ”6-ethoxy-3-(4-methanesulfonylphenyl)-4-
phenylpyran-2-one”[tw] OR ”7-methoxy-alpha-methyl-2-naphthaleneacetic acid”[tw] OR ”A 771726”[tw] 
OR ”Abatacept”[tw] OR ”aceclofenac”[tw] OR ”acemetacin”[tw] OR ”acetaminophen, aspirin, caffeine 
drug combination”[tw] OR ”acetaminophen, butalbital, caffeine drug combination”[tw] OR 
”acetaminophen, hydrocodone drug combination”[tw] OR ”acetosyringone”[tw] OR ”acetovanillone”[tw] 
OR ”acetylsalicylic acid lysinate”[tw] OR ”Adalimumab”[tw] OR ”Adapalene”[tw] OR ”Adapalene, Benzoyl 
Peroxide Drug Combination”[tw] OR ”alclofenac”[tw] OR ”Allopurinol”[tw] OR ”alminoprofen”[tw] OR 
”alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol”[tw] OR ”amiprilose”[tw] OR ”Ampyrone”[tw] OR 
”amylase, phosphates, proteases drug combinations”[tw] OR ”andrographolide”[tw] OR 
”anisodamine”[tw] OR ”anisodine”[tw] OR ”antiflammin P2”[tw] OR ”Antipyrine”[tw] OR ”Apazone”[tw] OR 
”apremilast”[tw] OR ”Arteparon”[tw] OR ”Arthrotec”[tw] OR ”Aspirin”[tw] OR ”aspirin, aluminum 
hydroxide, magnesium hydroxide drug combination”[tw] OR ”aspirin, butalbital and caffeine drug 
combination”[tw] OR ”aspirin, meprobamate drug combination”[tw] OR ”atrinositol”[tw] OR 
”Auranofin”[tw] OR ”Aurothioglucose”[tw] OR ”aurotioprol”[tw] OR ”Azathioprine”[tw] OR ”azulene”[tw] 
OR ”baicalin”[tw] OR ”balsalazide”[tw] OR ”bendazac”[tw] OR ”bendazac lysine”[tw] OR ”benorilate”[tw] 
OR ”benoxaprofen”[tw] OR ”Benzbromarone”[tw] OR ”benziodarone”[tw] OR ”benzobarbital”[tw] OR 
”berbamine”[tw] OR ”betulinic acid”[tw] OR ”bevonium”[tw] OR ”BI 607812 BS”[tw] OR ”biphenylylacetic 
acid”[tw] OR ”boldine”[tw] OR ”borage oil”[tw] OR ”boswellic acid”[tw] OR ”bromfenac”[tw] OR 
”bucillamine”[tw] OR ”Bufexamac”[tw] OR ”bumadizone”[tw] OR ”butibufen”[tw] OR ”carbaspirin 
calcium”[tw] OR ”carprofen”[tw] OR ”caryophyllene”[tw] OR ”castanospermine”[tw] OR ”CDP 571”[tw] OR 
”Celecoxib”[tw] OR ”cepharanthine”[tw] OR ”Certolizumab Pegol”[tw] OR ”Chloroquine”[tw] OR 
”chloroquine diphosphate”[tw] OR ”choline magnesium trisalicylate”[tw] OR ”chrysarobin”[tw] OR 
”Clonixin”[tw] OR ”Colchicine”[tw] OR ”CP 96345”[tw] OR ”Curcumin”[tw] OR ”CX 659S”[tw] OR 
”Cyclophosphamide”[tw] OR ”Cyclosporine”[tw] OR ”DAB(486)-interleukin 2”[tw] OR ”dauricine”[tw] OR 
”dexketoprofen trometamol”[tw] OR ”Diclofenac”[tw] OR ”diclofenac hydroxyethylpyrrolidine”[tw] OR 
”difenpiramide”[tw] OR ”Diflunisal”[tw] OR ”dimephosphon”[tw] OR ”Dipyrone”[tw] OR ”diucifon”[tw] OR 
”droxicam”[tw] OR ”DuP 697”[tw] OR ”E6011”[tw] OR ”ebselen”[tw] OR ”ecallantide”[tw] OR ”eltenac”[tw] 
OR ”enfenamic acid”[tw] OR ”enkephalin-Leu, Ala(2)-Arg(6)-”[tw] OR ”Epirizole”[tw] OR ”Etanercept”[tw] 
OR ”ethenzamide”[tw] OR ”Ethonium”[tw] OR ”Etodolac”[tw] OR ”etofenamate”[tw] OR ”Etoricoxib”[tw] 
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OR ”evening primrose oil”[tw] OR ”Febuxostat”[tw] OR ”fenamic acid”[tw] OR ”fenbufen”[tw] OR 
”fenclofenac”[tw] OR ”fenflumizole”[tw] OR ”Fenoprofen”[tw] OR ”fentiazac”[tw] OR ”fepradinol”[tw] OR 
”Feprazone”[tw] OR ”ferulic acid”[tw] OR ”flobufen”[tw] OR ”floctafenine”[tw] OR ”flosulide”[tw] OR 
”flunixin”[tw] OR ”flunixin meglumine”[tw] OR ”flunoxaprofen”[tw] OR ”fluproquazone”[tw] OR 
”Flurbiprofen”[tw] OR ”flurbiprofen axetil”[tw] OR ”FR 167653”[tw] OR ”FR 173657”[tw] OR ”Glatiramer 
Acetate”[tw] OR ”glucametacin”[tw] OR ”Gold Sodium Thiomalate”[tw] OR ”Gold Sodium Thiosulfate”[tw] 
OR ”guacetisal”[tw] OR ”Halofenate”[tw] OR ”helenalin”[tw] OR ”heliodermin”[tw] OR ”hemodes”[tw] OR 
”higenamine”[tw] OR ”Hydroxychloroquine”[tw] OR ”Ibuprofen”[tw] OR ”ibuproxam”[tw] OR 
”icatibant”[tw] OR ”IH 764-3”[tw] OR ”imidazole-2-hydroxybenzoate”[tw] OR ”indacrinone”[tw] OR 
”indobufen”[tw] OR ”Indomethacin”[tw] OR ”Indoprofen”[tw] OR ”Infliximab”[tw] OR ”Interleukin 1 
Receptor Antagonist Protein”[tw] OR ”Interleukin-4”[tw] OR ”iodoantipyrine”[tw] OR ”isoxicam”[tw] OR 
”kebuzone”[tw] OR ”Ketoprofen”[tw] OR ”ketoprofen lysine”[tw] OR ”Ketorolac”[tw] OR ”Ketorolac 
Tromethamine”[tw] OR ”L 745337”[tw] OR ”L 778736”[tw] OR ”lesinurad”[tw] OR ”Levamisole”[tw] OR 
”licofelone”[tw] OR ”lipoxin A4”[tw] OR ”lipoxin B4”[tw] OR ”lisofylline”[tw] OR ”lobenzarit”[tw] OR 
”lonazolac”[tw] OR ”lornoxicam”[tw] OR ”loxoprofen”[tw] OR ”LQFM-091”[tw] OR ”lumiracoxib”[tw] OR 
”Magnesium Salicylate”[tw] OR ”magnolol”[tw] OR ”manoalide”[tw] OR ”Masoprocol”[tw] OR 
”mavrilimumab”[tw] OR ”Meclofenamic Acid”[tw] OR ”Mefenamic Acid”[tw] OR ”Meloxicam”[tw] OR 
”Mesalamine”[tw] OR ”Methotrexate”[tw] OR ”methyl salicylate”[tw] OR ”mizoribine”[tw] OR ”MK 473”[tw] 
OR ”mofebutazone”[tw] OR ”mofezolac”[tw] OR ”N-(2-cyclohexyloxy-4-nitrophenyl)
methanesulfonamide”[tw] OR ”N-(9H-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine”[tw] OR 
”N-succinimidyl-1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetate”[tw] OR 
”Nabumetone”[tw] OR ”nafamostat”[tw] OR ”Naproxen”[tw] OR ”Nebacetin”[tw] OR ”nepafenac”[tw] OR 
”nifenazone”[tw] OR ”Niflumic Acid”[tw] OR ”nimesulide”[tw] OR ”nitroaspirin”[tw] OR ”Olopatadine 
Hydrochloride”[tw] OR ”olsalazine”[tw] OR ”olvanil”[tw] OR ”oren gedoku to”[tw] OR ”orgotein”[tw] OR 
”oxaceprol”[tw] OR ”Oxaprozin”[tw] OR ”Oxyphenbutazone”[tw] OR ”palmidrol”[tw] OR ”parecoxib”[tw] 
OR ”parthenolide”[tw] OR ”Penicillamine”[tw] OR ”peoniflorin”[tw] OR ”phenidone”[tw] OR 
”Phenylbutazone”[tw] OR ”pimecrolimus”[tw] OR ”pirfenidone”[tw] OR ”Piroxicam”[tw] OR ”piroxicam-
beta-cyclodextrin”[tw] OR ”pirprofen”[tw] OR ”Probenecid”[tw] OR ”proglumetacin”[tw] OR 
”propacetamol”[tw] OR ”propionylcarnitine”[tw] OR ”propyphenazone”[tw] OR ”proquazone”[tw] OR 
”Prospidium”[tw] OR ”pyranoprofen”[tw] OR ”pyrazolone”[tw] OR ”pyrogenal”[tw] OR ”rasburicase”[tw] 
OR ”Resveratrol”[tw] OR ”rifamycin SV”[tw] OR ”Rituximab”[tw] OR ”RNS60”[tw] OR ”rofecoxib”[tw] OR 
”rosmarinic acid”[tw] OR ”Rumalon”[tw] OR ”saiko-keishi-to”[tw] OR ”saikosaponin”[tw] OR ”salicin”[tw] 
OR ”salicylamide”[tw] OR ”Salicylates”[tw] OR ”salicylsalicylic acid”[tw] OR ”SB 203580”[tw] OR ”SC 
299”[tw] OR ”SC 41930”[tw] OR ”SC 560”[tw] OR ”semapimod”[tw] OR ”seratrodast”[tw] OR 
”serratiopeptidase”[tw] OR ”shikonin”[tw] OR ”sinapaldehyde”[tw] OR ”sinomenine”[tw] OR ”Sodium 
Salicylate”[tw] OR ”ST 679”[tw] OR ”Sul-121”[tw] OR ”Sulfasalazine”[tw] OR ”Sulfinpyrazone”[tw] OR 
”Sulindac”[tw] OR ”sulindac sulfide”[tw] OR ”sulindac sulfone”[tw] OR ”Suprofen”[tw] OR ”suxibuzone”[tw] 
OR ”T0001”[tw] OR ”tanshinone”[tw] OR ”taxifolin”[tw] OR ”tenidap”[tw] OR ”tenoxicam”[tw] OR 
”tepoxalin”[tw] OR ”tiaprofenic acid”[tw] OR ”tiaramide”[tw] OR ”Ticrynafen”[tw] OR ”tinoridine”[tw] OR 
”tisopurine”[tw] OR ”tolfenamic acid”[tw] OR ”Tolmetin”[tw] OR ”tramadol, dexketoprofen drug 
combination”[tw] OR ”tranilast”[tw] OR ”traxanox”[tw] OR ”tribenoside”[tw] OR ”upadacitinib”[tw] OR 
”ursolic acid”[tw] OR ”valdecoxib”[tw] OR ”verinurad”[tw] OR ”zileuton”[tw] OR ”zomepirac”[tw] OR 
”Zoxazolamine”[tw]) AND (”drug free remission”[tw] OR ”drug free remissions”[tw] OR ”drug free clinical 
remission”[tw] OR ”drug free disease remission”[tw] OR ”DMARD-free remission”[tw] OR ((”drug 
free”[tw] OR ”DMARD free”[tw]) AND (”remission”[tw] OR remiss*[tw] OR ”Remission Induction”[mesh])) 
OR ”stable remission”[tw] OR ”stable remissions”[tw] OR ”stable disease remission”[tw] OR ”sustained 
remission”[tw] OR ”sustained remissions”[tw] OR ”sustained disease remission”[tw] OR ”sustained 
disease remissions”[tw] OR ”stable clinical remission”[tw] OR ”sustained clinical remission”[tw] OR 
”sustained clinical remissions”[tw] OR ”sustained complete remission”[tw] OR ”sustained complete 
remissions”[tw] OR ”stable complete remission”[tw] OR ”stable complete remissions”[tw] OR ((”stable”[ti] 
OR ”sustained”[ti]) AND (”remission”[ti] OR remiss*[ti] OR ”Remission Induction”[mesh])) OR ((”drug 
tapering”[tw] OR ”drug taper”[tw] OR ”treatment tapering”[tw] OR ”medication taper”[tw] OR 
”medication tapering”[tw] OR ”tapering”[tw] OR ”taper”[tw] OR ”drug discontinuation”[tw] OR ”treatment 
discontinuation”[tw] OR ”discontinuation”[tw] OR ”cessation”[tw]) AND (”remission”[tw] OR remiss*[tw] 
OR ”Remission Induction”[mesh]))) AND (”Arthritis, Rheumatoid”[Mesh:noexp]  OR ”rheumatoid 
arthritis”[tw] OR (rheumatoid*[tw] AND arthriti*[tw]))) NOT ((“Case Reports”[ptyp] OR “case report”[ti] 




Supplementary table S2 – In- and exclusion criteria study selection
Inclusion criteria
(1) Study designs which will be included are all observational studies, including cross-sec-
tional, case-control, prospective and retrospective cohort studies, and intervention 
studies, controlled and uncontrolled.
(2) Patients with rheumatoid arthritis will be included, in which patients should meet the 
ACR/EULAR 1987 and/or 2010 criteria for RA or RA should been diagnosed by a Rheuma-
tologist (expert opinion).
(3) The study should clearly report on DMARD-free remission, i.e. complete discontinua-
tion of all DMARDs, including glucocorticoids is required. The study should report clearly 
on 
tapering and complete discontinuation of all DMARDs until eventually a complete 
DMARD-free state will be achieved.
(5) Only studies in English, and Dutch, with available full text will be included.
(6) Only studies with full paper articles available will be included.
(7) All years of publication will be included.
Exclusion criteria
(1) Case-report studies and reviews will be excluded. Reviews were screened for (extra) 
eligible studies.
(2) Studies focussing on disease other than rheumatoid arthritis (also unspecified ar-
thritis) will be excluded. However, studies focussing on other disease next to RA can be 
included from which the RA data will only be extracted
(3) Studies in which the use of not all DMARDs are tapered and completely discontinued. 
Studies which do not clearly describe if all DMARDs are completely stopped, i.e. no trans-
parency of the DMARD-free state, will also be excluded.
(4) Studies should focussing on other reasons for tapering and discontinuation of DMARD 
then remission, e.g. adverse events, retention etc. will be excluded.
Legend: In- and exclusion criteria used for study selection. ACR: American College of Rheumatology, 
EULAR: European League Against Rheumatism, RA: Rheumatoid arthritis, DMARD: Disease 
-modifying antirheumatic drug.








Study design: clinical trial/observational










Baseline characteristics (patient characteristics)
Primary outcome
Secondary outcomes
Intervention (arms) (if applicable)
Medication prescribed during study








DFR definition specified (y/n)
DFR criteria used
DFR duration reported









Legend: Data extraction form used for systematic data-extraction Data extraction forms were 
fulfilled independently by two reviewers (MV and EvM), disagreements were discussed until 




Supplementary table S4 – Risk assessment tool
QUALITY ASSESSMENT
DMARD-free remission (+) (-) (?)
1. DFR definition 
(description of DFR criteria/definition)
2. DFR duration 
(description of period between DMARD-stop and being appoint as DFR)
General study quality (+) (-) (?)
Study population
1. Selection of patients
(description of in-/exclusion criteria)
2. Criteria used for RA diagnosis
3. Baseline characteristics study population 
(description of characteristics)
Randomization
4. Randomization for different study treatments
Blinding (combined score)
5.1. Blinding outcome assessors
5.2. Blinding patients
Interventions
6. Treatment strategies 
(description of strategies)
7. Cut-off point tapering 
(description of cut-off point)
8. Tapering methods 
(description of methods)
Follow-Up
9. Organisation of follow-up 
(frequency of monitoring)
10. Lost-to-follow-up
Analysis & Data presentation
11. Outcome reporting
12. Analysis techniques 
(description of techniques)
13. Missing data
(handling of missing data described)
Legend: DMARD: Disease-modifying antirheumatic drug, DFR: DMARD-free remission, RA: 
Rheumatoid arthritis. 




























































































































































































































































































































































































































































   
   
   
   
   














   
   
   
   
   


















































































































































































































































































   
   
   
























































































































































































































































































































   
   
   
   
   



















   
   
   
   
   




















   
   
   
   
   










































































































































































































































































































   
   
   
   
































   
   
   
   












































































































































   
   
   
   

































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   

















   
   
   
   
















   
   
   
   

















   
   
   
   

































































































































   
   
   
   











































































































































   
   
   




























































































































































































































































































   
   
   
   




















   
   
   
   































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   




















   
   
   

















   
   
   
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table S6 – All predictors of DFR retrieved from the literature
CLINICAL BIOMARKERS
O Age 




age and DFR have been reported 
within the included articles
v.d. Woude et al. (2009)
 (LEAC, n=454)C
HR 1.02(0.99-1.03)
Kuijper et al. (2016)(tREACH, n=281)L
OR 0.995(CI not specified)
v.d. Woude et al. (2012) 
(LEAC, n=424) L
OR 1.02(0.998-1.04) 
v.d. Woude et al. (2009)
 (ERAS, n=895) C
HR 1.00(0.98-1.01)




v.d. Kooij et al. (2009) (BeSt, n=508)B
nDFR 54y, DFR 56y 
Ajeganova et al. (2016)(LEAC, n=886)
nDFR 57.4y, DFR 56.3y B
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
O Gender 
v.d. Woude et al. (2009)
(LEAC, n=454)C
Female: HR 1.28(0.74-2.19)
Kuijper et al. (2016)(tREACH, n=281)L
Female: OR 0.352* M  (CI not specified)
↑
v.d. Woude et al. (2009) 
(ERAS, n=895)C
Female: HR 0.78(0.50-1.2)
v.d. Woude et al. (2012) (BeSt, n=508) L
Male: OR 2.39(1.26-4.53)* M
↑
de Rooy et al. (2011)(LEAC) L
Female, OR 0.85 90.50-1.45)
 (not achieving DFR)
v.d. Kooij et al. (2008)(BeSt) L
Male:DFR 52% vs nDFR 29%*M
(OR not specified)
↑
v.d. Woude et al. (2012) 
(LEAC, n=424)L
Female, OR 1.19(0.62-2.28)
Nishimoto et al. (2014)
(DREAM, n=187)C




Ajeganova et al.(2016)(LEAC, n=886)B
Female: nDFR63%, DFR 68%
Emery et al. (2018)(PRIZE, n=65)L
Male (no estimates specified)
O BMI 
v.d. Woude et al. (2012) 
(LEAC, n=424)L
OR 0.95(0.83-1.08)
de Rooy et al. (2011)(LEAC) L
OR 1.11(1.01-1.23)*,U (not achieving DFR)
↓
v.d. Woude et al. (2012) 
(BeSt, n=508)L
O R0.96(0.88-1.04)




v.d. Woude et al. (2012)
 (BeSt, n=508)L
OR 0.69(0.36-1.33)
v.d. Woude et al. (2009) (LEAC, n=454)C
HR 0.56(0.34-0.94)* U
↓
v.d. Woude et al. (2009) 
(ERAS, n=895)C
HR 0.54(0.29-1.02)
v.d. Woude et al (2012) (LEAC, n=424) L
OR 0.48(0.25-0.93)*U
↓
Ajeganova et al. (2016)(LEAC, n=886)
Smoking ever: nDFR 54%, DFR 56% B
O Family history of RA 
v.d. Woude et al. (2009)
(LEAC, n=454)C
HR 0.55(0.30-1.04)
de Rooy et al. (2011) (LEAC, n=676) L
OR 2.27(1.18-4.36)* U (not achieving DFR)
↓




v.d. Woude et al. (2009)
 (LEAC, n=454) C
Absence comorbidities  
HR 0.98(0.59-1.61)
Kuijper et al. (2016)(tREACH, n=281) L
Dutch ethnicity OR 3.316U 
(CI not specified)
Kuijper et al. (2016)(tREACH, n=281) L
Paid work: OR 0.438* M (CI not specified)
↓




O       (shorter) Symptom duration 
v.d. Woude et al. (2012)(BeSt, n=508) 
(cont) C
O R0.99(0.98-1.00) (cont. in weeks)
v.d. Linden et al. (2010) (LEAC, n=598) C
≥12w symptoms vs <12w
HR 1.90* M  (1.18 - 3.05)(not achieving DFR)
↑
Kuijper et al. (2016)(tREACH, n=281) L
OR 1.00 (CI not specified) (measure symp 
duration not specified)




Akdemir et al. (2018)
(BeSt/IMPROVED, n=133/175)L
OR 0.98 (0.97-1.00) 
(continuous in weeks)
v.d. Woude et al. (2009) (LEAC, n=454) C
HR 0.94(0.88-0.99)* U 
(continuous in months)
↑
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)







Disease duration (<7.8y vs >7.8y
(median)) HR 0.81(0.60-1.00)
de Rooy et al. (2011)(LEAC, n=676) L
OR 1.02(1.01-1.03)* L, U
 (continuous in weeks)
(not achieving DFR)
↑
v.d. Woude et al. (2012) (LEAC, n=424) L
OR0.98(0.96-0.99)* U (cont. in weeks)
↑
Ajeganova et al. (2016)(LEAC, n=886) B
nDFR:4.7(2.4-8.6), DFR:2.9




 at baseline 
Akdemir et al. (2018)
(BeSt/IMPROVED, n=133/175)L
OR 0.94(0.58-1.53)
Only IMPROVED data selected for figure
v.d. Woude et al. (2012)(BeSt. N=508) L
OR 0.63(0.43-0.94)* M
↓
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
Kuijper et al. (2016)(tREACH, n=281) L
OR 0.587* M (CI not specified)
↓
v.d. Woude et al. (2009) (ERAS, n=895) C
HR 0.65**(0.55-0.76) U
↓
v.d. Kooij et al. (2008)(BeSt, n=508) B
nDFR 4.5 vs. DFR 4.1*
↓
Nishimoto et al. (2014)(DREAM, n=187) C
HR 0.59 (0.44-0.81) U
↓
O
Swollen Joint Count 
at baseline 
v.d. Woude et al. (2009)
 (LEAC, n=454)C – 44-SJC
HR 1.00(0.96-1.04)
v.d. Woude et al. (2009)
(ERAS, n=895) – 44-SJC
HR 0.97*(0.95-0.99) C,M
↓
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v.d. Woude et al. (2012)(BeSt, n=508)L
OR 1.01(0.97-1.06)
v.d. Woude et al. (2012)
(LEAC, n=424)L
OR 0.99(0.94-1.04)
de Rooy et al. (2011)(LEAC, n=676)L
OR 0.99(0.96-1.02)(not achieving DFR)
Ajeganova et al. (2016)
(LEAC, n=886)B – 66-SJC
nDFR 8(4-15), DFR 8(4-13)
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
O
Tender Joint Count 
at baseline 
Ajeganova et al. (2016)
(LEAC, n=886)B – 68-TJC
nDFR 7(5-11), DFR 8(5-11)
v.d. Woude et al. (2009) 
(ERAS, n=895) - RAI C
HR 0.92**(0.88-0.97) M
↓
O Morning stiffness 
v. Nies et al. (2015)(LEAC, n=807)C
HR 0.85(0.65-1.11)
v.d. Kooij et al. (2008)(BeSt, n=508)B
VAS morning stiffness: nDFR 60(24) vs DFR 
54(24)* 
↓
v. Nies et al. (2015)(ESPOIR, n=353)C
HR 0.80(0.50-1.29)
de Rooy et al (2011)(LEAC, n=676)L
OR 1.00(0.99-1.01) (not achieving DFR)
Ajeganova et al. (2016)(LEAC, n=886)B
Morning stiffness VAS: nDFR 64(36-81), 
DFR 57(36-76) 
O Miscellaneous 
v.d. Woude et al. (2009)
(LEAC, n=454)C
Acute onset  HR1.55(0.94-2.56)
Onset in small joints  HR1.48(0.91-2.40)
Onset symmetrical symptoms  
HR1.24(0.72-2.14)
v.d. Woude et al. (2009) 
(ERAS, n=895) - Acute onset symp C
HR 2.03*(1.15-3.59) M
v.d. Woude et al. (2009) 
(ERAS, n=895) C
Start small joints  HR1.27(0.80-2.04)
Start symm sympt 1.18(0.67-2.07)
Burgers et al. (2018)(LEAC) C
LJI HR1.4(1.0-2.0)* M
↑
de Rooy et al. (2011) (LEAC, n=676)L
 Chronic vs acute OR1.55(0.93-2.59)
↑
Small vs Large joints
OR 0.66(0.34-1.28)
Upper vs lower extremitites





Upper and lower vs lower extremities OR 
1.01(0.47-2.26)
Symm vs asymm symptoms 
OR 0.89(0.51-1.55)
O HAQ 
v.d. Woude et al. (2009)
(LEAC, n=454)C - m-HAQ 
HR 1.06(0.74-1.52)
v.d. Woude et al. (2012) (BeSt, n=508) L
OR 0.63(0.40-0.98)* U
↓
v.d. Woude et al. (2012)
(LEAC, n=424)B
OR 1.26(0.78-2.03)
Kuijper et al. (2016)(tREACH, n=281) L
OR 0.515* U
Ajeganova et al. (2016)
(LEAC, n=886)B
nDFR 1.0(0.63-1.50), DFR 1.0(0.62-1.50)
v.d. Woude et al. (2009)(
ERAS, n=895) - m-HAQ C
HR 0.66*(0.44-0.99) M
↓
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
v.d. Kooij et al. (2008)(BeSt, n=508) B
nDFR 1.4 vs. DFR 1.2*
↓
Nishimoto et al. (2014)(DREAM, n=187) C
HR 0.73(0.53-0.99)U
↓
O Visual Analogue Scale 
Ajeganova et al. (2016) - VAS pain B
nDFR 52(34-70), DFR 48(29-65)
v.d. Kooij et al. (2008)(BeSt, n=508)
VAS pain: nDFR 55 vs DFR 45** B
 VAS disease activity: nDFR 61(23) 
vs DFR 55(19)* B
↓
Emery et al. (2018)(
PRIZE, n=65) -VAS pain B
(no estimates specified)
Ajeganova et al. (2016)(LEAC, n=886) B
VAS patient: nDFR55(34-76), 
DFR:51(33-67)*
VAS fatigue: nDFR:50(17-70), 
DFR:40(12-60)*
↓
O                    Miscellaneous  
Kuijper et al. (2016)
(tREACH, n=281) – SF36 L
OR 1.056(CI not specified)
v.d. Linden et al. (2009)
(LEAC, n=687) C
HR 4.7 (2.8-8.0)* U 
(for not achieving DFR)
Emery et al. (2018)
(PRIZE) - SF36/mTSS/SGA score L
(no estimates specified)
Nishimoto et al. (2014)
(DREAM, n=187)
Steinbrocker stageC  HR 0.77(0.57-1.04)
Steinbrocker class C HR 0.82(0.20-3.33)
Kuijper et al. (2016)(tREACH, n=281) L
OR 1.399 (CI not specified)
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O                    Reuma factor          
v.d. Woude et al. (2012)(BeSt, n=508) L
OR 0.39(0.21-0.70)*U
v.d. Woude et al. (2009) 
(ERAS, n=895) C
HR0.28**(0.16-0.49),M
v.d. Woude et al. (2009)
 (LEAC, n=454) C
HR 0.17(0.10-0.31) U**
de Rooy et al. (2011) (LEAC, n=676) L
OR6.66(3.69-12.02)** U
 (not achieving DFR)
v.d. Linden et al. (2011)(LEAC) C
RF level >3x ref: HR 5.7(2.9-11.4)** C, M
RF50 HR 3.1(1.2-7.6)M
v.d. Woude et al. (2012)
(LEAC, n=424) L
OR 0.22(0.11-0.44)* U
Ajeganova et al. (2016)(LEAC, n=886) B
nDFR:65% RF+, DFR:31% RF+**
(low or high ACPA positive not isgn different 
nDFR/DFR)
v.d. Kooij et al. (2008)(BeSt, n=508) B
IgM RF neg: nDFR 33% vs DFR 48%*
Nishimoto et al. (2014)
(DREAM, n=187) C
HR 0.53(0.33-0.85) U
Emery et al. (2018)(PRIZE, n=65)L,U*
(no estimates specified)
O Anti-CCP 
Kuijper et al. (2016)(tREACH, n=281) L
OR 0.636 (CI not specified)
v.d. Woude et al. (2012)(BeSt, n=508) L
OR 0.20(0.10-0.39)** ,M
v.d. Linden et al. (2009)
(LEAC), n=687) C
v.d. Linden et al. (2009)
(LEAC), n=687) C
anti-CCP-2 HR 11.6(5.8-23.4) U
anti-CCP3 HR 6.0(3.4-10.4)  U
(for not achieving DFR)
v.d. Woude et al. (2009) 
(LEAC, n=454) C
HR0.09(0.04-0.20)** M




v.d. Linden et al. (2011)
(LEAC, n=598) C
HR 11.3 (5.6-22.7)** M
(not achieving DFR)
de Rooy et al. (2011)(LEAC, n=676) L
OR11.46(5.85-22.46)** U 
(not achieving DFR)
v.d. Kooij et al. (2008)(BeSt, n=508) L
Anti-CCP neg: DFR 57% vs nDFR 36%*M
(OR not specified)
Ajeganova et al. (2016)
(LEAC, n=886) B
nDFR 62% ACPA+, DFR 18% ACPA+**
Emery et al. (2018)(PRIZE, n=65)L,U*
(no estimates specified)
v.d. Broek et al.(2012)(BeSt, n=484) L
RR 0.4(0.3-0.7)*,M
O Anti-MCV 
v.d. Linden et al. (2009) C
HR 4.9 (3.0-8.2) U (not achieving DFR)
de Rooy et al. (2011, n=676) L
OR 6.13(3.48-10.79)* U 
(not achieving DFR)
O CRP 
v.d. Woude et al. (2012) (BeSt, n=508) L
OR 1.00(0.99-1.01)
v.d. Woude et al. (2009)
(LEAC, n=454) C
HR 0.99(0.98-1.0)* M
v.d. Woude et al. (2012)(LEAC, n=424)L
OR 1.00(0.99-1.01)
de Rooy et al. (2011)(LEAC, n=676)L
OR 1.01 (0.997-1.1013) (not achieving DFR)
v. Steenbergen et al. (2015)(LEAC, n=645)
rs1896368 (DKK-1)/rs1896367/rs1528873
Ajeganova et al. (2016)(LEAC, n=886)B
nDFR 15(6-38), DFR 16(16-33)
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
O ESR 
v.d. Woude et al. (2009) (LEAC, n=454)C
HR 0.99(0.98-1.00)
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v.d. Woude et al. (2012)(BeSt, n=508)
OR 0.99(-0.98-1.00)
v.d. Woude et al. (2009) (ERAS, n=895)C
HR 0.99(0.99-1.00)
de Rooy et al. (2011)(LEAC, n=676)L
OR 1.01(0.995-1.015)
v.d. Woude et al. (2012)(LEAC, n=424)L
OR 1.00(0.99-1.01)
Ajeganova et al. (2016)(LEAC, n=886)B
nDFR 32(18-53), DFR 29(16-48)
Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
O IL-2 
v. Steenbergen et al. (2015)
(LEAC) - serum IL2Rx levels C
Lower IL2 levels: HR0.83(0.70-0.98)* U
O IL-6 
Nishimoto et al. (2014)
 (DREAM, n=187) C
IL-6 (<35pg/ml vs >35pg/ml) HR 0.41 (0.27-
0.63) *M
O MMP-3 
Nishimoto et al. (2014)(DREAM, n=187) C
MMP-3 (normal vs abnormal) 
HR0.29(0.19-0.43) *M
O              Shared Epitope        
v. Heemst et al. (2015)(LEAC, n=441)
HLA DRB1*13 higher chance DFR*, 
but after stratification for ACPA status was 
this effect no longer present.
v.d. Woude et al. (2009) 




v.d. Woude et al. (2012)(BeSt, n=508) L
OR 0.46(0.25-0.85)*U
v.d. Woude et al. (2009)
(ERAS, n=895) - HLA C
HR 0.44(0.26-0.73)*M
de Rooy et al. (2011) 
(LEAC, n=676)- HLA L
OR2.25(1.35-3.74)**,U
 (not achieving DFR)




v.d. Woude et al. (2012)
(LEAC, n=424) L
OR0.35(0.19-0.66)*U
O                          Other 
de Rooy et al. (2011)(LEAC, n=676)L
CD40 non-G carrier OR 0.78(0.17-3.54)
v.d. Linden et al. (2009)
Combinations of auto-antibodies
anti-CCP2 & RF HR 15.6 (6.7-36.4) C, U
anti-CCP2 & 
anti-MCV HR 14.0(6.4-31.0) C, U
anti-MCV&RF HR11.5(5.4-24.5) C, U
1/2/3 auto-antibodies:
HR 3.7(1.1-12.3) C,U, HR 15.5(5.9-14.2) C,U 
HR17.1(6.8-43.3) C, U
(HRs for not achieving DFR)
v. Steenbergen et al. (2015) 
(ESPOIR, n=622) - IL2RAC
Teitsma et al. (2017)(U-Act-Early, n=60)
No networks in CD14+ cells could identified 
between DFR and nDFR.
Teitsma et al. (2017)
(U-Act-Early, n=60)
Pathways related to transcription/trans-
lation related to DFR in patients treated 
with MTx/TOCI and pathways  related to 
migration of white blood cells and G-pro-
tein coupled receptors in TOZI arm and 
pathways involved in response to bacterial/
biotic relates stimulus.
v. Steenbergen et al. (2015)
(LEAC, n=645) - IL2RA C
HR 2.27(1.06-4.84)*M
IMAGING BIOMARKERS
O        Sharp v.d. Heijden score 
Kuijper et al. (2016)(tREACH, n=281) L
OR 0.993(CI not specified)




v.d. Woude et al. (2012)(BeSt, n=508)L
OR0.98(0.94-1.02)
v.d. Kooij et al. (2008)(BeSt, n=508)B
Total SHS: nDFR 4.0(1.5-9.0), nDFR 3.3(1.0-6.9)
v.d. Woude et al. (2012)(Leiden EAC, n=424)L
OR0.97(0.93-1.01)
Akdemir et al. (2018)(BeSt/IMPROVED, 
n=133/175)L
OR 0.94(0.83-1.07)
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Emery et al. (2018)(PRIZE, n=65)L
(no estimates specified)
O                   Larsen score 
v.d. Woude et al. (2009)(ERAS, n=895)C
HR 0.94(0.88-1.00)
O               Erosive at baseline 
v.d. Woude et al. (2012)(LEAC, n=424)L
OR0.52(0.99-1.01)
v.d. Woude et al. (2012)(BeSt, n=508)L
OR0.70(0.37-1.31)
v.d. Kooij et al. (2008)(BeSt, n=508)B
Erosive (%): nDFR 72%, DFR 69%
O                               MRI 




Legend: All factors which were statistically tested for a potential association with achieving 
DFR were included in these overview, categorised by type of biomarker. Effect estimates were 
reported. If no regression analysis was conducted, numerical values compared between DFR 
and nDFR were reported.
** P<0.001, * p<0.05, DFR: DMARD-free remission, nDFR: no DMARD-free remission. 
B Differences in baseline characteristics between DFR and non-DFR tested with t-test etc. L 
Logistic regression analysis c Cox regression analysis U Univariate, M Multivariate
Anti-MCV: anti-mutated citrullinated vimentin, CRP: C-reactive protein, DFR: DMARD-free 
remission, ESR: estimated sedimentation ratio, IL: interleukin, nDFR: no DMARD-free remission, 
SJC: swollen joint count, symp: symptom, HR: Hazard ratio, HLA: Human leukocyte antigen, OR: 
Odds ratio.




Supplementary table S7 – The selection of predictors of DFR used for figure 3
O Age 
v.d. Woude et al. (2012) (BeSt, n=508)L
OR 1.01(0.98-1.03)
no associations between age and 
DFR 
have been reported within the 
included articles
v.d. Woude et al. (2009) (LEAC, n=454) C
HR 1.02(0.99-1.03) 
Kuijper et al. (2016) (tREACH, n=281) L
OR 0.995(CI not specified)
O Gender 
v.d. Woude et al. (2009) (LEAC, n=454)C
Female: HR 1.28(0.74-2.19)
Kuijper et al. (2016)
 (tREACH, n=281) L
Female: OR 0.352*,M  
(CI not specified)
↑
v.d. Woude et al. (2012) (BeSt, 
n=508) L
Male: OR 2.3 9*M (1.26-4.53)
↑
O BMI 
v.d. Woude et al. (2012) (LEAC, n=424)L
OR 0.95(0.83-1.08)
no associations between BMI and 
DFR 
have been reported within the 
included articles
v.d. Woude et al. (2012) (BeSt, n=508)L
OR 0.96(0.88-1.04)
O Smoking 
v.d. Woude et al. (2012) (BeSt, n=508)L
OR 0.69(0.36-1.33)
v.d. Woude et al. (2009) 
(LEAC, n=454) C
HR 0.56* U (0.34-0.94)
↓
O
(shorter) Symptom         
          duration 
v.d. Woude et al. (2012) (BeSt, n=508) (cont) C
O R0.99(0.98-1.00) (cont. in weeks)
v.d. Linden et al. (2010) (LEAC, 
n=598) C
≥12w symptoms vs <12w
HR 1.90* M  (1.18 - 3.05)(not 
achieving DFR)
↑
Kuijper et al. (2016) (tREACH, n=281) L
OR 1.00 (CI not specified)
(measure symp duration not specified)
O
Disease activity score  
         at baseline 
Akdemir et al. (2018) (IMPROVED, n=175)L
OR 0.94(0.58-1.53)
Only IMPROVED data selected for figure




Kuijper et al. (2016) 
(tREACH, n=281) L
OR 0.587* M (CI not specified)
↓




Swollen Joint Count at 
baseline    
v.d. Woude et al. (2009) (LEAC, n=454)C – 44-SJC
HR 1.00(0.96-1.04)
no associations between SJC 
and DFR 
have been reported within 
the included articles
v.d. Woude et al. (2012) (BeSt, n=508)L
OR 1.01(0.97-1.06)
O HAQ    
v.d. Woude et al. (2009) (LEAC, n=454)C - m-HAQ 
HR 1.06(0.74-1.52)
v.d. Woude et al. (2012)
 (BeSt, n=508) L
OR 0.63(0.40-0.98)*, U
↓




     O Reuma factor 
Kuijper et al. (2016) (tREACH, n=281) L
OR 1.399 (CI not specified)
v.d. Linden et al. (2009) 
(LEAC, n=687) C
HR 4.7 (2.8-8.0) *U 
(for not achieving DFR)
            ↓ 
v.d. Woude et al. 
(2012) (BeSt, n=508) L
OR 0.39(0.21-0.70)* U
            ↓ 
     O       Anti-CCP 
Kuijper et al. (2016) (tREACH, n=281) L
OR 0.636 (CI not specified)
v.d. Woude et al. 
(2012) (BeSt, n=508) L
OR 0.20(0.10-0.39)** M
            ↓ 






(for not achieving DFR)
            ↓ 
     O CRP 
v.d. Woude et al. (2012) (BeSt, n=508) L
OR 1.00(0.99-1.01)
v.d. Woude et al. 
(2009)(LEAC, n=454) C
HR 0.99* M (0.98-1.0)
            ↓ 
     O ESR 
v.d. Woude et al. (2009) (LEAC, n=454)C
HR 0.99(0.98-1.00)
no associations 
between ESR and DFR 
have been reported 
within the included 
articles
v.d. Woude et al. (2012) (BeSt, n=508) L
OR 0.99 (-0.98-1.00)
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O Sharp v.d. Heijden score 
Kuijper et al. (2016) (tREACH, n=281) L
OR 0.993(CI not specified)
v.d. Woude et al. 
(2009) (LEAC, n=454) C
HR 0.95* U (0.90-0.99)
            ↓ 
v.d. Woude et al. (2012) (BeSt, n=508)L
OR0.98(0.94-1.02)
O Erosive at baseline 
v.d. Woude et al. (2012) (LEAC, n=424)L
OR0.52(0.99-1.01)
no associations between erosive at 
baseline and DFR 
have been reported within the 
included articles
v.d. Woude et al. (2012) (BeSt, n=508)L
OR0.70(0.37-1.31)
O Shared Epitope 
v.d. Woude et al. 
(2009) 
(LEAC, n=454) - HLA C
HR 0.46 (0.29-.75)*U
            ↓ 
v.d. Woude et al. 
(2012) (BeSt, n=508) L
OR 0.46(0.25-0.85)*U
            ↓ 
Legend: Based on supplementary table S6 predictors were selected for a narrative overview 
(figure 3). Only high and moderate-quality studies were selected which reported on factors 
associated with DFR, tested by means of regression techniques. When more factors were 
repeatedly reported by the same study, the study including the largest study population and 
subsequent longest follow-up were included.
** P<0.001, * p<0.05, B Differences in baseline characteristics between DFR and non-DFR tested 
with t-test etc. L Logistic regression analysis c Cox regression analysis U Univariate, M Multivariate.
Anti-MCV: anti-mutated citrullinated vimentin, CRP: C-reactive protein, DFR: DMARD-free 
remission, ESR: estimated sedimentation ratio, nDFR: no DMARD-free remission, SJC: swollen 
joint count, symp: symptom, HR: Hazard ratio, HLA: Human leukocyte antigen, OR: Odds ratio.
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Objectives To evaluate the two-year clinical effectiveness of two gradual tapering 
strategies. The first strategy consisted of tapering the csDMARD first (i.e. methotrexate 
in ~90%), followed by the TNF-inhibitor, the second strategy consisted of tapering the 
TNF-inhibitor first, followed by the csDMARD.
Methods This multicenter single-blinded randomized controlled trial included 
rheumatoid arthritis (RA) patients with well-controlled disease for ≥3 consecutive 
months, defined as a DAS44≤2.4 and a swollen joint count (SJC)≤1, which was achieved 
with a csDMARD and a TNF-inhibitor. Eligible patients were randomized into gradual 
tapering the csDMARD followed by the TNF-inhibitor, or vice versa. The primary 
outcome was the number of disease flares. Secondary outcomes were DMARD-free 
remission(DFR), DAS, functional ability(HAQ-DI), and radiographic progression. 
Results 189 patients were randomly assigned to tapering their csDMARD (n=94) or 
TNF-inhibitor (n=95) first. The cumulative flare rate after 24-months was respectively 
61% (95%CI, 50%-71%) and 62% (95%CI, 52%-72%). The patients who tapered their 
csDMARD first were more often able to go through the entire tapering protocol and 
reached DFR more often than the group that tapered the TNF-inhibitor first (32% 
versus 20%(p=0.12) and 21% versus 10%(p=0.07), respectively). Mean DAS and HAQ-
DI over time, and radiographic progression did not differ between groups (p=0.45, 
p=0.17, p=0.8, respectively).
Conclusion The order of tapering did not affect flare rates, DAS or HAQ-DI. DFR was 
achievable in 15% of established RA patients, slightly more frequent in patients that 
first tapered csDMARDs. Because of similar effects from a clinical viewpoint, financial 
arguments may influence the decision to taper TNF-inhibitors first. 




In rheumatoid arthritis (RA) disease outcomes have improved tremendously in the 
last decades, mainly due to early initiation of therapy, a treat-to-target approach and 
intensive therapy with conventional synthetic disease-modifying anti-rheumatic drugs 
(csDMARDs) and biologicals. As a result, remission in RA occurs more frequently.[1] 
If patients are successfully treated and the disease is well-controlled, the patient as 
well as the treating physician will explore the possibility to taper medication. Reasons 
for tapering medication are among others reduction in costs, patient preference, 
and prevention of (long-term) side effects. Tapering treatment may, however, lead 
to more transient or persistent disease flares with potential harmful consequences.
[2-4] Previous research already showed that it is possible to taper DMARDs in RA and, 
therefore, current treatment recommendations advise to consider tapering therapy 
when RA patients are in sustained remission.[2, 5] However, there is no consensus on 
the best tapering strategy. 
With the possibility to taper, the final step in tapering is to fully stop DMARDs. It has 
been suggested that sustained DMARD-free remission (DFR, which is defined as 
the absence of synovitis after cessation of DMARD therapy) is a preferred ultimate 
outcome of RA. Previous research in early RA populations showed that 10-20% of RA 
patients is able to achieve this outcome, [6, 7] which was independent of the chosen 
treatment strategy.[7] However, it is currently unknown if reaching DFR is a reachable 
outcome in established RA.
Therefore, the aim of this study is to evaluate the two-year clinical effectiveness of two 
gradual tapering strategies, namely tapering the csDMARD first followed by the TNF-
inhibitor, or vice versa, in established RA patients. We will also explore the possibility 
to reach DFR within this population. 
PATIENTS AND METHODS
Patient population
Patients studied were included in the Tapering strategies in Rheumatoid Arthritis 
(TARA) trial (NTR2754). Inclusion started September 2011 and ended July 2016. The 
TARA trial was a multicenter, single-blinded randomized trial, and was carried out in 
twelve rheumatology centers in the south-western part of the Netherlands.[8] Adult 
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RA patients with well-controlled disease, defined as a disease activity score (DAS)≤2.4 
and a swollen joint count (SJC)≤1 at two consecutive time-points within a 3-month 
interval, using a combination of a csDMARD and TNF-inhibitor, were included. Medical 
ethics committees of each participating center approved the protocol and all patients 
gave written informed consent before inclusion.
Randomisation and blinding
Patients were randomized using minimization randomization stratified for center. 
Trained research nurses, blinded to the allocated tapering arm, examined patients 
and calculated the DAS.
Tapering schedule
Patients were randomized into tapering the csDMARD in the first year followed by 
tapering the TNF-inhibitor in the second year, or vice versa. The csDMARD as well as 
the TNF-inhibitor were gradually tapered to discontinuation in three steps. Tapering 
csDMARDs was realized by cutting the dosage into half, a quarter and thereafter it 
was stopped. TNF-inhibitors were tapered by doubling the dose interval, followed 
by cutting the dosage into half, and thereafter it was stopped. The total tapering 
schedule for each drug took 6 months, with dose adjustments every 3 months as 
long as there was still a well-controlled disease. At the start of the study, patients were 
asked to refrain from glucocorticoids (GCs). There were no restrictions on the use of 
non-steroidal anti-inflammatory drugs (NSAIDs) or intra-articular GC injections.
The protocol was terminated in case of a flare (DAS>2.4 and/or SJC>1). The previous 
effective dose was restarted and if necessary, medication was intensified further 
according to a treat-to-target approach, until low disease activity was reached again. 
After a flare, no further attempts were taken to taper medication during the remainder 
of the study. 
Assessments and outcomes
Patients were examined at baseline and every 3 months thereafter. At each time 
point, the DAS, medication usage, and self-reported questionnaires were collected, 
except for hand and foot radiographs, which were obtained at baseline and after 1 
and 2 years of follow-up. Throughout the whole study follow-up (serious) adverse 
event were recorded.
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The primary outcome was the proportion of patients with a disease flare within the 
entire follow-up period of two years. Secondary endpoints were (1) the proportion 
of patients going through the entire tapering protocol, (2) DMARD-free remission, 
(3) disease activity, (4) functional ability, (5) radiographic progression, and (6) adverse 
events. 
Disease activity was measured with the DAS. Functional ability was measured with the 
health assessment questionnaire disability index (HAQ-DI).[9] Higher HAQ-DI scores 
indicate poorer function. Radiographic progression was measured with the modified 
total Sharp score (mTSS).[10] Radiographs were scored chronologically by two out of 
three qualified assessors, who were blinded for study allocation and the identity of 
the patients.[11] Median mTSS are reported.[12] The weighted overall κ was 0.75 with 
>99% agreement. The percentage of patients with radiographic progression, defined 
as a change in mTSS>0.5 and >1.3 (the smallest detectable change over 2 years), are 
given.[12] Safety monitoring took place according to Dutch guidelines, and included 
laboratory tests every 3 months.[13-15] The medication was stopped or the dosage 
was lowered in case of adverse events related to medication use. 
Statistical analysis
The TARA trial was a superiority trial, powered to detect a 20% difference in flare rates 
between both tapering strategies after one year of follow-up, using a significance 
level of α=0.05 and a power of 80%, which was previously described elsewhere.[16] 
For the current analysis, outcomes were calculated in an intention-to-treat analysis. 
Differences between groups in (1) cumulative flare rates, (2) proportion of patients 
going through the entire tapering protocol and (3) proportion of patients who reached 
DMARD-free remission were analyzed using logistic regression models. Missing data 
was imputed for these three analyses making use of using the last observation 
carried forward method. Flare-free survival was visualized with Kaplan-Meier curves, 
in which patients who were lost to follow-up were censored. Linear mixed models 
with maximum likelihood optimization were used to compare DAS and HAQ-DI over 
time. Statistical comparisons of outcomes were made by Student’s t-test, χ2 test or 
Wilcoxon rank-sum test when appropriate. All data was analyzed using STATA15. A 
p-value ≤0.05 was considered statistically significant.
Patient and public involvement
Patient partners are regularly consulted as advisor for all ongoing projects in the 
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Erasmus MC. The patient panel of the Erasmus MC consist of 15-20 patients of different 
age, sex and with different rheumatic diseases. Study results and study proposals are 
discussed on a regular basis. For the TARA study, patients were consulted for the 
design of the study, developing the research question and outcome parameters.
RESULTS
Patients
A total of 189 patients were randomly assigned to taper their csDMARD (n=94) or TNF-
inhibitor (n=95) first (figure 1). After two years of follow-up 13 and 9 patients dropped 
out of the study, and complete follow-up data was obtained for 167 patients (figure 1). 
Patients had a median symptom duration of 6.2 years and were predominantly female 
(66%) with an average age of 56.6 years (table 1). Within the group who tapered the 
csDMARD first, 80% had DAS remission (DAS44<1.6), compared to 88% of patients 
who tapered their TNF-inhibitor first. Furthermore, 33% of patients in the group who 
tapered the csDMARD first and 37% of the group who tapered the TNF-inhibitor first 
were in Boolean remission, defined as TJC28≤1, SJC28≤1, CRP≤10mg/l, PGA≤10mm 




Not meeting inclusion criteria n=75 







inhibitor in year 1
n=95
Tapering TNF-













Figure 1 Flowchart of the TARA trial. Trial profile and patient participation are indicated as 
numbers of patients. csDMARD: conventional synthetic disease-modifying anti-rheumatic drug, 
LTFU: lost to follow-up, TNF-inhibitor: tumor necrosis factor inhibitor.
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Table 1 Baseline characteristics of patients 
Characteristics 





Age (years), mean (95% CI) 55.9 (53.0-58.8) 57.2 (55.0-59.4)
Gender, female, n (%) 67 (71) 58 (61)
Disease characteristics
Symptom duration (years), median 
(IQR)
6.0 (4.1-8.5) 6.4 (4.2-8.9)
RF positive, n (%) 50 (57) 59 (65)
ACPA positive, n (%) 62 (71) 67 (75)
Disease activity 
DAS44, mean (95% CI) 1.1 (0.9-1.2) 1.0 (0.9-1.1)
DAS clinical remission, DAS44<1.6, 
n (%)
75 (80) 84 (88)
Boolean remission, n (%) 31 (33) 35 (37)
HAQ-DI, mean (95% CI) 0.52 (0.42-0.62) 0.47 (0.35-0.58)
Use of csDMARDs* 
MTX monotherapy, n (%) 64 (69) 49 (52)
MTX + HCQ, n (%) 18 (19) 27 (29)
MTX + SASP + HCQ, n (%) 5 (5) 6 (6)
MTX + SASP, n (%) 3 (3) 2 (2)
MTX + LEF, n (%) 1 (1) 0 (0)
SASP monotherapy, n (%) 0 (0) 3 (3)
SASP + HCQ, n (%) 2 (2) 0 (0)
SASP + LEF, n (%) 0 (0) 1 (1)
LEF monotherapy, n (%) 1 (1) 3 (3)
LEF + HCQ, n (%) 0 (0) 1 (1)
HCQ monotherapy, n (%) 0 (0) 3 (3)
Use of TNF-inhibitor
Etanercept, n (%) 51 (54) 52 (55)
Adalimumab, n (%) 37 (39) 40 (42)
Certolizumab, n (%) 2 (2) 2 (2)
Golimumab, n (%) 4 (4) 1 (1)
Use of glucocorticosteroids, n (%)
Oral, n (%) 1 (1) 0 (0)
Radiographs (hand/foot)
mTSS (0-488), median (IQR) 2 (0-6.5) 1 (0-3.5)
Erosive disease, n (%) ** 37 (39) 26 (27)
*some patients used a combination of csDMARDs, ** Erosive disease is characterized as having >1 erosion 
in three separate joints. ACPA: anti-citrullinated protein antibody; CI: confidence interval; csDMARD: 
conventional synthetic disease modifying anti-rheumatic drug; DAS44: disease activity score measured 
in 44 joints; HAQ-DI: Health Assessment Questionnaire Disability Index; HCQ: hydroxychloroquine; IQR: 





After two years of follow-up, flare rates (95% CI) were 61% (50%-71%) in the group 
who tapered the csDMARD first, and 62% (52%-72%) in the group who tapered the 
TNF-inhibitor first (p=0.84)(figure 2). The median time-to-flare (IQR) was 9.5 (6.5-21) 
months for patients tapering the csDMARD first, and 12 (6.5-15.5) months for patients 
tapering the TNF-inhibitor first. Median flare duration (IQR) was for both tapering 
groups 3 (3-6) months. Use of glucocorticoids was similar for both tapering arms 
(supplemental table S1).
Figure 2 Disease activity over time. (A) Kaplan-Meier of flare-free survival, numbers below 
the graph indicate the number of patients at risk, (B) mean DAS based on 44 joints over time, 
(C) percentage of patients in DAS remission (DAS44<1.6) indicated with solid lines and the 
percentage of patients in Boolean remission: TJC28≤1, SJC28≤1, CRP≤10mg/l, PGA≤10mm (0-
100 mm scale) indicated with dotted lines, (D) functional ability measured with HAQ over time. 
Error bars indicate 95% confidence intervals. Numbers below graphs indicate mean values of 
Mean DAS
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No. of patients 
at risk
95 87 76 65 65 61 54 45 38
98 89 79 69 57 51 47 44 39
0.52 0.61 0.56 0.61 0.60 0.59 0.57 0.63 0.62
0.47 0.44 0.50 0.47 0.54 0.56 0.55 0.52 0.52
DAS 
remission
79.8 73.4 67.0 61.7 58.5 54.3 59.6 55.3 51.1
88.4 78.9 72.6 57.9 61.1 54.7 62.1 57.9 60.0
Boolean 
remission 
33.0 27.7 31.9 27.7 20.2 21.3 22.3 20.2 18.1
36.8 31.6 25.3 16.8 17.9 20.0 18.9 21.1 22.1
Tapering TNF-inhibitor first in year 1,
followed by tapering csDMARD in year 2
1.09 1.21 1.24 1.33 1.31 1.35 1.26 1.35 1.39
0.98 1.10 1.15 1.39 1.35 1.41 1.38 1.30 1.30
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the outcome per tapering arm, per time-point, unless other indicated. csDMARD: conventional 
synthetic disease-modifying anti-rheumatic drug, DAS: disease activity score, HAQ: health 
assessment questionnaire, TNF-inhibitor: tumor necrosis factor inhibitor.
DMARD-free remission
Of the patients who tapered respectively their csDMARD and TNF-inhibitor first 29 (31%) 
and 20 (21%) were able to go through the entire tapering protocol of tapering their 
TNF-inhibitor and 1 csDMARD (p=0.12, figure 3). None of these patients experienced 
a flare after withdrawal of the csDMARD and TNF-inhibitor (period between 18 and 
24 months of follow-up). Although these patients went through the entire tapering 
protocol, not all of them were in DFR, because some were using a combination of 
csDMARDs at baseline (table 1) and in the protocol only one csDMARD was tapered. 
This means that from the total amount of patients who tapered according to protocol, 
not all were in DFR. In total, 19 (20%) patients tapering csDMARDs first and 10 (11%) 
patients tapering TNF-inhibitor first were in DFR after 24 months of follow-up (p=0.07, 
figure 3). In both groups, all patients reached DFR after 18 months of follow-up, and 
none of them used glucocorticosteroids in the period thereafter. 
Disease activity, functional ability, and radiographic 
progression
No significant differences were found in disease activity (p=0.45) and functional 
ability (p=0.17) between both tapering groups over time (figure 2). The percentage 
of patients in Boolean remission after 1 year of follow-up decreased from 33% to 
20% in the group who tapered the csDMARD first and from 37% to 18% in the group 
who tapered the TNF-inhibitor first, and in the second year this percentage stabilized 
(figure 2).Median (IQR) mTSS scores were 3 (0-7.5) in the csDMARD and 1 (0-4.5) in the 
TNF inhibitor tapering group after 2 year of follow-up. The cumulative probability plots 
of both groups were similar (figure 4). Radiographic progression, defined as an mTSS 
increase of >1.3, occurred in 6.1% of the patients in the csDMARD-tapering group and 
7.5% of the patients in the TNF inhibitor tapering group (p=0.8). These percentage 
were respectively 16.3% and 20% if we use an mTSS increase of >0.5 as definition 
for radiographic progression (p=0.9). An increase in erosive disease (>1 erosion in 3 
separate small hand or feet joints) after 2 years of follow-up was observed in 6.4% of 




Figure 3 Overview of medication use throughout two years of follow-up. In the first year data 
was used of all patients, for the second year only data was shown for patients who actually 
tapered their medication. When patients had a flare, it was no longer allowed to continue 
tapering throughout the rest of the study. (A) DMARD usage over time indicated for the two 
tapering arms, given as percentages of patients. (B) DMARD usage after 24 months. Each bar 
represents a certain dosage of the csDMARD and the TNF-inhibitor, ranging from no tapering 
on top (full dose, FD) to discontinuation of the csDMARD and the TNF-inhibitor below. Numbers 
(%) next to bars indicate the number of patients who reached the indicated level of tapering 
after following the protocol for 24 months, as a percentage of the original TARA population. 
csDMARD: conventional synthetic disease-modifying anti-rheumatic drug, FD: full dose or the 
original dose before tapering commenced, TNF-inhibitor: tumor necrosis factor inhibitor.
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Figure 4 Radiological progression within the two years of follow-up. Radiological progression 
was measured with the modified total Sharp score (mTSS). csDMARD: conventional synthetic 
disease-modifying anti-rheumatic drug, mTSS: modified total Sharp Score, TNF-inhibitor: tumor 
necrosis factor inhibitor.
Adverse events
In total, 15 (8%) serious adverse events were reported. None of them were reported 
as being related to the study medication (table 2). At baseline, self-reported adverse 
events (AEs) were collected and 47.1% of all patients reported side effects. No 
differences were found between both tapering groups regarding the number of 
AEs reported and the burden of AEs (table 2). However, when assessing each drug 
separately then AEs were more often reported for methotrexate compared to the 
TNF-inhibitor (35% vs. 23%, p=0.02). The AEs related to MTX also had more impact 
on patients’ life compared to AEs related to the TNF-inhibitor (20 vs. 8.8, p<0.0001, 
measured with a visual analogue scale)(table 2). The self-reported AEs and their 
impact on patients’ lives were all measured before actual tapering commenced.
Radiological progression
















Tapering csDMARD first in year 1,
followed by tapering TNF-inhibitor in year 2
Tapering  TNF-inhibitor first in year 1,
followed by tapering csDMARD in year 2
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Table 2 Adverse events 
Adverse events





Patients reporting AE due to MTX 32 (34) 35 (37)
Off day 7 (7) 8 (8)
Nausea 22 (23) 18 (19)
Fatigue 7 (7) 8 (8)
Acne 0 (0) 3 (3)
Hair loss 5 (5) 5 (5)
Abnormalities of oral mucosa 1 (1) 3 (3)
Headache 1 (1) 0 (0)
Burden of AE due to MTX, VAS 
(0-100), mean (sd)
20 (27) 20 (27)
TNF-inhibitor
Patients reporting AE due to 
TNF-inhibitor
23 (24) 21 (22)
Pain of injection 13 (14) 7 (7)
Fear of injection 3 (3) 4 (4)
Irritation at place of injection 8 (9) 10 (11)
General skin changes 5 (5) 3 (3)
Itch 1 (1) 1 (1)
Gastro-intestinal complaints 2 (2) 2 (2)
Fatigue 2 (2) 1 (1)
Burden of AE due to TNF-inhibitor, 
VAS (0-100), mean (sd)
7.6 (12) 10 (19)
Serious adverse events* 10 (12) 5 (6)
*Serious AEs per tapering arm were respectively: tapering csDMARDs first 7x hospitalization (3x 
total hip replacement surgery, 1x pneumonia, 1x decompression shoulder, 1x pancreatitis, 1x 
angina pectoris), 1x herpes zoster, 1x basal cell carcinoma, 1x large-cell lung carcinoma; tapering 
TNF-inhibitor first 4x hospitalization (2x peripheral vascular disease, 1x total knee replacement, 
1x myocardial infarction), 1x bruised rib. csDMARD: conventional synthetic disease modifying 
anti-rheumatic drug; VAS: visual analogue scale




In this study, the two-year clinical effectiveness of two gradual tapering strategies in 
established RA were evaluated. The first strategy consisted of tapering the csDMARD 
first followed by the TNF-inhibitor, the second strategy consisted of tapering the TNF-
inhibitor first, followed by the csDMARD. After two years of follow-up, 61% and 62% of 
patients who respectively tapered their csDMARD or TNF-inhibitor first experienced 
a disease flare. Also, no differences were seen in disease activity, functional ability, 
radiographic progression, and serious adverse events. Furthermore, 31% and 21% of 
patients were able to complete the entire tapering protocol. After two years, 20% and 
11% of patients were in DMARD-free remission. 
The flare rates within the TARA trial were high, but within the range of previous 
reported flare rates (51%-77%).[17-20] Also, our median flare duration, which was 
3 months, is comparable with previous tapering studies.[3] This underlines the 
robustness of the current data and suggests that these flare rates are generalizable 
to clinical practice.
DFR is nowadays the closest to actual cure of RA, which might be reached by 
controlled tapering of medication in part of the patients. However, data on achieving 
DFR in established RA patients are sparse. The RETRO study showed that 13 out of 
27 established RA patients (48%) were able to reach DFR. However, these data were 
based on a very low sample size.[21] Our DFR rate is comparable with the Leiden Early 
Arthritis cohort (LEAC), 158/889 (17.8%), however direct comparison is hampered due 
to various reasons, among which the difference in study design, disease stage (early 
versus established RA) and duration of being in DFR.[6] In particular, the duration of 
DFR is an important measure of sustainability, and inversely related to the frequency 
of disease flares.[22] 
In both tapering groups all patients reached DFR after 18 months of follow-up. 
Interestingly, none of those patients experienced a flare in the 6 months after DMARD 
stop, whereas other studies reported flare rates between 5-25% in the first 6 months 
after achieving DFR.[23-26] Since clearance can take more than 6 months for certain 
TNF-inhibitors, we might have overestimated the proportion of patients in DFR, in the 
group who tapered their csDMARDs first. Nonetheless, differences between groups 
were not significant, and we found similar flare rates in both tapering groups, which 
indicates that our final results are valid. Still, optimal follow-up for assessing DFR 
should be longer than 6 months.
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A limitation of the TARA trial is that we allowed the use of >1 csDMARD. Because only 
one of them was tapered according to protocol, not all patients who went through 
the entire tapering protocol were in DFR. Ideally, we should have included only those 
patients who used one csDMARD combined with a TNF-inhibitor. However, subgroup 
analysis revealed that tapering was not more successful in patients who used multiple 
csDMARDs compared to the patients who used only one csDMARD. 
One could argue that tapering should only take place when patients are in a “deep” 
sustained remission to increase the chance at DFR and to minimize the risk of flare. 
Current EULAR guidelines advise to only taper medication in case of persistent 
remission, preferably Boolean-based.[5] For the TARA trial we used a DAS<2.4 
combined with maximum of 1 swollen joint, instead of the proposed remission 
criteria by the EULAR. This was chosen, because of a low inclusion rate. Furthermore, 
at time of recruitment another trial was setup making use of the same eligibility 
criteria. Although we used less stringent criteria to start tapering therapy, our flare 
rates were comparable to other tapering strategies. Furthermore, within our study no 
association was found between being in Boolean remission at baseline and staying 
flare-free during follow-up. This suggests that Boolean remission on its own is not 
a good predictor for flare-free survival when medication is tapered. Moreover, if 
persistent Boolean remission is the prerequisite for tapering therapy fewer patients 
will be eligible for tapering, while in our trial only 33 (17%) patients were not able to 
taper any treatment.
Although 15% of our established RA patients were able to reach DFR, it is arguable 
whether this outweighs the risk of a disease flare (61% in our study). Especially, since 
it was recently shown that disease flares have a significant effect on patients’ lives, 
with a duration of more than 6 months.[27, 28] 
Ideally, rheumatologists want to be more certain about which patient is able to 
taper successfully, as current tapering strategies are based upon a trial-and-error 
approach, which results in high flare rates that significantly influence patients’ lives. 
Unfortunately, we still do not know which patients are more eligible for tapering and 
whom will have a higher chance at reaching DFR. Present data (re)confirmed that 
tapering treatment is possible and that DFR is achievable in a small proportion of 
patients even within those with an established RA. In our opinion, future studies 
should focus on patient subsets eligible to (continue) taper medication to reduce the 
amount of flares and to increase the number of patients that reach DFR. 
Tapering towards DMARD-free remission in established RA
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In conclusion, the order of tapering did not affect flare rates, disease activity or 
physical functioning. In total, 61% of patients had a flare in the two years of follow-
up. DFR was achievable in a small proportion of patients and was seen slightly more 
frequent in patients that tapered their csDMARDs first. Because of similar effects 
from a clinical perspective, financial arguments may influence the decision to taper 
TNF-inhibitors first. 
Supplemental table S1 Glucocorticoid use within two years of follow-up




Oral glucocorticoids*, n (%) 5 (5) 6 (6)
Intra-articular
glucocorticoids*, n (%)
20 (21) 23 (24)
Intramuscular
glucocorticoids*, n (%)
7 (7) 11 (12)
*Numbers indicate number of patients who used glucocorticoids within the two years of follow-
up. 




1. Aletaha D, Smolen JS: Diagnosis and 
Management of Rheumatoid Arthritis: A 
Review. Jama 2018, 320(13):1360-1372.
2. Schett G, Emery P, Tanaka Y, Burmester 
G, Pisetsky DS, Naredo E, Fautrel B, 
van Vollenhoven R: Tapering biologic 
and conventional DMARD therapy in 
rheumatoid arthritis: current evidence 
and future directions. Ann Rheum Dis 
2016, 75(8):1428-1437.
3. Kuijper TM, Lamers-Karnebeek FB, 
Jacobs JW, Hazes JM, Luime JJ: Flare Rate 
in Patients with Rheumatoid Arthritis 
in Low Disease Activity or Remission 
When Tapering or Stopping Synthetic or 
Biologic DMARD: A Systematic Review. J 
Rheumatol 2015, 42(11):2012-2022.
4. Henaux S, Ruyssen-Witrand A, Cantagrel 
A, Barnetche T, Fautrel B, Filippi N, Lukas 
C, Raffeiner B, Rossini M, Degboe Y et 
al: Risk of losing remission, low disease 
activity or radiographic progression 
in case of bDMARD discontinuation 
or tapering in rheumatoid arthritis: 
systematic analysis of the literature and 
meta-analysis. Ann Rheum Dis 2018, 
77(4):515-522.
5. Smolen JS, Landewe RBM, Bijlsma 
JWJ, Burmester GR, Dougados M, 
Kerschbaumer A, McInnes IB, Sepriano 
A, van Vollenhoven RF, de Wit M et 
al: EULAR recommendations for the 
management of rheumatoid arthritis 
with synthetic and biological disease-
modifying antirheumatic drugs: 2019 
update. Ann Rheum Dis 2020.
6. Ajeganova S, van Steenbergen HW, van 
Nies JA, Burgers LE, Huizinga TW, van 
der Helm-van Mil AH: Disease-modifying 
antirheumatic drug-free sustained 
remission in rheumatoid arthritis: an 
increasingly achievable outcome with 
subsidence of disease symptoms. Ann 
Rheum Dis 2016, 75(5):867-873.
7. Akdemir G, Heimans L, Bergstra SA, 
Goekoop RJ, van Oosterhout M, van 
Groenendael J, Peeters AJ, Steup-
Beekman GM, Lard LR, de Sonnaville PBJ 
et al: Clinical and radiological outcomes 
of 5-year drug-free remission-steered 
treatment in patients with early arthritis: 
IMPROVED study. Ann Rheum Dis 2018, 
77(1):111-118.
8. Trial NL2625 (NTR2754) [trialregister.nl/
trial/2625]
9. Siegert CE, Vleming LJ, Vandenbroucke 
JP, Cats A: Measurement of disability in 
Dutch rheumatoid arthritis patients. Clin 
Rheumatol 1984, 3(3):305-309.
10. van der Heijde D: How to read 
radiographs according to the Sharp/van 
der Heijde method. J Rheumatol 2000, 
27(1):261-263.
11. van Tuyl LH, van der Heijde D, Knol 
DL, Boers M: Chronological reading of 
radiographs in rheumatoid arthritis 
increases efficiency and does not lead to 
bias. Ann Rheum Dis 2014, 73(2):391-395.
12. van der Heijde D, Simon L, Smolen J, 
Strand V, Sharp J, Boers M, Breedveld 
F, Weisman M, Weinblatt M, Rau R et 
al: How to report radiographic data in 
randomized clinical trials in rheumatoid 
arthritis: guidelines from a roundtable 
discussion. Arthritis Rheum 2002, 
47(2):215-218.
13. NVR Richtlijnen medicijnen: biologicals 




14. NVR Richtlijnen medicijnen: sulfazalazine 




Tapering towards DMARD-free remission in established RA
6
129 
15. NVR Richtlijnen medicijnen: methotrexaat 
[ h t t p s : / / w w w . n v r . n l / w p - c o n t e n t /
uploads/2014/11/NVR-Medicijnen-MTX-
richtlijn-2009-update-2011.pdf]
16. van Mulligen E, de Jong PHP, Kuijper 
TM, van der Ven M, Appels C, Bijkerk C, 
Harbers JB, de Man Y, Molenaar THE, 
Tchetverikov I et al: Gradual tapering 
TNF inhibitors versus conventional 
synthetic DMARDs after achieving 
controlled disease in patients with 
rheumatoid arthritis: first-year results 
of the randomised controlled TARA 
study. Annals of the Rheumatic Diseases 
2019:annrheumdis-2018-214970.
17. Ghiti Moghadam M, Vonkeman HE, Ten 
Klooster PM, Tekstra J, van Schaardenburg 
D, Starmans-Kool M, Brouwer E, Bos R, 
Lems WF, Colin EM et al: Stopping Tumor 
Necrosis Factor Inhibitor Treatment in 
Patients With Established Rheumatoid 
Arthritis in Remission or With Stable Low 
Disease Activity: A Pragmatic Multicenter, 
Open-Label Randomized Controlled Trial. 
Arthritis Rheumatol 2016, 68(8):1810-
1817.
18. van Herwaarden N, van der Maas A, 
Minten MJ, van den Hoogen FH, Kievit W, 
van Vollenhoven RF, Bijlsma JW, van den 
Bemt BJ, den Broeder AA: Disease activity 
guided dose reduction and withdrawal 
of adalimumab or etanercept compared 
with usual care in rheumatoid arthritis: 
open label, randomised controlled, non-
inferiority trial. Bmj 2015, 350:h1389.
19. Fautrel B, Pham T, Alfaiate T, Gandjbakhch 
F, Foltz V, Morel J, Dernis E, Gaudin P, 
Brocq O, Solau-Gervais E et al: Step-
down strategy of spacing TNF-blocker 
injections for established rheumatoid 
arthritis in remission: results of the 
multicentre non-inferiority randomised 
open-label controlled trial (STRASS: 
Spacing of TNF-blocker injections in 
Rheumatoid ArthritiS Study). Ann Rheum 
Dis 2016, 75(1):59-67.
20. Smolen JS, Nash P, Durez P, Hall S, Ilivanova 
E, Irazoque-Palazuelos F, Miranda P, 
Park MC, Pavelka K, Pedersen R et al: 
Maintenance, reduction, or withdrawal 
of etanercept after treatment with 
etanercept and methotrexate in patients 
with moderate rheumatoid arthritis 
(PRESERVE): a randomised controlled 
trial. Lancet 2013, 381(9870):918-929.
21. Haschka J, Englbrecht M, Hueber AJ, 
Manger B, Kleyer A, Reiser M, Finzel S, 
Tony H-P, Kleinert S, Feuchtenberger 
M et al: Relapse rates in patients with 
rheumatoid arthritis in stable remission 
tapering or stopping antirheumatic 
therapy: interim results from the 
prospective randomised controlled 
RETRO study. Ann Rheum Dis 2016, 
75(1):45-51.
22. Verstappen M, van Mulligen E, de Jong 
PHP, van der Helm-Van Mil AHM: DMARD-
free remission as novel treatment target 
in rheumatoid arthritis: A systematic 
literature review of achievability 
and sustainability. RMD Open 2020, 
6(1):e001220.
23. Kuijper TM, Luime JJ, de Jong PH, Gerards 
AH, van Zeben D, Tchetverikov I, de 
Sonnaville PB, van Krugten MV, Grillet 
BA, Hazes JM et al: Tapering conventional 
synthetic DMARDs in patients with early 
arthritis in sustained remission: 2-year 
follow-up of the tREACH trial. Ann Rheum 
Dis 2016, 75(12):2119-2123.
24. Emery P, Burmester GR, Bykerk VP, 
Combe BG, Furst DE, Barre E, Karyekar 
CS, Wong DA, Huizinga TW: Evaluating 
drug-free remission with abatacept in 
early rheumatoid arthritis: results from 
the phase 3b, multicentre, randomised, 
active-controlled AVERT study of 24 
months, with a 12-month, double-blind 
treatment period. Ann Rheum Dis 2015, 
74(1):19-26.
25. Bijlsma JWJ, Welsing PMJ, Woodworth 
TG, Middelink LM, Petho-Schramm A, 
 Chapter 6
130
Bernasconi C, Borm MEA, Wortel CH, 
Ter Borg EJ, Jahangier ZN et al: Early 
rheumatoid arthritis treated with 
tocilizumab, methotrexate, or their 
combination (U-Act-Early): a multicentre, 
randomised, double-blind, double-
dummy, strategy trial. Lancet 2016, 
388(10042):343-355.
26. Klarenbeek NB, van der Kooij SM, Guler-
Yuksel M, van Groenendael JH, Han KH, 
Kerstens PJ, Huizinga TW, Dijkmans BA, 
Allaart CF: Discontinuing treatment in 
patients with rheumatoid arthritis in 
sustained clinical remission: exploratory 
analyses from the BeSt study. Ann Rheum 
Dis 2011, 70(2):315-319.
27. Ghiti Moghadam M, Ten Klooster PM, 
Vonkeman HE, Kneepkens EL, Klaasen 
R, Stolk JN, Tchetverikov I, Vreugdenhil 
SA, van Woerkom JM, Goekoop-
Ruiterman YPM et al: Impact of Stopping 
Tumor Necrosis Factor Inhibitors on 
Rheumatoid Arthritis Patients’ Burden of 
Disease. Arthritis Care Res (Hoboken) 2018, 
70(4):516-524.
28. van Mulligen E, Weel AEAM, Kuijper TM, 
Hazes JMW, van der Helm- van Mil AHM, 
de Jong PHP: The impact of a disease flare 
during tapering of DMARDs on the lives 
of rheumatoid arthritis patients. Semin 
Arthritis Rheum 2020, 2020; in press.





RESPONSE TO “TAPERING 
TOWARDS DMARD-FREE 
REMISSION IN ESTABLISHED 
RHEUMATOID ARTHRITIS: TWO 
YEAR RESULTS OF THE TARA TRIAL” 
BY HAROON ET AL.
E van Mulligen, P.H.P. de Jong
 
Ann Rheum Dis 2020; Published Online First: 14 August 2020. 
 Chapter 7
134
We appreciate the interest in our paper by Haroon, et al. We presented the two 
year results of the TARA trial, in which we concluded that “financial arguments may 
influence the decision to taper TNF-inhibitors first”.[1] Based on this conclusion, 
Haroon, et al. decided to respond to that with their real-world data from a resource-
poor country.[2]
Ideally, if rheumatoid arthritis (RA) patients are in sustained remission, medication 
is quickly tapered and possibly stopped to reduce health care costs. DMARD-free 
remission is suggested as a preferred ultimate target in a treat-to-target management 
approach, however we previously showed, in a systematic literature review, that this 
outcome is achievable in 10-20% of the RA population.[3] Within the TARA trial we 
showed that DMARD-free remission was achievable in 15% of the included established 
RA patients. Haroon et al. on the other hand now report that 5 out of 45 (11%) RA and 
spondyloarthritis (SpA) patients were able to completely stop their bDMARDs. This 
confirms that DMARD-free remission is reachable for a minority of patients.
Although DMARD-free remission occurs less frequent, most of the RA patients with 
a well-controlled disease  can lower their DMARD dosage. To illustrate, 83% of the 
TARA patients were able to reduce their medication dosage, which is similar to the 
real-world data of Haroon et al. Another benefit of  gradual tapering with a treat-to-
target approach, which includes close monitoring, is that (severe) disease flares could 
possibly be prevented due to slower tapering and earlier detection. In our opinion, 
aforementioned approach  is currently the best way to taper treatment. Especially, 
since we have previously shown that a disease flare has a significant impact on 
patients’ lives, which outlast the effect of a flare on disease activity.[4] Noteworthy, is 
the fact that although most patients reach low disease activity within 6 months after a 
flare, most of them have a higher disease activity post-flare compared to pre-flare.[4] 
Unfortunately, current tapering strategies are still based on a trial-and-error approach 
which leads to high flare rates and, therefore, a tailor-made tapering approach is 
preferred. Moreover, no consensus had been reached on how to taper medication, 
because cohorts/trials directly comparing different tapering strategies are sparse.[5] 
Haroon, et al. showed that 60% of RA patients were able to reduce their bDMARD 
dosage when a 2-step tapering protocol was used, consisting of dose reductions 
every 4 months of 30% followed by 50%. Comparing this with our results from the 
TARA trial, in which we showed that 83% of the patients were able to reduce their 
Response to “Tapering towards DMARD-free remission in established rheumatoid arthritis”
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DMARD dosages with 50% every 3 months, leads to our advice to gradually taper 
DMARDs with 30-50% every 3-4 months in RA patients with well-controlled disease.
To summarize, by using a gradual tapering approach, almost all RA patients with a 
well-controlled disease can reduce their DMARD dosages. The real-world data of 
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Objectives To determine the impact of a disease flare on patient reported outcome 
measures (PROMs) in rheumatoid arthritis (RA) patients, who are tapering treatment.
Methods Data were used from the TARA trial; a multicenter, randomized controlled 
trial in which RA patients, with a well-controlled disease (DAS≤2.4&SJC≤1) for at least 
6 months, gradually tapered their DMARDs. PROMs of patients with a flare (DAS>2.4 
and/or SJC>1) were compared every three months before and after a flare with their 
own norm values. Linear Mixed Models were used to investigate whether a disease 
flare influenced functional ability (HAQ-DI), fatigue (BRAF-MDQ), quality of life (EQ-5D 
and SF36), anxiety and depression (HADS), morning stiffness, general health (GH) and 
worker productivity, and if so, the duration was determined. For unemployment and 
sick leave we used descriptive statistics. 
Results A flare negatively influenced GH, morning stiffness, HAQ-DI, EQ-5D, BRAF-
MDQ, and the SF36 physical component scale and this effect lasted >3 months. 
Except for the HAQ-DI, effect sizes exceeded the minimum clinically important 
differences(MCIDs). For the physical outcomes effects lasted >6 months. Worker 
productivity was not significantly affected by a flare.
Conclusion A disease flare influenced patients’ lives, the largest effect was seen in 
the physical outcomes, and lasted 6 months. Although on a group level effect sizes 
for the separate PROMs were not always significant or larger than specific MCIDs, a 
disease flare can still be of great importance for individual patients. 




Over the years the treatment of Rheumatoid Arthritis(RA) has improved enormously, 
which resulted in better outcomes, including achievement of sustained remission [1, 
2]. Nowadays, 50-60% of RA patients achieve sustained remission [3, 4]. Therefore, 
current guidelines recommend to consider tapering treatment if patients are in 
sustained remission [5, 6]. 
Previous studies have shown that it is possible to taper biologicals, but this is 
accompanied with a higher chance of disease flares [7-10]. Flare rates within these 
studies varied from 38% to 76.6%. It has also been shown that only 41 – 67% of the 
patients that experienced a flare will regain remission within 6 months after treatment 
intensification [7, 11, 12]. Thus, many patients will have a reduced or no response to 
previous effective therapy, which may lead to an altered disease state or prolonged 
flare duration. Despite the high flare rates, current guidelines recommend to taper 
biologicals, which is based on a clinical and societal viewpoint. 
At present, a paradigm shift in the delivery of health care is emerging, and is shifting 
towards patient centered healthcare. Patient-centered healthcare focuses on the 
individual patient preferences and needs, which can be objectified with patient 
reported outcome measures(PROMs) [13, 14]. In order to optimize the delivery of care 
during tapering we need to know how a disease flare affects these PROMs. However, 
data on the feasibility of tapering DMARDs from a patient’s perspective are sparse. 
Therefore, our objectives are (1) to determine the impact of a disease flare on patient’s 
lives by quantifying the changes in functional ability, general health, morning stiffness, 




Data were used from the Tapering strategies in Rheumatoid Arthritis (TARA) trial 
(NTR2754). Adult patients with well-controlled RA, defined as a disease activity score 
(DAS44)≤2.4 and a swollen joint count (SJC)≤1 for at least 6 months, who were 
using a combination of a conventional synthetic disease modifying anti-rheumatic 
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drug (csDMARD) and a TNF-inhibitor, were included. Patients were randomized into 
gradually tapering the csDMARD or TNF-inhibitor first. In the second year, the other 
drug was gradually tapered. The protocol was terminated if patients experienced 
a flare (DAS>2.4 and/or SJC>1). The previous effective dose was restarted and if 
necessary, medication was intensified further according to a treat-to-target approach, 
until low disease activity was reached. After a disease flare it was not allowed to restart 
tapering [12, 15]. 
For the current study we compared the PROMs and DAS44, within all patients that 
experienced a flare, at the moment of flare, 3 months prior to a flare, and every 3 
months thereafter with their own norm values. The norm was set at the average of 
DAS44 and PROMs 12, 9 and 6 months prior to a flare, which in our opinion was the 
best reference for well-controlled disease (Figure 1).
We also performed a sensitivity analysis with different flare criteria from other studies, 
which are less strict than our criteria, in order to assess the impact of different criteria 
on measured outcomes.  For example, we could have classified someone as having a 
disease flare, while in other studies these patients would continue tapering. 
Outcomes
Outcomes for the impact of a disease flare on patients’ lives were DAS, general 
health(GH), severity of morning stiffness, functional ability, quality of life, health status, 
fatigue, anxiety and depression, and worker productivity. 
Every three months the DAS44 and self-reported questionnaires were collected 
[12]. The DAS44 was used for measuring disease activity based on 44 joints[16]. 
The minimum clinically important difference(MCID) of the DAS44 is 0.6 [17]. GH was 
measured on a 0-100 mm visual analogue scale, in which 0 represented the lowest 
possible health state, and 100 perfect health. The MCID for GH is 10 [17]. Functional 
ability was measured with the health assessment questionnaire disability index (HAQ-
DI)[18]. Higher scores reflect greater disability, and the MCID is 0.22 [19]. Severity of 
morning stiffness was measured on a 0-10 likert-scale, in which 0 represented no 
morning stiffness, and 10 severe morning stiffness. The MCID for morning stiffness 
is 1 [17]. Quality of life(QoL) was measured with the European Quality of Life – 5 
Dimensions (EQ-5D). Higher scores indicate a higher quality of life, and the MCID 
is 0.04 [20]. Health status was measured with the short form 36 (SF36), the higher 
The impact of a disease flare on RA patients
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the score, the better the health status [21-23]. The MCID of the SF36 is between 
3 and 5 [23]. Fatigue was measured with the Bristol Rheumatoid Arthritis Fatigue 
Multi-dimensional Questionnaire (BRAF-MDQ). Higher scores represent higher levels 
of fatigue [24]. The MCID is 2.6 [25]. Anxiety and depression were measured with 
the Hospital Anxiety and Depression Scale (HADS), in which higher scores represent 
more anxiety and/or depression [26]. The HADS MCID for RA patients is unknown, 
however other chronic diseases show an MCID of 1.7 [27, 28]. Worker productivity 
was assessed with the iMTA Productivity cost Questionnaire (iPCQ) that addressed 
sick leave, reduction in work time, and productivity loss [29]. For all outcomes, the 
effect sizes were compared to aforementioned MCIDs. 
Statistical analysis
We used data from patients that experienced a flare to determine the impact and 
duration of a flare on DAS44 and PROMs. The moment of flare was set as T0 and we 
only took the first flare into account. We used Linear Mixed Models (LMMs) with a 
random intercept and an autoregressive covariance matrix, to account for repeated 
measurements within individuals, to compare DAS44 and PROMs 3 months prior to a 
flare, at the moment of flare, and 3, 6, 9, and 12 months after a flare with norm values. 
For each patient the norm was set at  the average value of DAS44 and PROMs for the 
combined values obtained at 12, 9 and 6 months prior to a flare. This was based on 
the mean DAS44 graph that showed minimal fluctuations between aforementioned 
timepoints in patients who experienced a flare and at those time-points these patients 
still had a well-controlled disease(Figure 1). Because of aforementioned reasoning 
we had to exclude 17, because they experienced a flare within the first 3 months of 
follow-up and, therefore, we could not set a norm value for these patients.  
First, we examined whether there was a difference in each PROM and DAS44 over 
time. If there was a significant difference, the duration of this effect was determined. 
The duration was calculated by comparing each time-point separately with the norm, 
using aforementioned LMMs. For worker productivity we used descriptive statistics. 
For visualization purposes, we also plotted the patients that did not have a disease 
flare. In this group we reclassified the 12 month visit as the new T0, because mean 
(sd) time to flare was 12 (6.7) months.
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Outcomes were calculated in an intention-to-treat analysis, using all available data. 
A Bonferroni correction was applied to account for multiple testing. The calculated 
p-values for the impact of a flare on PROMs or DAS44 were corrected by multiplying 
the p-value with the total number of variables tested (n=11). The calculated 
p-values for the duration of a disease flare were multiplied with the total number of 
measurements tested (n=42). In this manner we could still consider a p-value ≤0.05 
statistically significant. Corrected and uncorrected p-values are reported. All data 
were analyzed using STATA 15.
RESULTS
Patients
A total of 189 patients were randomized, of those 113 patients experienced a 
flare. Table 1 shows the norm values for patients with and without a flare. Disease 
characteristics and PROMs were the same for both groups, except for DAS44 (sd), 
which was 0.86 (0.50) in the non-flare group and 1.08 (0.52) in the flare group 
(p=0.0055). This difference is probably caused by a significant difference in Erythrocyte 
Sedimentation Rate(ESR) between both groups(p=0.008). 
Table 1 Patient characteristics





Demographic at moment of randomization
• Age (years), mean (sd) 58.2 (12.0) 54.1 (12.8) 0.025
• Gender, female, n (%) 77 (68.1) 48 (63.2) 0.48
Disease characteristics at moment of
randomization 
• Symptom duration (years), median (IQR) 6.1 (4.3-9.1) 6.2 (3.8-8.5) 0.42
• RF positive, n (%) 61 (58.7) 45 (63.4) 0.53
• ACPA positive, n (%) 75 (72.8) 52 (74.3) 0.83
Treatment at moment of randomization
• MTX, n (%) 106 (94) 68 (89) 0.28
• Anti-TNF, n (%)
-   Etanercept 65 (58) 38 (50) 0.31
-   Adalimumab 43 (38) 33 (43) 0.46
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• DAS44, mean (sd) 1.08 (0.52) 0.86 (0.50) 0.0055
• TJC44, median (IQR) 0 (0-1) 0 (0-0) 0.16
• SJC44, median (IQR) 0 (0-0) 0 (0-0) 0.12
• General health (0-100 mm), median (IQR) 14 (5-27) 14 (2-25.5) 0.82
• ESR (mm/h), median (IQR) 9.5 (5-16) 6 (2-12) 0.008
• CRP (mg/L), median (IQR) 2 (1-5) 2 (1-5.2) 0.73
• Erosive disease on initial radiograph, n (%)a 40 (42) 29 (38) 0.64
• Morning stiffness, severity 0-10, median 
(IQR)
1 (0-3) 1 (0-4) 0.46
Patient reported outcomes
• HAQ, median (IQR) 0.38 (0.13-0.75) 0.25 (0-0.63) 0.57
• EQ-5D index, mean (sd) 0.86 (0.12) 0.87 (0.12) 0.51
• BRAF-MDQ, mean (sd) 16.2 (11) 16.6 (12) 0.80
• SF36, mean (sd)
-   PCS







• HADS, mean (sd)
-   Anxiety







• Worker productivity (0-10), median (IQR) 8 (6-10) 8 (6-9) 0.14
aErosive disease is characterized as having >1 erosion in three separate joints. ACPA: anti-
citrullinated protein antibody; CRP: C-reactive protein; csDMARDs: conventional synthetic 
DMARD; DAS: disease activity score; ESR: erythrocyte sedimentation rate; EQ5D: European 
Quality of Life – 5 Dimensions; HAQ: Health Assessment Questionnaire; IQR: inter quartile 
range; MCS: mental component scale; PCS: physical component scale; RF: rheumatoid factor; sd: 
Standard Deviation; SJC: swollen joint count; TJC: tender joint count.
Clinical outcomes
At the moment of flare(DAS44>2.4 or SJC>1), mean DAS44 (sd) was higher in the 
flare group(1.84 [0.76]) compared to the non-flare group (1.04 [0.51])(figure 1A). Most 
of the separate components of the DAS44; TJC44, SJC44, and general health (GH); 
were also higher in the flare group(figure 1B, C, E). We found an overall significant 
effect for the DAS44 compared to the norm(p<0.0001, table 2). The same accounted 
Table 1 Patient characteristics (Continued)
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for the DAS44 components, namely GH(p<0.0001, table 2), SJC44(p<0.0001), 
TJC44(p<0.0001), ESR(p<0.0001), and CRP (p<0.0007)(data not shown). The effect of 
a flare on DAS44 and GH lasted >12 months, while the clinically meaningful effect 
lasted 6 months (MCID DAS44>0.6 and MCID GH>10)[17]. 
The degree of morning stiffness, ranging from 0-10, was on average 3.7 (sd 2.8) in 
the flare group, and 2.5(sd 2.3) in the non-flare group at T0 (figure 2B). The degree of 
morning stiffness significantly differed over time(p<0.0001, table 2). When comparing 
the separate time-points to the norm, we found that morning stiffness significantly 
worsens at the moment of flare and regains its norm value 9 months after a flare. At 
the moment of flare and 3 months thereafter the difference with the norm was also 
above the MCID of 1 (table 3)[17].
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Figure 1 Clinical outcomes. (A) DAS44 scores for the flare group and the non-flare group with 
corrected time-points. (B) mean CRP, (C-F) separate components of the DAS44 scores: mean 
swollen joint count in 44 joints (SJC44), mean tender joint count in 44 joints (TJC44), mean 
erythrocyte sedimentation rate (ESR), and visual analogue scale for general health (GH).
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Table 2 Overall differences between norm and moments thereafter.
Patient reported outcomes P-value Bonferroni corrected 
p-valuea
DAS44 P<0.0001 P<0.0001
VAS general health P<0.0001 P<0.0001
Morning stiffness P<0.0001 P<0.0001
HAQ-DI P<0.0001 P=0.0003
SF36 PCS P<0.0001 P=0.0004
SF36 MCS P=0.68 P=1
EQ5D P<0.0001 P<0.0001
BRAF-MDQ P=0.0037 P=0.041
HADS anxiety P=0.75 P=1
HADS depression P=0.62 P=1
Worker productivity P=0.32 P=1 
an=11. BRAF-MDQ: Bristol Rheumatoid Arthritis fatigue multidimensional questionnaire; DAS: 
disease activity score; EQ5D: European quality of life with 5 dimensions; HADS: hospital anxiety 
and depression scale; HAQ-DI: health assessment questionnaire disability index; MCS: mental 
component scale; PCS: physical component scale; SF36: short form 36; VAS: visual analogue 
scale.
Table 3 Comparison of separate time-points with the norm values to assess the 
duration of the effect of flare. 
Difference with 







-T3 0.16 0.039 - 0.27 0.0089 0.37
T0 0.68 0.56 - 0.81 <0.0001 <0.0001
T3 0.57 0.44 - 0.70 <0.0001 <0.0001
T6 0.57 0.43 - 0.71 <0.0001 <0.0001
T9 0.33 0.18 - 0.47 <0.0001 0.0004





-T3 4.4 1.10 - 7.78 0.0091 0.38
T0 14.8 11.18 - 18.35 <0.0001 <0.0001
T3 12.4 8.53 - 16.21 <0.0001 <0.0001
T6 12.7 8.65 - 16.74 <0.0001 <0.0001
T9 7.6 3.34 - 11.92 0.0005 0.021





-T3 0.41 0.028 - 0.78 0.036 1
T0 1.32 0.93 - 1.72 <0.0001 <0.0001
T3 1.15 0.73 - 1.57 <0.0001 <0.0001
T6 0.86 0.41 - 1.30 0.0001 0.0062
T9 0.26 -0.21 - 0.73 0.28 1




-T3 0.016 -0.039 - 0.071 0.57 1
T0 0.13 0.074 - 0 .19 <0.0001 0.0002
T3 0.12 0.065 - 0.18 <0.0001 0.0019








T6 0.078 0.015 - 0.14 0.015 0.61
T9 0.046 - 0.021 - 0.11 0.18 1




-T3 -1.03 -3.67 - 1.62 0.45 1
T0 -4.25 -6.57 - -1.93 0.0003 0.014
T3 -4.05 -6.84 - -1.27 0.0044 0.18
T6 -3.95 -6.64 - -1.26 0.0041 0.17
T9 1.37 -1.71 - 4.45 0.38 1




-T3 -0.020 -0.048 - 0.0070 0.15 1
T0 -0.086 -0.11 - -0.059 <0.0001 <0.0001
T3 -0.042 -0.071 - -0.014 0.0039 0.16
T6 -0.036 -0.067 - -0.0064 0.018 0.73
T9 -0.037 -0.069 - -0.0052 0.023 0.95




-T3 1.41 -1.22 - 4.03 0.29 1
T0 3.15 0.94 - 5.36 0.0053 0.68
T3 3.25 0.60 - 5.90 0.016 1
T6 4.33 1.85 - 6.82 0.0006 0.026
T9 1.58 -1.32 - 4.49 0.29 1
T12 1.76 -1.14 - 4.66 0.23 1
an=42. BRAF-MDQ: Bristol Rheumatoid Arthritis fatigue multidimensional questionnaire; CI: 
confidence interval; DAS: disease activity score; EQ5D: European quality of life with 5 dimensions; 
HADS: hospital anxiety and depression scale; HAQ-DI: health assessment questionnaire 
disability index; MCID: minimal clinically important difference; MCS: mental component scale; 
PCS: physical component scale; SF36: short form 36; VAS: visual analogue scale.
Functional ability
Functional ability was 0.69(sd 0.61) at T0 in the flare group, and 0.47 (sd 0.56) in the 
non-flare group(figure 2B). When we visually compare the flare and non-flare group, 
we observed a difference that already starts six months prior to a flare and lasts until 
the end of the follow-up period. Not surprisingly the overall effect of a flare on the 
HAQ-DI was significant(p=0.0003, table 2). However, when comparing the separate 
time-points to the norm, a significant difference was only observed at the moment of 
flare and 3 months thereafter. When taking uncorrected p-values into account, the 
effect would last longer, namely up to 9 months. However, the difference with norm 
values was never above the MCID of 0.22(table 3)[19]. 
Health status
For the health status we compared the flare group with the non-flare group based 
on the physical (PCS) and mental (MCS) component score of the SF36(figure 2C, D). 
Table 3  (Continued)
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Mean PCS was 36.0(sd 12.5) in the flare group and 42.8(sd 11.0) in the non-flare 
group. The mean MCS was respectively 55.8(sd 9.5) and 56.1(sd 10.0) in the flare and 
non-flare group. The overall effect of flare was not significant for the MCS(p=1), but it 
was for the PCS(p=0.0004). If we compare the separate time-points to norm values, 
a significant effect was only present at the moment of flare(table 3)[23]. Using the 
uncorrected p-values, there was a significant and also a clinically meaningful effect, 
which lasted up to 6 months after a flare (MCID SF36 PCS 3-5). 
Quality of life
Quality of life shows a small dell in the graph at the moment of flare(figure 2E). The 
mean EQ-index at T0 was, respectively 0.75(sd 0.21) and 0.85(sd 0.13) for the patients 
who did and did not experienced a flare. The overall effect of a flare on EQ-5D was 
significant(p<0.0001, table 2), which was also seen in the separate domains(p<0.01), 
except for the domain anxiety and depression (p=0.46, data not shown). This significant 
effect was only seen at the moment of flare, which also exceeded the MCID threshold 
of 0.04[20]. If we look at the uncorrected p-values, there was a significant effect that 
lasted >12 months with an effect size ≥MCID for all significant time-points(table 3)
[20].  
Fatigue
At T0 we encountered a mean fatigue score of 19.6(sd 11.5) in the flare group and 
15.7(sd 13.1) in the non-flare group(figure 2F). The effect of a flare on fatigue was 
significant(p=0.042, table 2). However, when comparing separate time-points the 
corrected p-values were not significant, while the uncorrected p-values showed a 
duration of 6 months. During this time period the difference with norm also exceeded 
the MCID of 2.6(table 3)[25]. 
Anxiety and depression
At visual inspection of the anxiety and depression graphs an erratic course of the 
scores is observed(figure 2G, H). At the moment of flare the mean anxiety scores were 
3.63(sd 2.89) and 3.25(sd 2.96) for the flare and non-flare group. Mean depression 
scores were respectively 2.44(sd 2.22) and 2.32(sd 3.36)  for the flare and non-flare 
group. Depression as well as anxiety scores were not influenced by a flare(p=1 for 
both scores, table 2).
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Figure 2 Patient reported outcome measures (PROMs). EQ5D: European quality of life with 
5 dimensions; HAQ-DI: health assessment questionnaire disability index; SF36: short form 36; 
MCS: mental component scale; PCS: physical component scale.
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We first determined how many patients had payed work (figure 3A). At T0, 48% of 
the flare group and 59% of the non-flare group had payed work. Over time there 
were only minor differences in these numbers. Of the eligible working population 
respectively 27% and 18% of patients with and without a flare were unemployed at 
T0 (figure 3B). These percentages did not vary much over time. Sick leave was 6.2% 
in the flare group, and 2.6% in the non-flare group at T0, which was measured over 
the entire working population (figure 3C). Sick leave was not clearly affected by a flare, 
although we did saw a 10% drop in productivity in the 3 months after a flare, which 
was not significant (figure 3). 
Figure 3 Worker productivity. (A) The percentage of patients with payed work, (B) unemployment 
as a percentage of the total labor force, (C) the amount of sick leave indicated as number of 
patients calling in sick within a 3 month period, (D) productivity on a scale from 0-10.
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We performed a sensitivity analysis to evaluate the effect of different flare criteria on 
our PROMs(Supplementary table S1). For all flare definitions we found that DAS44, 
GH, morning stiffness, HAQ-DI and the EQ5D were affected(Supplementary table 
S1). The effect of these different flare definitions on PROMs might even be larger 




We showed that a disease flare has a significant effect on all components of the 
disease activity score, but also on functional ability, quality of life and fatigue, which 
lasted at least 3 months. Worker productivity did not seem to be affected by a flare. 
In the TARA study it was shown that tapering csDMARDs or anti-TNF in established 
RA patients resulted in an average flare rate of 38% during the first year of follow-up. 
The two tapering arms did not differ in flare rates, functional ability or quality of life 
[12]. Six months after the flare, 67% of the patients regained well-controlled disease 
[12]. These results were comparable with other tapering studies [7, 9, 11, 30]. In all 
these studies PROMs were merely not taken into account to assess the severity of a 
flare. Furthermore, it was not investigated if PROMs differed between patients with 
and without a flare. 
However, the POET trial did show that stopping the TNF-inhibitor had a significant 
short-term impact on physical and mental health status compared to patients who 
continued their TNF-inhibitor [31]. Furthermore, the STRASS trial investigated whether 
the patient’s perspective of a flare was the same as the physician’s perspective of a 
flare, which was measured with the DAS28 [32]. The investigators concluded that 
the patient reported flare overlapped with the DAS28-based flare. The OPTIRRA trial 
investigators explored whether PROMs could predict a flare [33]. They showed that 
mental health status was independently associated with a flare during tapering. Also 
fatigue and functional ability were associated with a flare, but this effect disappeared 
after correction for possible confounders. 
Although we showed a significant effect of a flare on various PROMs, this effect was 
not always above the MCID. For the HAQ-DI, for example, the MCID is 0.22, which was 
not reached in our analysis. However, the differences with the norm were statistically 
significant up to 6 months after a flare. Not reaching the MCID, while finding a significant 
differences, might be due to our assumption for the norm values. The norm was set 
at the average of the visits 12, 9 and 6 months prior to a flare, which was based upon 
the DAS44 graph. If we look at the HAQ-DI graph, we see that the HAQ-DI already 
worsens 6 months prior to a flare. Therefore, by taking this visit as part of the norm 
value, we might have underestimated the effect of flare on the HAQ-DI. For the EQ5D 
and the SF36 PCS we can apply a reverse reasoning of the foregoing explanation. 
For both PROMs we only found a significant difference at the moment of flare, while 
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the MCID was reached for almost every time-point after the flare, which indicates 
that a disease flare might have great impact on individual patients. Moreover, we 
corrected for multiple testing, which might have canceled out a possible meaningful 
effect and, therefore, underestimated the significance of our results. On the other 
hand, our sensitivity analysis showed similar findings for different flare definitions, 
which strengthens our current findings. 
Strengths of the current study include the completeness of the data, including 
containment of recommended outcomes measures by ICHOM and OMERACT [14, 
34]. Furthermore the TARA trial used a gradual tapering scheme combined with a 
treat-to-target approach. Therefore, we think this is an ideal trial to investigate the 
effect of a flare on PROMs. 
Limitations of this study were that it is a post-hoc analysis. However, due to our 
statistical approach in which we compared patients with their own norm values, 
we think we can still report valid results. The results on worker productivity on the 
other hand are less reliable, because of the low occurrence of absenteeism and 
presenteeism, giving rise to a potential power issue. Furthermore, the TARA trial only 
had a follow-up period of 2 years, whereby potential long term effects could not be 
determined. For some of the investigated PROMs we already saw a long lasting effect 
(>6 months). Ideally, we would like to know exactly how long aforementioned effects 
are present, but unfortunately we do not have the data for this. There is also not 
always consensus about the MCIDs for specific PROMs. We used known MCIDs from 
the literature to place our result into perspective, but it is debatable if those values 
are correct. 
Recently, there has been some debate on the measurement of morning stiffness, 
and efforts are made to create a validated PROM  according to OMERACT guidelines.
[35, 36]. Current used measures do not capture all aspects that are involved with 
morning stiffness due to RA disease activity. However, the OMERACT working group 
does advice not to use morning stiffness duration as outcome, because it is very 
aspecific.[35] Fortunately, we used the severity of morning stiffness as outcome in our 
analyses, but one should be cautious when interpreting these outcomes. 
Due to the long-lasting effect of a flare on a patient’s live, it would be ideal if we 
were able to predict who can safely taper medication. Current tapering strategies 
are based upon a trial-and-error approach, which leads to high flare rates. Our study 
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showed that some PROMs already worsen before a flare occurs, i.e. HAQ-DI, severity of 
morning stiffness and the DAS44, which might be useful for flare prevention during tapering. 
These changes before the actual flare occurred were all non-significant, still it indicates that 
patients already have more complaints before the actual flare was objectified by the treating 
physician. Therefore, the results of this study could be used for future research to establish 
a more personalized tapering approach, even though prediction of flares is not yet possible. 
In conclusion, a disease flare has a significant effect on patients’ lives. A disease flare affects 
functional ability, quality of life, fatigue, and all components of the disease activity score. The 
largest effect was seen in the physical outcomes, and lasted 6 months. Although on a group 
level the effect size for several PROMs did not exceed the specific MCID, a disease flare can 
still be of great importance for individual patients.
Table S1 Overall differences between norm and moments thereafter for different flare 
criteria.
ΔDAS28-CRP > 0.6 DAS28 > 2.6 & 
ΔDAS28 > 0.6


















DAS44 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
GH <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Morning 
stiffness
0.0050 0.055 0.0003 0.0032 0.0002 0.0021 0.0018 0.02
HAQ-DI 0.0043 0.047 0.019 0.21 0.0032 0.036 0.0013 0.014
EQ5D 0.0001 0.0006 <0.0001 0.0001 <0.0001 0.00015 0.0001 0.0011
BRAF-MDQ 0.13 1 0.18 1 0.042 0.46 0.24 1
HADS
 anxiety
1 1 0.28 1 0.35 1 0.91 1
HADS 
depression
0.82 1 0.86 1 0.02 0.22 0.66 1
SF36 MCS 0.62 1 0.41 1 0.37 1 0.55 1
SF36 PCS 0.12 1 0.42 1 0.40 1 0.087 0.96
Worker 
productivity
0.23 1 0.47 1 0.012 0.13 0.011 0.12
*n=11. BRAF-MDQ: Bristol Rheumatoid Arthritis fatigue multidimensional questionnaire; DAS: disease 
activity score; EQ5D: European quality of life with 5 dimensions; GH: visual analogue scale (VAS) 
general health; HADS: hospital anxiety and depression scale; HAQ-DI: health assessment questionnaire 
disability index; MCS: mental component scale; PCS: physical component scale; SF36: short form 36; 
VAS: visual analogue scale.
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Objective The aim of the current study was to evaluate the two year cost-utility 
ratio between tapering csDMARD first followed by the TNF-inhibitor, or vice versa, in 
rheumatoid arthritis patients.
Methods Two-year data of the TARA tapering trial were used. RA patients who 
used both a csDMARD and a TNF-inhibitor and had a well-controlled disease 
(DAS≤2.4&SJC≤1) for at least 3 months, were randomized into gradual tapering 
the csDMARD first followed by the TNF-inhibitor, or vice versa. Quality-adjusted life 
years (QALYs) were derived from the EQ5D. Health care and productivity costs were 
calculated with data from patient records and questionnaires. The incremental cost-
effectiveness ratio (ICER) and the incremental net monetary benefit (iNMB) were used 
to assess cost-effectiveness between both tapering strategies. 
Results 94 patients started tapering their TNF-inhibitor first, while the other 95 
tapered their csDMARD first. QALYs (sd) were, respectively, 1.64 (0.22) and 1.65 
(0.22). Medication costs were significantly lower in the patients who tapered the TNF-
inhibitor first, while indirect cost were higher due to more productivity loss (p=0.10). 
Therefore, total costs (sd) were €38,833 (€39,616) for tapering csDMARDs first, and 
€39,442 (€47,271) for tapering the TNF-inhibitor (p=0.88). For willingness-to-pay 
(WTP) levels <€83,800 tapering the csDMARD first has the highest probability of being 
cost-effective, while for WTP levels >€83,800 tapering the TNF-inhibitor first has the 
highest probability.
Conclusion Our economic evaluation shows that costs are similar for both tapering 
strategies. Regardless of the WTP, tapering either the TNF-inhibitor or the csDMARD 
first is equally cost-effective. 




The optimal management for Rheumatoid Arthritis (RA) comprises an early, intensive 
and treat-to-target management approach, which has the highest chance of inducing 
remission and preventing joint damage.[1, 2] In case of sustained remission, tapering 
of treatment can be considered to reduce side-effects and save costs.[3] In the 
Netherlands more than 300 million euros are spent on the use of biological therapy 
for rheumatic diseases.[4] On the other hand, treatment with conventional synthetic 
disease-modifying anti-rheumatic drugs (csDMARDs) generally costs only one tenth 
of the cost of a biological.[5] Although rheumatologists carefully consider initiation of 
biologicals, uniform tapering decisions are lacking, and therefore biological tapering 
is not always directly performed when sustained remission is achieved.[6] Tapering of 
biologicals could reduce health care costs.
In the TARA trial two tapering strategies were compared, namely tapering the TNF-
inhibitor first followed by the csDMARD, or vice versa. Within the first year, in which 
either the TNF-inhibitor or the csDMARD was gradually tapered within 6 months, 
there were no significant differences in flare rates, disease activity, functional ability 
and quality of life, although we did observe numerical differences (10% in flare rates), 
and less patients in clinical remission.[7] From a clinical viewpoint  one could argue 
that the order of tapering is not relevant. On the other hand, TNF-inhibitors are far 
more expensive than csDMARDs, therefore from a health economics perspective it is 
more sensible to taper the TNF-inhibitor first. Previous studies already showed that 
tapering biologicals leads to a reduction of medication and medical consumption 
costs, also known as direct costs, but could also result in a decrease in quality of 
life.[8-11] Tapering of medication might lead to an increase in disease activity and 
consequently to a disease flare. This could lead to more pain and disability, possibly 
resulting in more productivity loss and sick leave. However, not much is known about 
aforementioned possible effects. Furthermore, none of the aforementioned studies 
compared two active tapering strategies.[11, 12] 
Moreover, a previous study already showed that disease flares have a significant 
impact on patients’ lives, which among other things could lead to productivity loss.
[13] As mentioned earlier, the effect of a flare on societal costs is not known. Nor do 
we know whether the health care (direct) cost reduction due to tapering treatment 
outweigh the possible increase in productivity (indirect) costs. 
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Therefore, our aim is to investigate which gradual tapering strategy has the best cost-
utility ratio over a period of two years. Furthermore, we want to explore the effect of 
tapering on both medical and societal costs.
PATIENTS AND METHODS
Patients
For this study data were used from the Tapering strategies in Rheumatoid Arthritis 
(TARA) trial (NTR2754). TARA, a multicenter, single-blinded trial was carried out in 
twelve rheumatology centers in the Netherlands between September 2011 and July 
2016. Medical ethics committees at each participating center approved the study 
protocol and all patients gave written informed consent before inclusion.
Primary aims of the TARA study were to assess effectiveness and cost-effectiveness 
of two tapering strategies, from a societal perspective. An extended description of 
the TARA study and clinical effectiveness outcomes can be found elsewhere.[7, 14] 
Inclusion criteria for the TARA trial were: adult RA patients, with a well-controlled 
disease, defined as a disease activity score (DAS44)≤2.4 and a swollen joint count 
(SJC)≤1 at two consecutive time points within a 3-month interval, who were using a 
combination of a csDMARD and a TNF-inhibitor. 
Randomization and masking
Patients were randomized using minimization randomization stratified for center 
into tapering the csDMARD in the first year followed by tapering the TNF-inhibitor 
in the second year, or vice versa. No other factors were used for the minimization 
randomization. Trained research nurses, blinded to the allocated treatment arm 
throughout the study, examined the patients.
Design
The csDMARD and TNF-inhibitor were both gradually tapered in three steps. csDMARD 
tapering was realised by cutting the dosage into half, a quarter and thereafter it 
was stopped. The TNF-inhibitor was tapered by doubling the interval between gifts, 
followed by cutting the dosage into half, and thereafter it was stopped. If patients 
remained flare-free, the first drug was completely tapered after 6 months. 
Two-year cost-effectiveness between two gradual tapering strategies in RA
9
165 
Both tapering strategies had a treat-to-target approach with three-monthly visits. 
At each visit patients were assessed whether they maintained low disease activity 
(DAS≤2.4) while tapering their medication. If a disease flare occurred, defined as a 
DAS>2.4 and/or SJC>1, tapering was stopped and the last effective treatment, when 
the patient still had well-controlled disease, was restarted. No further attempts were 
taken to taper medication. Treatment was intensified at each visit until low disease 
activity was reached again.
Concurrent treatment with non-steroidal anti-inflammatory drugs and intra-
articular glucocorticoid injections were allowed. In case of a flare, one intra-muscular 
glucocorticoid injection was allowed to be given as bridging therapy, in addition to 
switching to the last effective dosage of the csDMARD or TNF-inhibitor. 
Effectiveness and cost assessment
The primary outcome of the TARA study was the number of disease flares. For the cost-
effectiveness the main outcome was the incremental cost-effectiveness ratio (ICER). 
The ICER is the ratio of the difference in costs compared to the difference in quality 
adjusted life years (QALYs) between both tapering strategies. Costs per QALY were 
calculated, since coverage of prescribed drugs by Dutch health insurance companies 
depends on this outcome. The required threshold per additional QALY gained to be 
funded for a new intervention in the Netherlands is €50,000.[15-17] QALYs express 
the impact of the disease on patients’ health over time. Living in perfect health for 
one year corresponds to 1 QALY, living in perfect health for two years corresponds 
to 2 QALYs. Zero QALYs reflects death at baseline.[18] QALYs were determined by 
calculating the area under the curve of the EuroQol questionnaire with 5 dimensions 
(EQ-5D) with 3 levels over a two year period.[19]
Total costs are divided into health care (direct) and productivity (indirect) costs. We 
analyzed health care and productivity costs from a societal perspective. Health care 
costs are the costs of treatment and medical consumption, whereas productivity 
costs are costs due to presenteeism, i.e. working while sick, and absenteeism, i.e. sick 
leave and unemployment.[20] 
Medication costs were calculated from doses reported in the patients’ case records, 
valued according to the Dutch college of health insurances (supplementary table S1).
[5] Duration of hospitalizations and admission diagnosis were recorded every three 
months with the iMTA medical consumption questionnaire. Medical consumption, 
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including hospital admissions, was valued at Dutch standard prices, except for costs 
of complementary and alternative medicine, which were based upon American data, 
because no Dutch data are available (supplementary table S2).[21, 22]
Productivity costs included absenteeism, such as sick leave and reduction in work 
time, and presenteeism, including working while sick. Every three months patients 
filled out the iMTA productivity cost questionnaires (iPCQ).[23] The friction cost 
method was used to calculate the productivity costs, which assumes replaceability of 
every employee in time.[19] The friction cost period is the time between the start of 
long-term sick leave, and filling the position again. Costs due to sick leave are solely 
counted during this period, which encompasses 85 days in the Netherlands.[24] 
Productivity losses were valued at age- and sex-dependent standard hourly costs 
(supplementary table S3).[25, 26] All prices were obtained for the year 2019. Costs 
were not discounted, because of only two years of follow-up. 
Willingness-to-pay
To help decide which tapering strategy has the highest chance of being cost-effective, 
two indicators were used. First, the cost-effectiveness acceptability curves were 
derived to show the probability of each tapering strategy being cost-effective at 
different levels of willingness-to-pay (WTP) thresholds in comparison with each other.
[27] Second, the incremental net monetary benefit (iNMB) was used to express the 
incremental value of the tapering strategies in monetary terms at different levels of 
willingness-to-pay per QALY. This results in an alternate measure which reports on 
cost-effectiveness without using the ICER. The iNMB was calculated as the incremental 
benefit times different levels of WTP, minus the incremental costs. A positive iNMB 
indicates that the tapering the TNF-inhibitor first is cost-effective compared to 
tapering the csDMARD first.[27] 
Statistical analysis
The cost-effectiveness analysis follows a superiority design. Sample size calculation 
was based on the number of disease flares after one year, which was described 
previously.[7] All analysis were performed following an intention-to-treat approach.
After two years of follow-up, 13/94 (13.8%) in the tapering the csDMARD first group 
had dropped out, versus 9/95 (9.5%) in the tapering the TNF-inhibitor first group. 
Furthermore 7.6% of patients who completed the trial did not completely fill out 
the questionnaires. Multiple imputations with chained equations (MICE), with 40 
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imputations, were used to handle missing data in baseline variables as well as in the 
follow-up data.[28]  An imputation regression model was constructed to impute EQ-
5D, unemployment, loss of productivity due to sick leave (absenteeism) and not fully 
functioning (presenteeism) and the (decrease in) number of working hours. 
For EQ-5D, presenteeism and the amount of working hours linear regression was 
used. The percentages of missingness for these variables were, respectively, 14.9%, 
6.7%, 18.6%. For presenteeism we log transformed the variable and used linear 
regression to impute values. For unemployment (13.6% missing values) we used 
logistic regression, and for sick leave (7.9% missing values) we used a Poisson 
regression model. The choice of imputation models were based on the distribution 
of the individual variables. In the regression models we used age, gender, baseline 
values, and the tapering strategy as independent variables. Differences between 
imputed data, created with aforementioned models, and complete cases were 
minimal and showed that our imputation models are reliable (supplemental table S4).
The main outcome was the incremental cost-effectiveness ratio (ICER). A probabilistic 
sensitivity analysis for the estimation of the ICER was performed by bootstrapping 
with 1000 iterations using a Monte Carlo simulation. Results were plotted in a cost-
effectiveness plane and were used to estimate the 95% confidence interval (CI) of the 
ICER. 
Differences in outcomes between groups were analyzed with linear regression 
models, and to account for stratified randomization by center, intercepts for each 
center were included. 




A total of 189 patients were randomly assigned to taper the csDMARD (n=94) or TNF-
inhibitor (n=95) first. Over two years, 22 patients (11.6%) withdrew from the study, 
resulting in 167 patients with a complete follow-up. At baseline, patients had an 
average symptom duration of 6.8 years and were predominantly female (66.1%) with 
an average age of 56.6 years (table 1). The majority of patients (55%) used etanercept 
as their TNF-inhibitor. At baseline, 47 (25%) of patients were aged above 65, which 
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was the average age of retirement in the Netherlands in 2018.[29] Of the 142 patients 
under 65, 99 patients (70%) had paid work at baseline (table 1). 








Age (years), mean (sd) 55.9 (14) 57.2 (11)
Aged above 65, n (%) 22 (23) 25 (26)
Gender, female, n (%) 67 (71) 58 (61)
Quality of life
EQ5D index, mean (sd) 0.86 (0.12) 0.87 (0.11)
Disease characteristics
Symptom duration (years), median (IQR) 6.0 (4.3-8.5) 6.3 (4.1-8.9)
RF positive, n (%) 49 (57) 56 (64)
ACPA positive, n (%) 61 (72) 65 (75)
DAS, mean (sd) 1.1 (0.6) 1.0 (0.5)
Use of csDMARDs a 
MTX, n (%) 89 (95) 84 (88)
SASP, n (%) 10 (11) 12 (13)
HCQ, n (%) 24 (26) 37 (39)
Leflunomide, n (%) 2 (2) 4 (4)
Use of TNF-inhibitors
Etanercept, n (%) 52 (55) 52 (55)
Adalimumab, n (%) 36 (39) 40 (43)
Other, n (%) b 6 (7) 3 (3)
Worker related outcomes
Paid work, n (%) c 47 (61) 52 (68)
Working hours per week, mean (sd) 28 (8) 29 (11)
a some patients used a combination of csDMARDs, b certolizumab or golimumab, c number 
of patients with paid work and aged under 65. ACPA: anti-citrullinated protein antibody; 
csDMARDs: conventional synthetic disease modifying anti-rheumatic drugs; DAS: disease activity 
score based on 44 joints; EQ5D: European Quality of life questionnaire with 5 dimensions; HCQ: 
hydroxychloroquine; IQR: interquartile range; MTX: methotrexate; RF: rheumatoid factor; SASP: 
salazopyrine; sd: standard deviation.
Health care costs
Mean health care costs (sd) were €22,484 (€8,069) for tapering the csDMARD first and 
€13,616 (€9,162) for tapering the TNF-inhibitor first (p<0.001)(table 2). Respectively, 
86% and 71% of health care costs were medication costs. The faster savings due 
to less TNF-inhibitor use within the group that tapered the TNF-inhibitor first was 
the main driver of the difference in direct costs. Within the group who tapered the 
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csDMARDs first, 81 (86%) were using full dose TNF-inhibitor after 12 months, and 32 
(34%) patients after 24 months. In the TNF-inhibitor tapering first group this was 16 
(17%) after 12 months, and 25 (26%) after 24 months. 
Table 2 Health care costs over two years of follow-up in the TARA study according to 
intention-to-treat.
Tapering csDMARDs first 
(n=94)













csDMARDs * €436 (€87) €972 (€123)
TNF-inhibitor * €19,417 (€738) €9,673 (€863)
Prednisone €2.46 (€0.54) €2.84 (€0.59)
Medical consumption
Hospitalization 13 a €326 (€1313) 15 a €558 (€2271)
Standard health care 
Primary care 
physician
7.7 (9) €260 (€302) 8.9 (9) €303 (€318)
Specialist 12.0 (6) €1,153 (€647) 12 (6) €1,203 (€738)
Psychologist 0.5 (2) €18 (€83) 1.2 (8) €40 (€266)
Paramedical care 
Physical therapy 14.4 (32) €506 (€1,110) 15.9 (31) €554 (€1,063)
Dietitian 0.46 (2) €14 (€62) 0.040 (0.3) €1.31 (€8.95)
Social worker 0.14 (0.6) €9.40 (€41) 0.20 (0.8) €14 (€52)
Speech therapist 0.04 (0.3) €1.32 (€10) 0.02 (0.2) €0.65 (€6.36)
Alternative medicine 
Homeopathy 0.83 (3) €26 (€97) 0.44 (2) €14 (€67)
Total health care 
costs, mean (sd)
€22,484 (€8,069) €13,616 (€9,162)
* p<0.001 (linear regression adjusted for stratified randomisation. a Number reflects the number 
of patients who got hospitalized within the two years of follow-up. csDMARDs: conventional 
synthetic disease modifying anti-rheumatic drugs; sd: standard deviation.
Productivity costs
Average productivity costs (sd) for tapering csDMARDs first and TNF-inhibitor first were, 
respectively €16,349 (€38,277) and €25,826 (€46,289)(p=0.10)(table 3, 4). Within the 
two years of follow-up 20 (43%) patients with paid work called in sick with an average 
duration of 9 days in the initial csDMARD tapering group versus 26 patients (50%) 
with an average duration of 12 days within the initial TNF-inhibitor tapering group. Of 
those patients, respectively 2 and 1 had long-term sickness (>3 months). Two patients 
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who tapered the csDMARD first became unemployed, versus six in the group who 
tapered the TNF-inhibitor first. The working population had an average workweek of 
32 hours after 24 months of follow-up. A decrease in working hours was seen in 8 and 
11 patients in respectively the csDMARD and TNF-inhibitor tapering first group. Their 
average workweek decreased with 15 hours in the csDMARD tapering first group and 
19 hours in the TNF-inhibitor tapering first group. Within the working population 34 
patients in the csDMARD tapering first group and 41 patients in the TNF-inhibitor 
tapering first group indicated that they had days on which they were less productive. 
On average, this were 5 and 6 days per month, with a mean productivity loss on these 
days of 28% and 26%, respectively (table 3). Sub analyses of males and females did 
not result in differences in productivity costs (data not shown). 
Table 3 Productivity costs over two years of follow-up.
Tapering







 Became unemployed, n (%) 2 (4) 6 (11)
Sick leave (during 2-year follow-up)
 Occurrence, n (%) 20 (21) 26 (27)
 Long-term sickness, n (%) 2 (2) 1 (1)
 Days absent, mean (sd) a 9.0 (23) 12.3 (22)
Contract hours b
 Working hours per week after 2 years, mean (sd) 32 (8.9) 33 (12)
 Reduction of working hours per week, n (%) 8 (8) 11 (11)
 Amount of reduction, hours, mean (sd) c 15 (11) 19 (17)
Presenteeism
Number of patients, n (%) 34 (36) 41 (43)
-   Number of days per month, mean (sd) d 5.3 (0.9) 6.1 (1.1)
-   Average productivity loss, proportion (sd) e 27.9% (13%) 26.4% (15%)
a Only indicated when patients reported sick leave 
b Only indicated when patients had paid work 
c Only indicated for those with a reduction in working hours 
d Average productivity score was only obtained for patients indicating that they had loss of 
productivity. 
e Productivity loss was indicated only for the days with productivity loss for those who reported 
to suffer from loss of productivity. 
csDMARDs: conventional synthetic disease modifying anti-rheumatic drugs, sd: standard 
deviation
Cost-effectiveness analysis
The mean EQ5D index (sd) after 24 months of follow-up was 0.81 (0.13) for tapering 
the csDMARD first, and 0.83 (0.16) for tapering the TNF-inhibitor first. Average QALYs 
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(sd) over two years for tapering csDMARDs first or TNF-inhibitor first were, respectively, 
1.64 (0.22) and 1.65 (0.22)(table 4). Total costs (sd) were €38,833 (€39,616) for tapering 
csDMARDs first, and €39,442 (€47,271) for tapering the TNF-inhibitor (p=0.88)(table 
4).
The ICER (95% CI) between tapering csDMARDs first minus the TNF-inhibitor first was 
€60,919 per QALY (-€90,638 per QALY to €212,475 per QALY), indicating that tapering 
TNF-inhibitor first was on average €60,919 less expensive per QALY compared to 
tapering the csDMARD first. However, the confidence interval is very wide due to 
a minimal difference in QALYs and costs between the two tapering strategies. To 
illustrate this the analysis of uncertainty in the estimation of the ICER was visualized 
with the cost-effectiveness planes for the two tapering strategies compared to each 
other (figure 1A). The iNMB was €1134 (95% CI €761 to €1507) in favor of tapering 
TNF-inhibitor first for a willingness-to-pay (WTP) level of €50,000, which is the current 
level of WTP in the Netherlands for treatment of RA (supplemental figure S1).[15-17] 
Our cost-effectiveness acceptability curve (CEAC) shows similar results (figure 1B). For 
WTP levels <€83,800 tapering the csDMARD first has the highest probability of being 
cost-effective, while for WTP levels >€83,800 tapering the TNF-inhibitor first has the 
highest probability. In between WTP levels of €53,800 and €83,800 both strategies 
were evenly cost-effective (probability 50%). This indicates that depending on the WTP 
threshold either tapering the TNF-inhibitor or csDMARD first is more cost-effective. 
Moreover, the CEAC shows that both lines are almost horizontal after the crossing 
and that the difference is small, which is due to the small differences in QALYs and 
costs.
Table 4 Total costs and QALYs over the 2 year follow-up period
Tapering csDMARD first Tapering 
TNF-inhibitor first
Total costs €38,833 (€39,616) €39,442 (€47,271)
Total health care costs * €22,484 (€8,069) €13,616 (€9,162)
• Medication * €19,858 (€7,343) €10,648 (€8,642)
• Medical consumption €2,297 (€1,684) €2,393 (€1,775)
• Hospitalization €330 (€1,319) €575 (€2,305)
Total productivity costs €16,349 (€38,277) €25,826 (€46,289)
• Absenteeism €17,581 (€39,576) €23,577 (€45,382)
• Presenteeism €3,290 (€9,952) €4,777 (€14,620)
QALYs (EQ5D, AUC), mean (sd) 1.64 (0.22) 1.65 (0.22)
* p<0.0001 (linear regression adjusted for stratified randomisation). All values are indicated 
as mean (sd). AUC: area under the curve; csDMARDs: conventional synthetic DMARDs; EQ-5D: 
Dutch European quality of life; QALY: quality adjusted life year; sd: standard deviation.
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Figure 1 Summary of economic evaluation of tapering csDMARDs first minus tapering TNF-
inhibitor first. (A) Results of 1000 bootstrapped replications, presented in a cost-effectiveness 
plane which represents uncertainty of the cost-effectiveness ratio. (B) Cost effectiveness 
acceptability curve for tapering csDMARDs first versus tapering TNF-inhibitor first. Results of 
1000 bootstrapped replication, presented for several levels of willingness to pay, indicated 
per quality adjusted life year (QALY) csDMARDs: conventional synthetic DMARDs; QALY: 
quality adjusted life year; WTP: willingness to pay.
DISCUSSION
In this study, we showed that health care costs were significantly lower in patients 
who tapered the TNF-inhibitor first, but productivity costs in this group were higher 
due to more absenteeism and presenteeism compared to the patients who tapered 
the csDMARD first. The ICER (95% CI) between tapering csDMARDs first minus the 
TNF-inhibitor first was €60,919 per QALY (-€90,638 to €212,475). Total costs (sd) were 
€38,833 (€39,616) for tapering csDMARDs first, and €39,442 (€47,271) for tapering 
the TNF-inhibitor first (p=0.88). Depending on the WTP threshold either tapering the 
TNF-inhibitor or csDMARD first has the highest probability of being cost-effective. 
Previous studies showed that savings on health care and societal costs could be 
obtained by treating to target within newly diagnosed RA patients.[30] More savings 
could be obtained by tapering quickly, and possibly stopping the medication when 
RA patients reach sustained remission. Currently, several trials have reported on the 
feasibilty of tapering, however cost-effectiveness analyses are scarce. A systematic 
review on tapering and stopping treatment in RA patients reported that only 2 out 
of 14 included studies performed a cost-effectiveness analysis, although costs are 
nowadays an important reason why tapering or stopping treatment is considered by 
treating rheumatologists.[31]
Previous studies reported on the cost-effectiveness of tapering or stopping 
medication versus a continuation group. The DRESS study for example showed a 
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significant cost-saving after tapering of adalimumab or etanercept, without a clinically 
meaningful loss in QALYs.[12] The STRASS trial also reported on cost-effectiveness. 
Within this trial the interval between TNF-inhibitor injections was extended and 
compared to a control group that continued their medication. Health care costs were 
significantly lower in the tapering group, but this was accompanied with a signficant 
loss in QALYs.[11] Although both studies also reported on productivity costs, they did 
not take presenteeism into account. In our study the QALYs did not differ between 
both tapering strategies and were comparable to the QALYs of the control groups in 
previous mentioned trials (DRESS 1.67 and STRASS 1.68).[11, 12]
The strengths of the current study include the randomized design. Although originally 
the TARA trial was powered to find a 20% difference in disease flares, cost-effectiveness 
was a parallel primary outcome. Also, validated outcome measures were used for 
the QALY calculation. Furthermore, we used real data to calculate health care and 
productivity costs, instead of using a model. Moreover, for calculating productivity 
costs we included absenteeism as well as presenteeism, thereby taking into account 
all costs due to productivity loss. Finally, the TARA trial is the first randomized 
controlled trial reporting on the cost-utilty between two gradual tapering strategies. 
Some limitations should also be noted. First of all, the targeted sample size was not 
reached. This was due to difficulties with inclusion, and the start of another trial 
using the same pool of eligible patients. For the primary outcome (disease flares) 
we performed a sensitivity analysis, which showed similar outcomes.[7] Furthermore, 
the follow-up duration was only 2 years. Ideally, longterm effects of tapering and 
stopping treatment should be taken into account as well. In our current design, 
patients completely tapered their medication after 18 months, if no flare occurred. 
This means that we only have 6 months of follow-up when patients are in DMARD-free 
remission. Late flares were, therefore, not considered in our study and might change 
current outcomes by an increase in health care costs on the long term, but might also 
influence productivity costs and quality of life. 
Generalizability of the current study might be difficult, since every country has its own 
social security and healthcare system. Also treatment prices differ. Costs of labor vary 
between countries, and more importantly, rules and regulations for social security 
regulation differ across countries. The possibility to stay at home when not feeling 
well is very different across countries within Europe.[32] In the Netherlands, people 
can call in sick without consulting a doctor, while this is obligatory in some other 
countries. This could cause a shift between presenteeism and absenteeism when 
comparing the Netherlands to other countries. Fortunately, in our current analysis 
 Chapter 9
174
we do take into account both. Since we found that the group that tapered the TNF-
inhibitor first encountered more costs due to both presenteeism and absenteeism 
(table 3, p=0.39 and p=0.20, respectively), we believe that our indirect costs are 
generalizable to all countries.
In the current study we found a significant difference in medication costs between 
both tapering groups. The difference in health care costs could change due to price 
variations of csDMARD and especially biologicals between countries. To investigate 
this, we performed a sensitivity analysis with varying levels of biological prices of 30%, 
50%, and 200% of the prices we currently used (supplemental figure S2). Lowering 
biological prices was in favor of tapering the csDMARD first, while higher biological 
prices showed the opposite. However, biological costs are consistantly higher than 
csDMARD costs in any country, meaning that the direction of the medication cost 
difference could be generalizable to other countries. For the current analysis we used 
2019 prices to make our results as relevant as possible, since the prices for biologicals 
have decreased dramatically. 
In conclusion, medication costs are lower when the TNF-inhibitor is tapered first, but 
this is counterbalanced with a higher loss of productivity and, therefore, cost savings 
are similar for both tapering strategies. Regardless of the WTP threshold, tapering the 
TNF-inhibitor or csDMARD first is equally cost-effective. 
    















Figure S1 Mean incremental net monetary benefit (iNMB) for tapering csDMARDs minus 
tapering TNF-inhibitors first. Results are plotted against different levels of willingness to pay 
(WTP) per quality adjusted life year (QALY), and with 95% confidence intervals. The iNMB was 
calculated as the incremental benefit times different levels of WTP, minus the incremental costs. 
csDMARDs: conventional synthetic DMARDs; iNMB: incremental net monetary benefit; QALY: 
quality adjusted life year; WTP: willingness to pay.



























































































































































































































































































































































-   Oral 2.5mg tablet €0.18
-   Subcutaneous
• 2.5 tot 10 mg per piece €13.72
• 12.5 tot 20 mg per piece €27.45
• 22.5 tot 25 mg per piece €34.31
Sulfasalazine (oral) 500mg tablet €0.11
Hydroxychloroquine (oral) 200mg tablet €0.14
Leflunomide (oral)
-   20 mg tablet per piece €1.48
-   10 mg tablet per piece €1.14
Glucocorticoids
Prednisone (oral) 
-   Oral 5mg tablet €0.05
Triamcinolone (im) 80mg €6.72
Methylprednisolone (im) 120mg €6.74
Biologicals
Etanercept (sc)
-   25 mg per piece €105.63
-   50 mg per piece €211.25
Adalimumab (sc)
-   20 mg per piece €269.22
-   40 mg per piece €538.44
Certolizumab (sc)
-   200 mg per piece €505.77
Golimumab (sc)
-   50 mg per piece €1125.84
Abatacept (sc)
-   125 mg per piece €277.95
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-   General hospital (day) €461
-   University hospital (day) €668
Intensive care unit (day) €1234
Daycare treatment (day) €495
Outpatient visit
-   Specialist
• General hospital €83
• University hospital €170
Emergency room visit €269
Primary care physician €34
Paramedical care
-   Physical therapy €34
-   Occupational therapy  €34
-   Speech therapy €31
-   Dietary advice (hour) €31
Mental healthcare
-   Social worker €68
-   Psychologist €67
Complementary medicine
Alternative medical systems
-   Homeopathic treatment €31
Supplementary table S3 Average hourly productivity costs, stratified for age and 
sex [35, 36]
Age (years) Men Women
15 to 19 € 8.77 € 7.97
20 to 24 € 16.56 € 16.13
25 to 29 € 22.53 € 23.12
30 to 35 € 28.14 € 27.81
35 to 40 € 33.91 € 30.62
40 to 45 € 39.13 € 30.87
45 to 50 € 42.61 € 29.67
50 to 55 € 44.13 € 28.75
55 to 60 € 44.48 € 28.68
60 to 65 € 43.34 € 28.83
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EQ5D, mean (sd) 0.83 (0.16) 0.83 (0.15) 0.002 (0.0053) 0.69
Paid work, 
proportion (se)
0.506 (0.0019) 0.506 (0.0019) 0.0002 (0.0027) 0.94
LOG days with 
productivity loss,
 mean (sd)
1.80 (0.82) 1.80 (0.81) 0.000027 (0.0066) 1
Productivity score, 
mean (sd)
7.63 (1.81) 7.63 (1.81) 0.000000070 1
LOG number of times 
absent due to sick leave, 
mean (sd)
0.26 (0.53) 0.26 (0.53) 0.00000067 1
Duration of sick leave, 
mean (sd)
2.94 (2.49) 2.94 (2.49) 0.00070 0.97
Working hours per 
week, mean (sd)
30.3 (11.8) 30.3 (11.7) 0.0015 0.99
EQ5D: EuroQol with 5 dimensions; sd: standard deviation
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As a result of better treatment outcomes in rheumatoid arthritis (RA), many patients 
have a well-controlled disease. Continuation of treatment for these patients is 
not always necessary, and options for tapering of treatment have been previously 
explored. However, RA remains a chronic, fluctuating, incurable disease. Since it is 
unclear how and when tapering treatment should take place, it should always be 
carefully considered. 
Within this thesis the following questions concerning tapering of treatment were 
answered for an established RA population:
• Clinical perspective: How should we taper treatment, and is it possible to 
discontinue medication completely?
• Patient perspective: What is the impact of a disease flare during tapering 
on patients’ lives?
• Societal perspective: What is the cost-effectiveness of different tapering 
strategies?
The answers to these questions were addressed using data from the TApering 
strategies in Rheumatoid Arthritis (TARA) trial. 
Clinical perspective
Tapering treatment has been recommended by the EULAR guidelines. They state 
that when a patient is in persistent remission, after tapering glucocorticoids, 
rheumatologists could consider tapering bDMARDs, especially when combined with a 
csDMARD. Also, when a patient is in remission with only a csDMARD, tapering of that 
csDMARD can be considered.[1] However, no consensus has been reached on the 
definition of sustained remission, nor is there a pre-specified tapering strategy (i.e. 
stopping versus gradually tapering).[2] Previous literature has shown that tapering 
treatment is possible, however, there are no studies directly comparing different 
tapering strategies.[3-6] 
From the results of the TARA trial we concluded that from a clinical perspective the 
tapering order was not relevant. The flare rates between both tapering strategies, 
namely tapering the csDMARDs first followed by the TNF-inhibitor or vice versa, were 




flare rates occurred after 12 months, but this difference disappeared in the second 
year and after two years we found a flare rate of 61% in both tapering arms (chapter 
6). Tapering TNF-inhibitors first was, therefore, not superior to tapering csDMARDs 
first from a clinical perspective. 
Nonetheless, a 61% flare rate seems high, but one must keep in mind that these 
reported flare rates also include flares that would normally occur without tapering. It is 
known that RA patients who are in sustained remission and are using a stable DMARD 
dosage can experience a flare. For example, tapering trials with a control arm that 
continued medication, and thus not tapered, showed flare rates between 12%-48% 
after one year of follow-up. Flare rates within the tapering arms of aforementioned 
studies ranged between 51%-77%.[4, 5, 7, 8] In these studies there is an increased 
risk of flare in the tapering arm, but there is also a risk of flare when medication is 
not tapered. Flare rates within the TARA trial were comparable with previous tapering 
trials. These comparisons, however, should be interpreted carefully, because of 
differences in study design, i.e. differences in patient population, flare definition and 
starting point of tapering, which resulted in a wide range of flare rates.[9-11] 
Besides flare rates, also medication use was taken into account in chapter 3 and 6. 
Due to the gradual tapering scheme and large amount of tapering steps, six in total, 
tapering of treatment was stopped at several dosage levels if a flare occurred. After 
two years, some patients were able to completely stop all DMARDs (15%, chapter 
6). On the other hand, only a minority of the patients were not able to taper any 
medication at all (16%, chapter 6). This indicates that although DMARD-free remission 
is rare, almost all RA patients can reduce their medication dosages if they have a well-
controlled disease. This was also confirmed with real-world data in chapter 7. Future 
tapering strategies might, therefore, not only be targeted at complete withdrawal, but 
also at finding the lowest possible DMARD dosage on which patients still have a well-
controlled disease. Previous studies investigating reduced dose regimens versus full 
dose regimens showed non-inferiority, underlining the potential of dose reduction.
[4, 7, 11, 12] 
If treatment is completely tapered while maintaining remission, patients reach a state 
of DMARD-free remission, which is the closest to an actual cure for RA nowadays.[13] 
In chapter 5 we showed that this outcome is achievable for 10%-20% of the whole RA 
population, and in chapter 6 we showed that this is also achievable in an established 
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RA population (15% of the TARA patients were in DMARD-free remission). Because 
only a minority of RA patient are able to reach this goal, DMARD-free remission as a 
target in a treat-to-target management approach is debatable. 
Nowadays, the greatest challenge is to find those patients who are able to (partly) 
taper medication without flares to prevent the associated negative effects. Current 
known predictors for flare-free tapering are absence of auto-antibodies and shared 
epitope (chapter 5). Other (clinical) factors related to flare-free tapering were 
ambiguous (i.e. symptom duration), or did not show any correlation (i.e. age, erosions 
at baseline). Within the TARA trial, no relation was found between being in deep 
remission (DAS<1.6) and the ability to completely taper medication (chapter 6). This 
implies that current EULAR recommendations concerning eligibility of patients for 
tapering are too strict, since they recommend to only taper medication when patients 
are in sustained remission, preferably Boolean based.[1, 2, 14] 
Current tapering strategies are still based on a trial-and-error approach, because we 
cannot adequately predict a disease flare before its occurrence. As a result, high flare 
rates were seen in all previous tapering trials.[15] Interestingly, in the TARA trial no 
flares occurred after 18 months, when our patients reached DMARD-free remission, 
until the end of follow-up, while other studies reported flare rates between 5-25% 
in the first 6 months after achieving DMARD-free remission.[16-19] This implies that 
flares in the TARA trial were detected early compared to the previous mentioned 
trials, which is probably due to the slower and gradual tapering strategy within the 
TARA trial. Until we find good predictors for flare-free tapering, a stepwise tapering 
approach with close monitoring still seems to be the safest way to taper medication.
Patient perspective
In the TARA trial we found an overall flare rate of 61% (chapter 6). Of the patients 
who experienced a flare, 67% regained low disease activity after 6 months. These 
results were comparable with other tapering studies [3-6, 8]. In all these studies, 
flare duration was solely based on disease activity measures. The impact of a flare on 
patients’ lives was not taken into account, while it is known that flares can impact daily 
functioning and can decrease productivity.
Besides the primary outcome (disease flare), secondary outcomes in the TARA 




strategies, no differences were found in functional ability and quality of life (chapter 
3). In chapter 6 adverse events of DMARDs were investigated at baseline, and patients 
reported a higher burden for use of csDMARDs compared to use of TNF-inhibitors. 
This might demonstrate that patients have a preference for tapering csDMARDs over 
TNF-inhibitors.
The impact of a flare on TARA patients was objectified by quantifying changes in PROs 
(chapter 8). We showed that a disease flare has a significant effect on all components 
of the disease activity score, and also on functional ability, quality of life and fatigue. 
The largest PRO effects were found in the physical outcomes, which were almost all 
above the minimal clinically important difference (MCID) and lasted for more than six 
months. Most importantly, the effect of a flare on patient relevant outcomes could still 
be observed after the disease activity normalized. This implies that the effect of flare 
can be detected for a longer period of time than what we now measure with disease 
activity only. Furthermore, all analyses were performed on a group level, so the effect 
on the individual patient might be even worse. The true effect of a flare on a patient, 
therefore, cannot only be visualized with a disease activity measure. Possibly PROs 
could be monitored more often in daily practice. 
Moreover, some of the investigated PROs already worsened before the actual flare 
occurred, i.e. functional ability and severity of morning stiffness, which might be 
useful for flare prediction during tapering. These changes before the actual flare 
occurred were all non-significant, which was also found by a study on prediction on 
flares by changes in PROs.[20] However, within this study a disease flare was always 
accompanied with worsening of the PROs, and results from the TARA still indicate 
that patients already have more complaints before the actual flare was objectified by 
the treating physician. Due to the long-lasting effect of a flare on patients’ lives, it is of 
great importance that we find good predictors for flare-free tapering. By preventing 
flares before its occurrence, we automatically prevent the impact of the flare itself. 
Since we are unable to predict a flare, close monitoring by using PROs seems to be 
valuable to assess patients’ wellbeing before, during, and also after a flare.
Societal perspective
An important reason for tapering medication is reduction of health care costs. On 
the short term, tapering medication can reduce medication costs, but also long term 
costs should be taken into account, such as societal costs. Societal costs are costs 
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due to loss of productivity. In a cost-utility analysis it is important to take into account 
all associated costs, thus health care costs as well as societal costs.[21]
Cost-effectiveness of tapering csDMARDs or TNF-inhibitors first was investigated in 
chapter 9. Previous studies investigated the cost-effectiveness of tapering versus 
continuation of medication. Tapering treatment resulted in cost-savings and a small 
loss of quality adjusted life years (QALYs).[22, 23] However, these studies were not 
consistent in their societal costs calculation; often productivity loss was omitted, 
therefore, the true effect on society remained unclear. 
Within the TARA trial we found significant higher medication costs when the csDMARDs 
were tapered first, however this was counterbalanced by higher societal costs due to 
more productivity loss in the group who tapered the TNF-inhibitor first (chapter 9). 
It is known that decreasing costs for bDMARDs might influence outcomes of cost-
effectiveness analyses. In chapter 9 the impact of changes in prices of medication 
was, therefore, investigated. In case of higher bDMARDs costs, the strategy in which 
the TNF-inhibitors were tapered first appeared to be more cost-effective. If, on the 
other hand, prices of bDMARDs decreased, the strategy in which csDMARDs were 
tapered first was more cost-effective. Future prices of bDMARDs will probably decline 
further, because of the introduction of biosimilars.[24] Therefore, I expect that 
tapering of csDMARDs first will become more cost-effective compared to tapering the 
TNF-inhibitor first. 
In the TARA trial, the societal costs were more than half of the total costs and had 
a major impact on the outcome. So, despite the differences in medication costs, no 
difference in overall cost-effectiveness were found between both tapering strategies. 
This underlines the importance of including all costs, including those caused due to 
productivity loss, to prevent that tapering decisions are solely based on medication 
costs. 
Previous studies showed that savings on health care and societal costs could be 
obtained by treating to target within newly diagnosed early RA patients.[25] Ideally, 
if RA patients are in sustained remission, medication is quickly tapered and possibly 
stopped to reduce health care costs. On the short term, this requires regular 
monitoring of patients who want to taper their medication, which could increase the 
costs for medical consumption. Possibly, future monitoring might be also possible 




On the long term, some patients will be able to reach DMARD-free remission. This 
means that these patients neither require medication nor do they need regular visits 
to the outpatient clinic, which leads to reductions in health care costs. 
General considerations
The TARA study is a single-blinded randomized controlled trial, which has been 
conducted in 13 hospitals in the South-Western part of the Netherlands. The study 
was initiated in 2011 and finished in 2018. The TARA trial was designed without a 
control arm, which might seem odd for a randomized controlled trial. However, 
previous research already showed that tapering treatment is possible in RA patients 
with a well-controlled disease. The TARA trial was, therefore, the logical next step by 
comparing different tapering strategies.
A general limitation of the TARA trial was that, due to difficulties with inclusions, the 
targeted sample size was not reached. Inclusion criteria at the start of the TARA trial 
were a DAS ≤ 1.6 and a maximum of one swollen joint, and use of methotrexate 
and either etanercept or adalimumab. These inclusion criteria were broadened 
to a DAS ≤ 2.4 and a maximum of one swollen joint, use of csDMARDs combined 
with etanercept, adalimumab, certolizumab or golimumab. Despite these changes, 
the inclusion difficulties remained, and eventually led to preliminary termination of 
inclusion in December 2017. Instead of the targeted 208 patients, which included a 
drop-out percentage of 10%, 189 patients were included. After one year of follow-up, 
we encountered a slightly lower drop-out rate of 8%. For the primary outcome we 
performed a sensitivity analysis in chapter 3, and our results appeared to be valid.
Except for chapters 2 and 5, all chapters were based on data derived from the TARA 
trial. The primary outcome (disease flares after one year of follow-up) was investigated 
in chapter 3. Other outcomes were secondary (chapter 6, 7, 9), including one post-
hoc analysis (chapter 8). In chapter 2 real-world data was used from a retrospective 
cohort study. 
The TARA trial has several strengths, including being a randomized controlled trial. 
Advantages of randomized controlled trials are minimizing confounding and selection 
bias due to randomization, and information bias due to blinding. 
Selection bias occurs when the patient sample is not representative for the targeted 
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population, and can affect generalizability of outcomes. For the TARA trial patients 
were selected who were willing to try to taper their medication, and our result will 
therefore be generalizable to established RA patients who are willing to taper their 
medication. Some selection bias might have occurred due to the preference of 
rheumatologists to recruit patients based on their opinion on feasibility of tapering. 
However, based on the baseline characteristics (chapter 3, 4) the TARA population 
appeared to be a reflection of a normal, established RA population. 
Information bias leads to errors in results due to misclassification or measurement 
errors. Information bias can be non-differential or differential. Non-differential 
information bias occurs due to random measurement errors in outcomes and will 
lead to dilution of the effect towards the null, which we cannot correct for. Differential 
information bias is related to the outcome, and can lead, in case of the TARA trial, 
to overestimation of the effect. Differential information bias can be minimized by 
blinding of outcome assessment. Within the single-blinded TARA trial, the research 
nurses, who performed the DAS assessment, were blinded to the allocated treatment 
arm. Treating rheumatologists and patients were aware of the allocated treatment 
arm. Their believes on tapering of treatment might have influenced decisions to 
intensify or taper treatment. Based on the reported adverse events (chapter 7) I 
suspect that patients preferred to taper the csDMARD, also because all participating 
patients previously had to intensify their treatment with a bDMARD to reach well-
controlled disease. Most likely, both rheumatologists and patients therefore expected 
that tapering of the bDMARDs would lead to more flares than tapering csDMARDs, 
in which the effect could be overestimated. Since we did not observe a significant 
difference in flare rates between tapering arms, I believe our outcomes are valid. 
Confounding will occur when there is an external factor (confounder) that has an 
association between the factor of interest and the outcome. If one does not correct 
for confounding, the results may be distorted. Due to randomization, confounding 
was minimized. Within the TARA trial minimization randomization was used, which 
aims at reducing imbalances between patients in each group, taking into account 
certain predefined factors. Normally, randomization leads to a balanced allocation of 
patients over two arms. Because of 13 participating centers at different locations with 
different non-blinded rheumatologists (with different believes), it was a concern that 
when allocation would not be balanced within the participating centers, comparison 




and/or hospital specific treatment strategies for RA patients. Therefore, minimization 
randomization was stratified and balanced for each participating center. As a result, 
we also had to correct for this in all analyses. On the other hand, by stratifying the 
randomization, potential confounding could be introduced. To investigate this, the 
corrected outcomes were compared to the uncorrected outcomes, and no differences 
were observed. This indicates that no confounding was introduced by stratifying the 
randomization.
In chapter 8 a post hoc analysis was performed and new groups were made (i.e. flare 
versus non-flare patients). A major drawback of post hoc analyses are the risk on ‘data 
dredging’. However, in this case the research question was created before the data 
was analyzed and corrections for multiple testing were made. As far as I know, no 
confounding factors were present. 
All perspectives combined: personal recommendations for 
clinical practice
Disease activity guided tapering of DMARDs has proven to be feasible, safe and effective 
in RA patients with low disease activity or remission, but is known to be accompanied 
with a higher risk of flares. Taking into account the clinical perspective, the patient 
perspective, and the societal perspective, I have the following recommendations for 
clinical practice:
• In the TARA trial it was shown that almost all established RA patients with 
a sustained, well-controlled disease, defined as a DAS<2.4 and no swollen 
joints, were able to taper medication. Therefore I suggest that tapering 
could be initiated when patients have a DAS  ≤ 2.4 and no swollen joints 
for at least 6 months. 
• The order of tapering, i.e. csDMARDs or bDMARDs first, is not relevant based 
on both clinical outcomes (flare rates), as well as the cost-effectiveness 
analysis. Tapering treatment should always be carefully considered, and 
should always be based on a shared decision between the rheumatologist 
and the patient. Given the facts that (1) patients experience more burden 
from csDMARDs usage compared to TNF-inhibitor usage, (2) the majority 
of patients is able to taper part of their medication, especially in the group 
who tapered csDMARDs first, and (3) prices of bDMARDs will probably 
decline in the future, I would propose to taper csDMARDs first.
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• Tapering treatment is associated with an increased risk of flares. 
Therefore, my advice is to gradually taper medication and closely monitor 
patients during tapering to detect a possible disease flare early, and 
intensify medication if necessary. Monitoring could be improved by 
not only focusing on measuring disease activity, but also on patients’ 
wellbeing. Measuring PROs on a regular basis could help rheumatologists 
in identifying a flare early. Since the effect of a flare is still apparent after 
disease activity normalizes, monitoring PROs might help evaluate patients’ 
wellbeing.
Future research suggestions
   -   Tapering strategies 
• Although the majority of the TARA patients were not able to completely 
taper all medication, and thus did not reach DMARD-free remission, almost 
all TARA patients were capable of tapering some of their medication. 
Therefore, future research should focus on finding a more tailor-made 
tapering approach, in which the ultimate aim is to reach the lowest 
medication dosage at which patients still have a well-controlled disease. 
• The flare rates in the TARA trial were comparable with other studies 
in which no gradual approach was used. In total, it took 18 months to 
completely taper medication. Because of the similar flare rates, those 18 
months might not be necessary for gradual tapering. Future research 
could explore whether if it is required to taper DMARDs separately and 
one by one, while possibly multiple DMARDs can be tapered at once or 
tapering can be alternated between DMARDs. Also tapering of other 
DMARDs (i.e. bDMARDs with another mode of action) could be explored. 
Furthermore, shared decision making can be used to determine how 
tapering should take place, as well as which DMARD(s) will be tapered.
• Within this thesis we highlighted several aspects of tapering from 
different viewpoints. Still, the decision on when to commence tapering 
of treatment remains unanswered. Often it is suggested that tapering 
can only be initiated when patients reach ‘deep’ or ‘true’ remission, 




is. If a stricter definition of remission is used, less patients are eligible to 
taper medication. However, we have already shown that tapering is also 
possible for patients with a well-controlled disease, defined as a DAS ≤ 
2.4 without any swollen joints. Future research should, therefore, focus 
more on criteria that make flare-free tapering possible, thereby not only 
focusing on the currently existing remission criteria.
   -   Prediction of flares 
• The best study design for comparing treatment strategies is a 
randomized controlled trial. However, trials are known to have limited 
generalizability and usually have a relative short follow-up period. For 
the prediction of flares, I believe a real-world cohort is the best way to 
assess factors influencing flare-free survival. Besides results from clinical 
trials, it is important to obtain more real-world information to improve 
generalizability. 
• Future research should focus on finding biomarkers that predict who is 
eligible for tapering treatment, and, following this, to identify factors that 
predict flare-free survival. If patients can be stratified according to their 
chances at flare-free tapering of treatment, tapering can be initiated. 
Possible predictors should also include patient reported outcomes, 
because we have already shown that they worsen before an actual flare 
occurs. 
   -   DMARD-free remission
• Future research on tapering should focus more on the long term, in 
which also DMARD-free remission should be assessed at least six months 
after complete withdrawal of medication. A follow-up of only one year 
is too short to correctly evaluate DMARD-free remission rates. Since 
recruitment of patients for tapering trials has shown to be difficult, and 
a trial with a long follow-up is costly, this research could be performed 
in large registries in which tapering occurs. I expect that tapering of 
treatment will occur more often in the future due to the incorporation of 
DMARD tapering in the guidelines and the growing knowledge on tapering 
of treatment in general. 
 Chapter 10
194
1. Smolen JS, Landewe RBM, Bijlsma JWJ, 
Burmester GR, Dougados M, Kerschbau-
mer A, McInnes IB, Sepriano A, van Vol-
lenhoven RF, de Wit M et al: EULAR rec-
ommendations for the management of 
rheumatoid arthritis with synthetic and 
biological disease-modifying antirheu-
matic drugs: 2019 update. Ann Rheum Dis 
2020.
2. Studenic P, Felson D, de Wit M, Alasti F, 
Stamm TA, Smolen JS, Aletaha D: Testing 
different thresholds for patient global as-
sessment in defining remission for rheu-
matoid arthritis: are the current ACR/EU-
LAR Boolean criteria optimal? Ann Rheum 
Dis 2020, 79(4):445-452.
3. Smolen JS, Nash P, Durez P, Hall S, Iliva-
nova E, Irazoque-Palazuelos F, Miranda 
P, Park MC, Pavelka K, Pedersen R et al: 
Maintenance, reduction, or withdrawal of 
etanercept after treatment with etaner-
cept and methotrexate in patients with 
moderate rheumatoid arthritis (PRE-
SERVE): a randomised controlled trial. 
Lancet 2013, 381(9870):918-929.
4. van Herwaarden N, van der Maas A, 
Minten MJ, van den Hoogen FH, Kievit 
W, van Vollenhoven RF, Bijlsma JW, van 
den Bemt BJ, den Broeder AA: Disease 
activity guided dose reduction and with-
drawal of adalimumab or etanercept 
compared with usual care in rheumatoid 
arthritis: open label, randomised con-
trolled, non-inferiority trial. Bmj 2015, 
350:h1389.
5. Fautrel B, Pham T, Alfaiate T, Gand-
jbakhch F, Foltz V, Morel J, Dernis E, 
Gaudin P, Brocq O, Solau-Gervais E et al: 
Step-down strategy of spacing TNF-block-
er injections for established rheuma-
toid arthritis in remission: results of the 
multicentre non-inferiority randomised 
open-label controlled trial (STRASS: Spac-
ing of TNF-blocker injections in Rheuma-
toid ArthritiS Study). Ann Rheum Dis 2016, 
75(1):59-67.
6. Haschka J, Englbrecht M, Hueber AJ, Man-
ger B, Kleyer A, Reiser M, Finzel S, Tony 
H-P, Kleinert S, Feuchtenberger M et al: 
Relapse rates in patients with rheuma-
toid arthritis in stable remission tapering 
or stopping antirheumatic therapy: in-
terim results from the prospective ran-
domised controlled RETRO study. Ann 
Rheum Dis 2016, 75(1):45-51.
7. van Vollenhoven RF, Ostergaard M, Lei-
risalo-Repo M, Uhlig T, Jansson M, Lars-
son E, Brock F, Franck-Larsson K: Full 
dose, reduced dose or discontinuation of 
etanercept in rheumatoid arthritis. Ann 
Rheum Dis 2016, 75(1):52-58.
8. Ghiti Moghadam M, Vonkeman HE, Ten 
Klooster PM, Tekstra J, van Schaarden-
burg D, Starmans-Kool M, Brouwer E, Bos 
R, Lems WF, Colin EM et al: Stopping Tu-
mor Necrosis Factor Inhibitor Treatment 
in Patients With Established Rheumatoid 
Arthritis in Remission or With Stable Low 
Disease Activity: A Pragmatic Multicenter, 
Open-Label Randomized Controlled Tri-
al. Arthritis Rheumatol 2016, 68(8):1810-
1817.
9. Kuijper TM, Lamers-Karnebeek FB, Ja-
cobs JW, Hazes JM, Luime JJ: Flare Rate in 
Patients with Rheumatoid Arthritis in Low 
Disease Activity or Remission When Ta-
pering or Stopping Synthetic or Biologic 
DMARD: A Systematic Review. J Rheuma-
tol 2015, 42(11):2012-2022.
10. Edwards CJ, Fautrel B, Schulze-Koops 
H, Huizinga TWJ, Kruger K: Dosing down 
with biologic therapies: a systematic re-
view and clinicians’ perspective. Rheuma-
tology (Oxford) 2017, 56(11):1847-1856.
11. Verhoef LM, van den Bemt BJ, van der 
Maas A, Vriezekolk JE, Hulscher ME, van 





waarden N, den Broeder AA: Down-titra-
tion and discontinuation strategies of tu-
mour necrosis factor-blocking agents for 
rheumatoid arthritis in patients with low 
disease activity. Cochrane Database Syst-
Rev 2019, 5:CD010455.
12. Kavanaugh A, Lee SJ, Curtis JR, Green-
berg JD, Kremer JM, Soto L, Etzel CJ, Cox 
V, Yoshida K, Reed GW et al: Discontinua-
tion of tumour necrosis factor inhibitors 
in patients with rheumatoid arthritis in 
low-disease activity: persistent bene-
fits. Data from the Corrona registry. Ann 
Rheum Dis 2015, 74(6):1150-1155.
13. Boeters DM, Burgers LE, Toes RE, van 
der Helm-van Mil A: Does immunological 
remission, defined as disappearance of 
autoantibodies, occur with current treat-
ment strategies? A long-term follow-up 
study in rheumatoid arthritis patients 
who achieved sustained DMARD-free 
status. Ann Rheum Dis 2019, 78(11):1497-
1504.
14. Felson DT, Smolen JS, Wells G, Zhang B, 
van Tuyl LH, Funovits J, Aletaha D, Allaart 
CF, Bathon J, Bombardieri S et al: Amer-
ican College of Rheumatology/European 
League against Rheumatism provisional 
definition of remission in rheumatoid 
arthritis for clinical trials. Ann Rheum Dis 
2011, 70(3):404-413.
15. Schett G, Emery P, Tanaka Y, Burmester 
G, Pisetsky DS, Naredo E, Fautrel B, van 
Vollenhoven R: Tapering biologic and 
conventional DMARD therapy in rheu-
matoid arthritis: current evidence and 
future directions. Ann Rheum Dis 2016, 
75(8):1428-1437.
16. Kuijper TM, Luime JJ, de Jong PH, Gerards 
AH, van Zeben D, Tchetverikov I, de Son-
naville PB, van Krugten MV, Grillet BA, 
Hazes JM et al: Tapering conventional 
synthetic DMARDs in patients with early 
arthritis in sustained remission: 2-year 
follow-up of the tREACH trial. Ann Rheum 
Dis 2016, 75(12):2119-2123.
17. Emery P, Burmester GR, Bykerk VP, 
Combe BG, Furst DE, Barre E, Karyekar 
CS, Wong DA, Huizinga TW: Evaluating 
drug-free remission with abatacept in 
early rheumatoid arthritis: results from 
the phase 3b, multicentre, randomised, 
active-controlled AVERT study of 24 
months, with a 12-month, double-blind 
treatment period. Ann Rheum Dis 2015, 
74(1):19-26.
18. Bijlsma JWJ, Welsing PMJ, Woodworth 
TG, Middelink LM, Petho-Schramm A, 
Bernasconi C, Borm MEA, Wortel CH, Ter 
Borg EJ, Jahangier ZN et al: Early rheu-
matoid arthritis treated with tocilizum-
ab, methotrexate, or their combination 
(U-Act-Early): a multicentre, randomised, 
double-blind, double-dummy, strategy 
trial. Lancet 2016, 388(10042):343-355.
19. Klarenbeek NB, van der Kooij SM, Gul-
er-Yuksel M, van Groenendael JH, Han 
KH, Kerstens PJ, Huizinga TW, Dijkmans 
BA, Allaart CF: Discontinuing treatment 
in patients with rheumatoid arthritis in 
sustained clinical remission: exploratory 
analyses from the BeSt study. Ann Rheum 
Dis 2011, 70(2):315-319.
20. Walter MJ, Mohd Din SH, Hazes JM, Le-
saffre E, Barendregt PJ, Luime JJ: Is tightly 
controlled disease activity possible with 
online patient-reported outcomes? J 
Rheumatol 2014, 41(4):640-647.
21. Alemao E, Al MJ, Boonen AA, Stevenson 
MD, Verstappen SMM, Michaud K, Wein-
blatt ME, Rutten-van Molken M: Concep-
tual model for the health technology 
assessment of current and novel inter-
ventions in rheumatoid arthritis. PLoS 
One 2018, 13(10):e0205013.
22. Vanier A, Mariette X, Tubach F, Fau-
trel B, Group SS: Cost-Effectiveness of 
TNF-Blocker Injection Spacing for Pa-
tients with Established Rheumatoid Ar-
thritis in Remission: An Economic Eval-
uation from the Spacing of TNF-Blocker 
Injections in Rheumatoid Arthritis Trial. 
Value Health 2017, 20(4):577-585.
 Chapter 10
196
23. Kievit W, van Herwaarden N, van den 
Hoogen FH, van Vollenhoven RF, Bijlsma 
JW, van den Bemt BJ, van der Maas A, 
den Broeder AA: Disease activity-guided 
dose optimisation of adalimumab and 
etanercept is a cost-effective strategy 
compared with non-tapering tight con-
trol rheumatoid arthritis care: analyses 
of the DRESS study. Ann Rheum Dis 2016, 
75(11):1939-1944.
24. Kim H, Alten R, Avedano L, Dignass A, 
Gomollón F, Greveson K, Halfvarson J, 
Irving PM, Jahnsen J, Lakatos PL et al: The 
Future of Biosimilars: Maximizing Bene-
fits Across Immune-Mediated Inflamma-
tory Diseases. Drugs 2020, 80(2):99-113.
25. de Jong PH, Hazes JM, Buisman LR, Bar-
endregt PJ, van Zeben D, van der Lubbe 
PA, Gerards AH, de Jager MH, de Son-
naville PB, Grillet BA et al: Best cost-ef-
fectiveness and worker productivity with 
initial triple DMARD therapy compared 
with methotrexate monotherapy in early 
rheumatoid arthritis: cost-utility analysis 

















Treatment outcomes in rheumatoid arthritis (RA) have improved enormously in the 
last decades due to early initiation of therapy, a treat-to-target approach, and use of 
biological disease-modifying anti-rheumatic drugs (bDMARDs). As a result, remission 
in RA occurs more often. This has raised the question whether we need to continue 
or taper treatment. Reasons for tapering are reduction in costs, since treatment 
with bDMARDs  is very expensive, prevention of possible long term side effects and 
patient preference. However, by tapering medication the risk of having a disease 
flare increases, which can have a great impact on patients’ lives and on society due 
to productivity loss, i.e. sick leave or unemployment. Therefore, before tapering 
treatment is considered, it is important to consider these different viewpoints before 
making a (shared) decision. Moreover, the optimal tapering strategy leading to the 
least amount of flares has not been developed yet. 
Therefore, the aim of this thesis was to study the clinical-, patient-, and the societal 
perspective of tapering to help rheumatologist and RA patients with their decisions 
whether they should taper or not. These perspectives were addressed using data 
from the TApering strategies in Rheumatoid Arthritis (TARA) trial. The TARA trial was 
set-up to investigate the best tapering strategy in RA patients with a well-controlled 
disease. Adult RA patients with a disease activity score (DAS) ≤2.4 and a swollen joint 
count (SJC) ≤1 for more than three months, using a combination of a csDMARD and 
TNF-inhibitor, were included. Patients were randomised into gradual tapering either 
the csDMARD in the first year followed by the TNF-inhibitor in the second year, or 
vice versa. csDMARD tapering was realized by cutting the dosage into half, a quarter 
and thereafter it was stopped. The TNF-inhibitor was tapered by doubling the dose 
interval, followed by cutting the dosage into half, and thereafter it was stopped. The 
total tapering schedule took 6 months, with dose adjustments every 3 months as 
long as there was still a well-controlled disease. If a disease flare occurred, defined 
as DAS>2.4 and/or SJC>1, tapering was stopped and the last effective treatment was 
restarted and if necessary, medication was intensified further according to a treat-to-
target approach, until low disease activity was reached again. After a flare, no further 
attempts were taken to taper medication during the remainder of the study. 
To objectify the possible impact of tapering treatment in daily clinical practice, we 




in chapter 2. We stratified real-world biological survival data for discontinuation 
reason and determined its influenceability. Discontinuation reasons for the first-line 
biological were mainly ineffectiveness, adverse events, or remission. Biological survival 
diminished with the number of biologicals used. Biological survival was prolonged if 
patients had concomitant use of csDMARDs. Rheumatoid factor and Anti-Citrullinated 
Protein Antibody were negatively associated with respectively biological survival 
and discontinuation due to remission. Therefore, tailoring treatment based upon 
autoantibody status might be the first step towards personalized medicine in RA.  
In chapter 3 the first year results of the TARA trial were presented. The primary 
outcome was the difference in flare rates during the first year of follow-up, between 
two gradual tapering strategies, namely tapering the TNF-inhibitor of the csDMARD. 
Up to 9 months, flare rates of tapering csDMARDs or TNF-inhibitors were completely 
similar. After one year, a non-significant 10% difference was found, favoring csDMARD 
tapering. Also, no differences were found in disease activity, functional ability, and 
quality of life. Therefore, tapering the TNF-inhibitors first was not superior to tapering 
the csDMARDs first and thus from a clinical viewpoint it does not matter which 
medication is tapered first. 
In chapter 4 more information was given on the treatment strategies that included 
RA patients in the TARA trial were using. Half of the patients used more than one 
csDMARD at baseline. Furthermore, an additional sub analysis was performed in 
which patients using oral glucocorticoids were excluded, whereafter the flare rates 
between both tapering strategies were compared again. This sub analysis showed 
similar results and,  therefore, the conclusion drawn in chapter 3 is still valid. 
If treatment is completely tapered, a patient will be in DMARD-free remission (DFR). 
In chapter 5 we performed a systematic literature review investigating the feasibility 
of DFR as a novel and sustainable outcome for RA. DFR appeared to be achievable in 
RA, and is sustainable in 10%-20% of patients. However, flares occurred frequently 
during DMARD-tapering and in the first year after achieving DFR. Although absence 
of auto-antibodies and shared epitope alleles increased the chance of achieving 
DMARD-free remission, many other (known) risk factors/patient characteristics lacked 
association with DFR. DFR can become an important outcome measure for clinical 
trials, and requires consistency in the definition. Considering the high rate of flares in 




Following this, in chapter 6 we investigated whether DMARD-free remission is also 
an achievable treatment outcome in an established RA population using data from 
the TARA trial. Also, the two-year clinical effectiveness of the two gradual tapering 
strategies in the TARA trial was assessed. DMARD-free remission was achievable in 
15% of established RA patients, and was slightly more frequent in patients who tapered 
their csDMARD first. Although DMARD-free remission occurs less frequent, most of 
the RA patients with a well-controlled disease could lower their DMARD dosages. 
To illustrate, 83% of the patients were able to reduce their medication dosages. 
However,  the tapering  order did not influence aforementioned results. Moreover, no 
difference in flare rates, disease activity, functional ability, or radiographic progression 
were seen after two years and over time. Because of similar effects from a clinical 
viewpoint, financial arguments may influence the decision to taper TNF-inhibitors 
first.  In chapter 7 we compared the TARA data with data from a real-world cohort 
from Pakistan, which confirmed that the majority of RA patients are able to gradually 
taper DMARDs.
In chapter 8 the impact of a disease flare on patient’s lives was determined. This 
was investigated by measuring patient reported outcomes (PROs) during  tapering of 
treatment and comparing the PRO norm values, defined as the average of each PRO 
12, 9 and 6 months prior to a flare, with the values at the moment of flare, 3 months 
prior to a flare and every 4 months after a flare. A flare negatively influenced general 
health, morning stiffness, functional ability, quality of life, and fatigue and this effect 
lasted for 6 months. The effect sizes exceeded the minimum clinically important 
difference for the specific outcome measure, except for functional ability. Although on 
a group level effect sizes for the separate PROs were not always significant or larger 
than specific MCIDs, a disease flare can still be of great importance for individual 
patients. 
An important reason for tapering treatment is to save costs. In chapter 9 we, 
therefore, investigated the societal impact of tapering. For this, the two year cost-
utility ratio between both tapering strategies in the TARA trial was evaluated. Health 
care costs were lower in the patients who tapered the TNF-inhibitor first, while costs 
due to productivity loss were higher. Overall, total costs did not differ between both 
tapering strategies. Regardless of the willingness-to-pay (WTP) threshold, tapering 




In chapter 10 a general discussion of the main findings of this thesis are provided. New 
insights from findings within this thesis and their clinical implications are discussed. 
Also methodological considerations are discussed and their possible implications for 
the results. Finally, recommendations for clinical practice and suggestions for future 
research are presented. The recommendations are that tapering can be commenced 
as soon as patients have a DAS<2.4 for at least six months, without swollen joints. The 
order of tapering is not relevant, however because patients reported more burden 
for use of csDMARDs, most patients are able to taper some medication, especially in 
the group who tapered csDMARDs first, and prices of bDMARDs will decline in the 
future, I recommend to taper the csDMARD first. Furthermore, to reduce the impact 
of flares, patients should follow a gradual tapering protocol with close monitoring, 




Behandeluitkomsten bij reumatoïde artritis (RA) zijn de afgelopen jaren sterk 
verbeterd door vroegdiagnostiek met snelle initiatie van therapie, doelgerichte 
behandeling en het gebruik van biologicals. Patiënten hebben hierdoor steeds vaker 
een goed gecontroleerde ziekte of zelfs remissie, waarbij geen gezwollen of pijnlijke 
gewrichten waarneembaar zijn. Logischerwijs kan men zich dus afvragen of de 
behandeling voortgezet dient te worden bij deze groep RA patiënten die (langdurig) 
in remissie zijn. Andere voordelen van afbouwen van medicatie zijn besparing van 
kosten, het voorkomen van bijwerkingen bij (langdurig) medicatiegebruik en de wens 
van de patiënt. Een groot nadeel van afbouwen is dat de reuma weer kan opvlammen, 
wat een groot effect kan hebben op het leven van de patiënt, maar ook op de 
samenleving door verlies van productiviteit door ziekteverzuim of werkloosheid. De 
keuze om medicatie af te bouwen dient daarom vanuit verschillende perspectieven 
worden belicht. Daarnaast is er nog veel onduidelijkheid over wat de optimale 
afbouwstrategie is.
In dit proefschrift hebben worden twee verschillende afbouwstrategieën vanuit een 
klinisch-, patiënten-, en maatschappelijk perspectief met elkaar vergeleken. Het 
uiteindelijke doel was om de reumatoloog beter te informeren over de positieve en 
negatieve gevolgen van het afbouwen van medicatie om zodoende beter tot een 
gezamenlijke beslissing te komen. Alle informatie komt uit de Tapering strategies 
in Rheumatoid Arthritis (TARA) trial. In dit gerandomiseerd onderzoek werden twee 
afbouwstrategieën met elkaar vergeleken, namelijk het eerst afbouwen van de 
conventionele reuma-remmers (csDMARDs) gevolgd door de TNF-inhibitor, of eerst 
afbouwen van de TNF-inhibitor gevolgd door de csDMARD. Deelnemers aan dit 
onderzoek waren RA patiënten met een rustige ziekte,  gedefinieerd als een DAS ≤2.4 
en maximaal één gezwollen gewricht gedurende ten minste drie maanden. Voor het 
afbouwen van de csDMARD werd eerst de dosis gehalveerd, na 3 maanden werd dit 
nogmaals gehalveerd en na 6 maanden werd de csDMARD gestopt. De TNF-inhibitor 
werd afgebouwd door eerst het interval tussen twee giften te verdubbelen, vervolgens 
werd de dosis gehalveerd en daarna werd het medicijn gestopt. Het afbouwen van 
één van beide medicijnen nam zes maanden in beslag, met elke drie maanden een 
dosisaanpassing zo lang de ziekte rustig was. Per jaar werd één medicijn afgebouwd. 
Indien er een ziekteopvlamming was, gedefinieerd als DAS>2.4 of meer dan één 




ziekteactiviteit, weer werd bereikt. Na een opvlamming werd tijdens de gehele studie 
niet weer geprobeerd af te bouwen. 
Om de impact van het afbouwen van medicatie bij RA patiënten in de dagelijkse 
praktijk in kaart te brengen, beschrijven we het gebruik van biologicals in Nederland 
in hoofdstuk 2. We stratificeerden de stopredenen van biologicals en bepaalden 
hoe dit eventueel beïnvloed kan worden. Redenen om biologicals te staken waren 
voornamelijk ineffectiviteit, bijwerkingen of remissie. Des te meer biologicals een 
patiënt gebruikt had, des te korter de gebruiksduur. De gebruiksduur was echter 
langer wanneer een biological met een csDMARD werd gecombineerd. Verder 
was aanwezigheid van reumafactor negatief geassocieerd met gebruiksduur en 
aanwezigheid van en anti-CCP negatief geassocieerd met de mogelijkheid om 
medicatie af te bouwen. In de toekomst kan behandeling mogelijk meer op maat 
worden gegeven indien rekening wordt gehouden met de aan- of afwezigheid van 
auto-antistoffen. 
In hoofdstuk 3 worden de resultaten van het eerste jaar van de TARA trial 
gepresenteerd vanuit een klinisch perspectief. De primaire uitkomstmaat was het 
procentuele verschil in ziekte-opvlammingen tussen de twee afbouwstrategieën. Tot 
negen maanden was er geen enkel verschil in het aantal ziekteopvlammingen tussen 
beide afbouwstrategieën. Echter, na 12 maanden hadden patiënten die eerst hun 
TNF-inhibitor afbouwden 10% meer kans (niet-significant) op een ziekte-opvlamming 
ten opzichte van de patiënten die eerst hun csDMARD afbouwden. Verder werden 
geen verschillen gevonden in ziekteactiviteit, functioneren of kwaliteit van leven na 
één jaar en over de tijd. Vanuit een klinisch oogpunt maakt het dus niet uit welk 
medicament als eerst wordt afgebouwd. 
In hoofdstuk 4 wordt meer informatie gegeven over welke csDMARDs werden 
gebruikt door patiënten bij inclusie in de TARA studie. Het merendeel van de 
patiënten gebruikte meer dan één csDMARD naast hun TNF-inhibitor. Daarnaast 
werd een sub-analyse verricht met weer als uitkomst het procentuele verschil in 
ziekte-opvlammingen tussen beide afbouwstrategieën, maar waarbij patiënten die 
glucocorticosteroïden gebruikten werden uitgesloten. Dit leverde dezelfde resultaten 
op als hoofdstuk 3, waardoor onze conclusie valide bleek. 
Indien alle medicatie volledig is afgebouwd, komt de patiënt in DMARD-vrije remissie, 
wat op dit moment het dichtst in de buurt van genezing van RA ligt. In hoofdstuk 5 
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wordt een systematisch literatuuronderzoek uitgevoerd waarin gekeken wordt naar 
de haalbaarheid van DMARD-vrije remissie. Ongeveer 10-20% van de RA patiënten 
kan DMARD-vrije remissie bereiken. Voornamelijk bij het afbouwen van medicatie 
en in het eerste jaar na het stoppen van de medicatie kregen veel patiënten een 
ziekteopvlamming. Alleen de afwezigheid van auto-antistoffen en shared epitope 
allelles verhoogde de kans op het bereiken van DMARD-vrije remissie, terwijl andere 
(bekende) risicofactoren niet geassocieerd waren met het bereiken van DMARD-vrije 
remissie. DMARD-vrije remissie kan in de toekomst een belangrijke meetuitkomst 
worden voor onderzoek, maar hiervoor is wel een eenduidige definitie van DMARD-
vrije remissie nodig. Door de hoge aantallen opvlammingen in het eerste jaar na 
stoppen van DMARDs, is een periode van minimaal 12 maanden na het stoppen van 
de DMARDs nodig om het als echte DMARD-vrije remissie te kunnen definiëren.
Vervolgens onderzochten we in hoofdstuk 6 of DMARD-vrije remissie ook een 
haalbare behandeluitkomst is voor patiënten met een langer bestaande RA. 
Wederom werd hiervoor data van de TARA studie gebruikt, maar nu werd gekeken 
over een periode van twee jaar. Slechts 15% van de geïncludeerde RA patiënten was 
in DMARD-vrije remissie en dit was niet afhankelijk van de afbouwstrategie. Hoewel 
een klein percentage van de RA patiënten na twee jaar in DMARD-vrije remissie was, 
kon het overgrote gedeelte (83%) van de geïncludeerde RA patiënten een deel van 
hun medicatie afbouwen. Verder constateerde we wederom dat de volgorde van 
medicatie afbouwen geen invloed had op het aantal opvlammingen, ziekteactiviteit, 
functioneren en radiologische progressie. In hoofdstuk 7 worden onze klinische 
uitkomsten vergeleken met de dagelijkse reumatologische zorg in Pakistan. Onze 
resultaten waren vergelijkbaar met de aangedragen real-world data, het blijkt dat ook 
in de dagelijkse praktijk de meerderheid van de RA patiënten in staat is om medicatie 
gradueel af te bouwen.
In hoofdstuk 8 werd onderzocht wat de impact van een ziekteopvlamming is op het 
leven van de patiënt. In de TARA studie werden frequent patiënt relevante uitkomsten 
(PROs) gemeten. Deze PROs werden genormeerd door het gemiddelde te nemen 
van de bezoeken die respectievelijk 12, 9 en 6 maanden voor een ziekteopvlamming 
lagen. Deze genormeerde PROs werden vergeleken met de PROs ten tijde van 
een ziekteopvlamming, de PROs 3 maanden voor een opvlamming en de PROs 
3-maandelijks na een opvlamming. Het bleek dat een ziekteopvlamming een negatief 




leven en vermoeidheid. Deze negatieve effecten waren vaak ook klinisch relevant en 
hielden tenminste 6 maanden aan. Alhoewel op groepsniveau de negatieve effecten 
van een ziekteopvlamming niet altijd groot lijken, kan dit voor een individuele patiënt 
alsnog van groot belang zijn. 
Een belangrijke reden om medicatie af te bouwen is om kosten te besparen. 
In hoofdstuk 9 onderzochten we daarom het afbouwen van medicatie vanuit 
maatschappelijk perspectief. We vergeleken de kosteneffectiviteit van de twee 
afbouwstrategieën in de TARA studie. Gezondheidszorgkosten waren lager in de 
groep patiënten die de TNF-inhibitor als eerste afbouwden, maar de patiënten 
in deze groep hadden daarnaast hogere maatschappelijke kosten als gevolg van 
productiviteitsverlies (meer ziekteverzuim en toename werkloosheid). Onderaan de 
streep waren dan ook de totale kosten vergelijkbaar tussen beide afbouwstrategieën. 
Daarnaast hebben we voor verschillende niveaus van betalingsbereidheid 
(willingness-to-pay, WTP) gekeken welke van de twee afbouwstrategieën het meest 
kosteneffectief is. De uitkomsten hiervan lagen zeer dicht bij elkaar. Het afbouwen 
van eerst de csDMARDs of eerst de TNF-inhibitor is daardoor even kosteneffectief en 
onafhankelijk van de WTP. 
Hoofdstuk 10 bevat een algemene discussie van hoofdbevindingen van alle 
voorgaande hoofdstukken. De hoofdbevindingen worden besproken vanuit klinisch-, 
patiënt- en maatschappelijk perspectief. De nieuw verkregen inzichten en de 
mogelijke implicaties voor de dagelijkse praktijk worden hier besproken. Ook worden 
methodologische overwegingen bediscussieerd en mogelijke gevolgen daarvan op de 
resultaten. Als laatste worden aanbevelingen gedaan voor de reumatologische praktijk 
en worden er voorstellen gegeven voor toekomstig onderzoek. De aanbevelingen zijn 
dat afbouwen van medicatie kan worden gestart wanneer patiënten ten minste 6 
maanden een DAS<2.4 hebben en eveneens geen gezwollen gewrichten. De volgorde 
voor afbouwen is niet relevant, vanwege invoegen meer bijwerkingen rapporteren 
van de csDMARDs, dat de meeste patiënten deels hun medicatie kunnen afbouwen, 
vooral in de groep die begon met afbouwen van csDMARDs, en de dalende biological 
prijzen, geef ik het advies om de csDMARD eerst af te bouwen. Daarnaast is mijn 
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